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Abstract 
 Inflammatory bowel disease (IBD) is an illness of chronic intestinal inflammation 
comprised of Crohn's disease (CD) and ulcerative colitis (UC).  Specialists rely heavily 
on drugs that target a dysregulated immune system.  There is a staggering degree of 
variation in drug response in CD.  Our understanding of drug metabolism and response in 
IBD is limited.  Gaining new insights into IBD-specific modifications of drug 
metabolism may allow for improved drug efficacy and reduced toxicity. 
 Cytochrome P450 (CYP) 3A4 is the most relevant determinant of drug 
metabolism and exposure for medications prescribed today.  CYP3A4 is highly expressed 
in the liver, but is also important to intestinal drug metabolism.  Little is known about 
CYP3A4 activity in disease states.  We tested the hypothesis that CD affects the activity, 
expression and regulation of CYP3A4. 
 Acute, non-hepatic inflammatory states are reported to reduce hepatic CYP3A4 
activity.  Using midazolam pharmacokinetics and the cholesterol metabolite, 4β-
hydroxycholesterol as in vivo probes of CYP3A4 activity, we were able to demonstrate 
and confirm that CYP3A4 activity is lower in CD.  Conversely, we were unable to show, 
using in vitro modeling, that differences in CYP3A4 activity were due to differential 
nuclear receptor-signaling in CD. 
 CYP3A4 plays a key role in hepatic and intestinal first-pass metabolism, likely in 
concert with the xenobiotic exporter, P-glycoprotein (P-gp). The intestinal and colonic 
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expression of CYP3A4 in CD has not been well characterized.  Using an immunobloting 
technique, we were able to demonstrate that the intestinal and colonic expression of 
CYP3A4 are reduced in CD.   
 Lastly, nuclear receptors such as FXR and PXR are important regulators of 
CYP3A4.  Both are down-regulated in IBD.  This may have important consequences for 
drug response in IBD.  We confirm that a novel single nucleotide polymorphism in FXR 
results in a reduction in its downstream products in vivo and reveal a link between genetic 
variation in FXR and outcomes of CD severity, such as risk and time to surgery, 
particularly relevant to women affected by CD.  
 Ultimately, these studies demonstrate the impact of CD on drug metabolism 
pathways and offer insight into the overlap between CD pathogenesis and drug 
metabolism.  
  
 
Keywords 
Crohn's disease, inflammatory bowel disease, drug metabolism, nuclear receptor, 
farnesoid X receptor, pregnane X receptor, cytochrome P450 3A4, pharmacokinetics, 
single nucleotide polymorphism; biomarker 
iii 
 
Co-Authorship Statement  
Chapter 1:  
Wilson A, Teft WA, Morse BL, Choi Y, Woolsey S, DeGorter MK, Hegele RA, Tirona 
 R, Kim RB.  Trimethylamine-N-oxide: a Novel Biomarker for the Identification 
of Inflammatory Bowel Disease. Digestive Diseases & Sciences 2015; 60(12): 3620-30. 
AW, RGT, SW, MKD, RAH, and RBK were involved in patient selection and data 
collection.  AW, WAT,  and RBK contributed to the research design.  AW, BLM and 
WAT carried out TMAO level analysis and FMO3 genotyping.  YC and AW contributed 
to the statistical analysis of the data.  AW wrote the final paper with assistance from 
WAT, YC, and RBK. 
Wilson A, Mclean C.  Kim, RB.  Trimethylamine-N-oxide: a link between the gut 
microbiome, bile acid metabolism and atherosclerosis.  Current Opinion in Lipidology 
2016; 27(2): 148-54. 
AW wrote the paper with assistance from CM and RBK. 
Chapter 3:  
Wilson A, Tirona R, Kim RB. CYP3A4 is markedly lower in patients with Crohn's 
disease.  Inflammatory Bowel Diseases 2017; 23(5); 804-813. 
AW was involved in patient selection and data collection.  AW, RGT, and RBK 
contributed to the research design.  AW and RGT carried out budesonide, midazolam, 
and fexofenadine plasma concentration analysis.  AW performed the statistical analysis 
of the data.  AW wrote the final paper with assistance from RBK.  All authors had full 
access to all the data.  All authors reviewed and approved the final version of this 
manuscript. 
 
 
iv 
 
Chapter 4:  
Wilson A, Urquhart B, Ponich T, Chande N, Gregor JC, Beaton M, Kim RB.  The 
negative effect of Crohn's disease on intestinal first-pass metabolism.  Drug Metabolism 
and Disposition 2018   
AW, BU, TP, NC, JCG, and MB were involved in patient selection and data collection.  
AW and RBK contributed to the research design.  AW performed all immunoblot 
analyses.  AW performed the statistical analysis of the data.  AW wrote the final paper 
with assistance from RBK.  All authors had full access to all the data.  All authors 
reviewed and approved the final version of this manuscript. 
Chapter 5:  
Wilson A, Almousa AA, Jansen LE, Choi Y, Teft WA, Kim RB. Genetic variation in the 
Farnesoid X-Receptor Predicts Crohn’s Disease Severity in Female Patients. 
Gastroenterology 2018 (submitted). 
RBK supervised the study.  AW was involved in data acquisition.  AW, WAT and RBK 
contributed to the study concept and design. AA, LJ and AW carried out all sample 
analyses.  RBK, AW and WAT were involved in data interpretation.  Statistical analyses 
were performed by AW and YC.  AW drafted the manuscript.  Critical revisions were 
carried out by RBK, WAT.  All authors had full access to all the data.  All authors 
reviewed and approved the final version of this manuscript. 
 
  
v 
 
Dedication 
To my husband Jon and my mother Susan.  And mostly gratefully to my children Ava and 
Harry, who inspire me to lead by example. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vi 
 
Acknowledgments  
 I never thought I would be someone who completed a PhD; certainly not a PhD in 
a basic science.  At my first advisory committee meeting, when Dr. Michael Rieder 
suggested I think about making "a go" at a PhD instead of a Master's degree, I felt giddy.  
Not the I'm-so-happy-you-see-how-much-work-I've-done-giddy, but the giddiness of 
having something so seemingly implausible suggested that I could hardly imagine it 
being a reality.  And now, here I am, on the other side of that "feeling": that implausible, 
almost impossible-to-imagine sensation of having completed my PhD thesis.  It's funny to 
say that one of the things I have learned most in this time is that a PhD takes a lot of hard 
work.  And not just on the part of the candidate.  My supervisor, my mentors, my 
colleagues and most importantly my family have worked, contributed and invested in this 
goal right along side of me.  Some in ways that can be seen and are tangible: my 
approach to experiments, the analysis of my data, the description of my findings.  Others 
have contributed in ways, unseen, but deeply felt: the provision of time, the sacrifice of 
time, the listening ear, the helping hand and the wise words.   In the end, beyond the 
results and the conclusions and the many revisions, I am left with a time capsule of the 
last 5 years of my life.  There is something uniquely privileged about being able to reflect 
back on what you’ve done and to say "look what I have learned" and to have it in hard 
copy. I am humbled by this experience. 
 I would like to use this moment to deeply thank my supervisor and mentor, Dr. 
Richard Kim.  He has invested in my growth as a researcher and provided the platform to 
achieve my goals.  His drive for success and to make a difference in the provision of 
health care have shaped my outlook on research and make me truly want to make a 
meaningful contribution to our understanding of inflammatory bowel diseases.  I would 
like to make special mention of my Advisory Committee: Drs. Rommel Tirona, Ute 
Schwarz and Michael Rieder for their insights, feedback and support through this 
process.  To the Richard Kim Personalized Medicine Laboratory members past and 
present, I am wholly grateful.  Wendy Teft, Crystal Schmerk, Cameron Ross, Sara 
Lemay-Gallien, Heidi Liao, Laura Russell, Ahmed Almousa, Cheynne McLean, Markus 
Gulilat, Adrienne Borrie, Michelle Kim, Mandy Li, Laura Jansen, Sarah Woolsey, and 
Michael Knauer have all generously shared their knowledge, time and advice in a way 
that made this an experience to remember.  Through all of my training, I have never had 
such a sense of community, support and friendship.  In particular, I would like to 
recognize Drs. Wendy Teft and Crystal Schmerk, two strong women who have become 
great friends and know much more about  basic and translational science than I and were 
kind enough to make time, on an almost-daily basis, to help me.  Additionally, Dr. Yun-
hee Choi and Rhiannon Rose generously contributed to data analyses for many projects.   
vii 
 
 I owe a big "thank you" to the division members of Western University 
Gastroenterology who have supported me from trainee to clinician to scientist.  In 
particular, to Dr. Jamie Gregor who has been involved in more than a decade of my 
training, who always asks questions I do not know the answer to, and greatly contributed 
to my interest in pursuing research.  In addition, Dr. Alan Thomson is a mentor who 
challenges my thinking and inspires me to ask tough questions about myself, what I want 
and how I'm going to get there.  My colleague, mentor, role model and friend, Dr. 
Melanie Beaton has provided invaluable support over many years.  Whenever I'm 
struggling with what to do or am feeling overwhelmed, I think "What would Melanie 
do?"   
 In addition, I am grateful to my patients and the patients of others who have 
kindly participated in my studies and donated their time. Their generosity is recognized 
and very much appreciated.    
  Lastly, I would like to acknowledge the contribution of my family.  My mother 
Susan has been my ultimate mentor.  She has inspired me by example and has provided 
invaluable guidance.  My husband, Jon, has been an invaluable partner who has lived 
every moment of this experience with me.  His confidence and approach to life have 
motivated me to move outside my comfort zone.  Most of all, I want to recognize my 
children Ava and Harrison.  As I see them learning, I've gained a new appreciation for 
learning.  The transformative thing for me about having children has been the opportunity 
to look at myself in a new light: to see myself as my children see me - as a person of 
great worth, beyond what I have, what I know or who I know.  The work herein and the 
things I have learned are part of what I want to give back to my children: my dedication 
to a goal, my commitment to a cause, and my refusal to sell myself short (even if it's 
something that seems ridiculous, like Aze Wilson completing a basic science PhD). 
~ Aze Wilson, 2018 ~ 
viii 
 
Table of Contents 
Abstract…………………………………………………………………………………..ii 
Co-Authorship 
Statement…………………………………………………………………………………iv 
Dedication………………………………………………………………………………..vi 
Acknowledgements……………………………………………………………………...vii 
List of 
Tables…………………………………………………………………………………….xv 
List of 
Figures………………………………………………………………………………….xvii 
List of 
Appendices………………………………………………………………………………xx 
Abbreviations……………………………………………………………………………xxi 
1 INTRODUCTION………………………………………………………………..1 
1.1 Inflammatory Bowel Disease……………………………………………………...2 
  1.1.1 Intestinal Immunity………………………………………………..4 
  1.1.2 Barrier Function…………………………………………………...5 
  1.1.3 The Intestinal Microbiome and Inflammatory Bowel Disease…....6 
  1.1.4 Other Environmental Factors……………………………………...7 
  1.1.5 The Genetic Landscape of Inflammatory Bowel Disease………....8 
  1.1.6 Clinical Presentation, Diagnosis and Biomarkers………………..10 
  1.1.7 The Therapeutic Landscape……………………………………...13 
  1.1.8 Limitations of Treatment…………………………………...……16 
   1.1.8.1 Adverse Drug Risks……………………………………...17 
   1.1.8.2 Variability of Drug Response……………………………17 
`   1.1.8.3 The Effect of Inflammation on Drug Metabolism…….....18 
ix 
 
 1.2 Cytochrome P450……………………………………………………….19 
  1.2.1 Cytochrome P450 3A4………………………………………….22 
  1.2.2 Regulation of CYP3A4…………………………………………23 
  1.2.3 Role of Age, Sex and Genetics in CYP3A4 Variability………...24 
  1.2.4. Epigenetic Modification of CYP3A4 Expression……………….26 
  1.2.5. The Impact of Disease on CYP3A4………....………....………....27 
  1.2.6. Important Drug-Drug and Food-Drug Interactions and CYP3A4 
  …………………………………………………………………………..28  
  1.2.7. Quantifying CYP3A-Mediated Metabolism In Vivo………..........31 
 1.3 Nuclear Receptors………....………....………....………....……….........33 
  1.3.1 Nuclear Receptors: a Brief Overview………....………...............33 
  1.3.2 Pregnane X Receptor………....………....………....………........36 
  1.3.3 Farnesoid X Receptor………....………....………....……….......37 
  1.3.4 A Role for Bile Acids in Differential Nuclear Receptor Signaling  
   in IBD…………………………………………………………....38 
  1.3.4 Nuclear Receptors and a Role in IBD Pathogenesis……….........39 
   1.3.4.1 The Role of PXR in IBD………....………....………......39 
   1.3.4.2 Genetic variation in PXR and its Influence on IBD….....41 
   1.3.4.3 PXR as a Target for IBD Therapy: Rifaximin Studies In  
   Vivo……………………………………………………..42 
   1.3.4.4 The Role of FXR in IBD………....………....………......43 
   1.3.4.5 Genetic Variation in FXR and its Influence on IBD…....45  
   1.3.4.6 FXR as a Target for IBD Therapy………....………........46 
 1.4 Summary………....………....………....………....………....……….......46 
 1.5 References………....………....………....………....………....………….49 
x 
 
2 HYPOTHESES AND AIMS………....………....…………....………....………72 
 2.1 Hypothesis………....………....…………....………....…………....…….73  
 2.2 Aim 1………....………....…………....………....…………....………….73 
 2.3 Aim 2………....………....…………....………....…………....………….74 
 2.4 Aim 3………....………....…………....………....…………....………….75  
 2.5 References………....………....…………....………....…………....…….76 
 
3 EVALUATION OF CYP3A4 ACTIVITY IN CROHN'S DISEASE 
 ……....………....…………....………....…………....………....…………...........78 
 3.1 Introduction………....………....…………....………....………………...79 
 3.2 Materials and Methods………....………....…………....………....……..82 
  3.2.1 All Subjects………....………....…………....………....…………82 
   3.2.1.1 Subjects Included in the Pharmacokinetic Study ……….82 
   3.2.1.2 Subjects Included in the Cross Sectional Study…………84 
  3.2.2 Clinical Study Objectives and Outcomes..…………...................85 
  3.2.3 Pharmacokinetic Analysis..…………...........................................85 
  3.2.4 Quantification of Midazolam Plasma Concentrations…………..86 
  3.2.5 Quantification of Budesonide Plasma Concentrations………….87 
  3.2.6 Quantification of 4β-hydroxycholesterol Plasma Concentrations 
  …………………………………………………………………………..88 
  3.2.7 Quantification of Bile Acid Plasma Concentrations……………89 
  3.2.8 In vitro CYP3A4 Reporter Activity...………….....………….....90 
  3.2.9 Statistical Analyses..…………......…………....…………...........91 
 3.3 Results..…………......………….....…………......…………...................93 
  3.3.1 Subjects.....………….....…………......…………........................93 
xi 
 
  3.3.2 Pharmacokinetic Assessment……………………………………96 
  3.3.3 Comparison between drugs……………………………………..103 
  3.3.4 4β-hydroxycholesterol Plasma Concentrations Are Decreased in  
   CD……………………………………………………………....106 
 
  3.3.5 Plasma Bile Acid Profiles Differ Between Individuals with and  
   without Crohn's Disease………………………………………...108 
  3.3.6 Activation of PXR by Individual Bile Acids and Cohort-Specific  
   Bile Acid Profiles……………………………………………….114  
 3.4 Discussion………………………………………………………………116 
 3.5 References………………………………………………………………123 
4 EVALUATION OF CYP3A4 EXPRESSION IN CROHN'S DISEASE 
 …………………………………………………………………………………..128 
 4.1 Introduction……………………………………………………………..129 
 4.2 Materials and Methods………………………………………………….132 
  4.2.1 Subjects………………………………………………………....132 
  4.2.2 Study Objectives and Outcomes………………………………..132 
  4.2.3 Tissue Collection…………………………………………….....133 
  4.2.4 Protein Quantification………………………………………….133 
  4.2.5 Statistical Analysis: ……………………………………………134 
 4.3 Results………………………………………………………………….135 
  4.3.1 The effect of disease presence and activity on intestinal CYP3A4  
   protein expression……………………………………………....135 
  4.3.2 The Effect of Age and Sex on Intestinal CYP3A4 Expression 
   ………………………………………………………………….142 
  4.3.3 The Effect of Disease Presence and Activity on Intestinal P-Gp  
   Protein Expression……………………………………………...144 
   
xii 
 
  4.3.4 The Effect of Age and Sex on Intestinal P-gp Expression 
   ………………………………………………………………….148 
 4.4 Discussion……………………………………………………………....150 
 4.5 References……………………………………………………………...154 
5 GENETIC VARIATION IN CYP3A4-REGULATOR FXR PREDICTS 
 SEVERITY OUTCOMES IN CROHN'S DISEASE………………………….158 
 5.1 Introduction…………………………………………………………….159 
 5.2 Materials and Methods………………………………………………....162 
  5.2.1 Subjects………………………………………………………...162 
  5.2.2 Demographic and Covariate Data Abstraction………………...162 
  5.2.3 Genotypic Analysis…………………………………………….163 
  5.2.4 Fibroblast Growth Factor 19 Quantification…………………...164 
  5.2.5 Bile Acid Profile Determination………………………………..164 
  5.2.6 Study Objectives and Outcomes……………………………….165 
  5.2.7 Statistical Analysis……………………………………………...166 
 5.3 Results…………………………………………………………………..168 
  5.3.1 Study Population……………………………………………….168 
  5.3.2 FXR-1G>T Predicts Surgery Risk and Early Progression to  
   Surgery Most Significantly in Women…………………………172 
  5.3.3 Genetic Variation in PXR and MDR1 is not Associated with a  
   Severe CD Phenotype…………………………………………..182 
  5.3.4 FXR-1G>T is a Determinant of FGF19 Plasma Concentrations in  
   Women………………………………………………………….187 
  5.3.5 The Bile Acid Profile is not Significantly Altered in FXR-1GT  
   Carriers………………………………………………………….190 
 5.4 Discussion………………………………………………………………194 
 5.5 References………………………………………………………………198 
xiii 
 
6 DISCUSSION AND CONCLUSIONS……………………………………….203 
6.1 Summary and Discussion……………………………………………….204 
6.1.1 Chapter 3………………………………………………………..207 
6.1.2 Chapter 4………………………………………………………..209 
6.1.3 Chapter 5………………………………………………………..210 
6.2 Implications……………………………………………………………..211 
6.3 Future Directions……………………………………………………….214 
6.4 Conclusions……………………………………………………………..215 
6.5 References………………………………………………………………217 
Appendices……………………………………………………………………………...221 
Curriculum Vitae Aze Suzanne Aliu Wilson…………………………………………...232 
xiv 
List of Tables 
Table 1.1 A comparison of Crohn's disease and ulcerative colitis……………………….3 
Table 1.2 Clinical indices for the evaluation of disease activity in Crohn's disease and 
ulcerative colitis………………………………………………………………………….12 
Table 1.3 Selected CYP3A4 substrates, inducers and inhibitor…………………………30 
Table 3.1 Patient demographics (pharmacokinetic study) ………………………………94 
Table 3.2 Patient demographics (cross sectional study) ………………………………...95 
Table 3.3 Pharmacokinetic parameters in a cohort of Crohn's disease 
patients…………….………………………………..........................................................97 
Table 3.4 Comparison of the pharmacokinetic parameters of oral budesonide in a cohort 
of subjects with Crohn's disease to healthy populations………………………………..101 
Table 3.5 Comparison of the pharmacokinetic parameters of oral and intravenous 
midazolam in a cohort of subjects with Crohn's disease to healthy populations 
……………………….………………………………....................................................102 
Table 3.6 Multiple linear regression model for the effect on Ln-transformed 4βOHC 
plasma concentrations for the total population…………………………………………107 
Table 3.7 Bile acid profiles presented as concentrations by group…………………….109 
Table 3.8 Bile acid profiles presented as a percentage of the total bile acid pool by group 
………………………………………………………………………………………….110 
Table 4.1 Patient Demographics………………………………………………………..136 
Table 4.2 Multiple linear regression model for the effect on relative densities of ileal 
CYP3A4 for the total population……………………………………………………….141 
xv 
 
Table 4.3 Multiple linear regression model for the effect on relative densities of colonic 
CYP3A4 for the total population……………………………………………………….141 
Table 4.4 Multiple linear regression model for the effect on relative densities of ileal P-gp 
for the total population………………………………………………………………….147 
Table 4.5 Multiple linear regression model for the effect on relative densities of colonic 
P-gp for the total population……………………………………………………………147 
Table 5.1 Demographic Characteristics of Patients in Cohort 1 and Cohort 2 
……………………………………………………………………………….…………169 
Table 5.2 Demographic Characteristics of CD Patients Undergoing Surgical Intervention 
by FXR -1G>T Genotype………………………………………………………………170 
Table 5.3 Demographic Characteristics of CD Patients Who Did Not Undergo Surgical 
Intervention by FXR -1G>T Genotype…………………………………………………171 
Table 5.4 Cox regression for the effects of covariates on time to surgical intervention in a 
CD cohort………………………………………………………………………………177 
Table 5.5 Cox regression for the effects of covariates on time to surgical intervention in a 
female CD cohort………………………………………………………………………181 
Table 5.6 Multiple linear regression model for the effect on Ln-transformed FGF-19 
plasma concentration for all subjects…………………………………………………...188 
Table 5.7 Multiple linear regression model for the effect on Ln-transformed FGF-19 
plasma concentration for females………………………………………………………188 
Table 5.8 Bile acid profiles……………………………………………………………..191 
 
 
xvi 
 
List of Figures 
Figure 1.1 Distribution of hepatic and intestinal cytochrome p450 enzymes......………..21 
Figure 1.2 Model of nuclear receptor molecular structure as well as signaling sequence 
…………………………………………………………………………………………...35 
Figure 3.1 Concentration-time curves for oral and intravenous midazolam and 
budesonide in a CD population…………………………………………………………..98 
Figure 3.2 Concentration time curve for budesonide in a CD population stratified by 
subject……………………………………………………………………………………99 
Figure 3.3 Hepatic and intestinal extraction ratios and oral bioavailability of midazolam 
separated by subject.……………………………………………………………………104 
 Figure 3.4 Correlation between budesonide exposure and oral midazolam exposure or 
clearance………………………………………………………………………………..105 
Figure 3.5 The mean 4βOHC plasma concentrations for subjects with active and inactive 
Crohn's disease as well as controls……………………………………………………..107 
Figure 3.6 The ratio of the plasma concentration of conjugated to unconjugated bile acids 
stratified by cohort……………………………………………………………………...112 
Figure 3.7 The mean individual bile acid profiles expressed as mean concentrations in 
ng/ml  and as a percentage of the total bile acid pool, stratified by cohort 
………………………………………………………………………………………….113 
Figure 3.8 Effect of known bile acid PXR agonists and patient-derived bile acid profiles 
on CYP3A4-pGL3 basic reporter activity in HepG2 cells co-transfected with 
hPXR………..…………………………………………………………………………..115 
xvii 
 
Figure 3.9 A comparison of oral budesonide, and oral midazolam  exposure between our 
Crohn's disease population and reported values for healthy populations standardized to 
the same drug dose……………………………………………………………………...118 
Figure 4.1 Intestinal expression of CYP3A4 and P-gp by Western blot for Crohn's disease 
subjects………………………………………………………………………………….137 
Figure 4.2 T Intestinal expression of CYP3A4 and P-gp by Western blot for control 
subjects………………………………………………………………………………….138 
Figure 4.3 The relative protein expression of CYP3A4 to villin in the ileum and 
ascending colon of individuals with and without Crohn's disease……………………...139 
Figure 4.4 The influence of age on the relative densities of ileal and colonic CYP3A4 
protein in control and Crohn's disease populations…………………………………….143 
Figure 4.5 The relative protein expression of P-gp to villin in the ileum and ascending 
colon of individuals with and without Crohn's…………………………………………145 
Figure 4.6 The influence of age on the relative densities of ileal and colonic P-gp protein 
in control and Crohn's disease………………………………………………………….146 
Figure 5.1 FXR-1G>T genotype frequency separated by the presence or absence of an 
intra-abdominal surgical intervention related to the CD 
diagnosis……………………………….……………………………………………….173 
Figure 5.2 Time to first surgery following the diagnosis of CD stratified by FXR-1G>T 
genotype………………………………………………………………………………..175 
Figure 5.3 HR estimates for the evaluation of demographic, medication 
exposures/responses and FXR-1G>T genotype and the impact on time to first surgery 
………………………………………………………………………………………….178 
Figure 5.4 Time to first surgery following the diagnosis of CD stratified by FXR-1G>T 
genotype and female sex……………………………………………………………….180 
xviii 
 
Figure 5.5 Genotype frequency for MDR1 3435C>T and PXR -25385C>T separated by 
the presence or absence of an intra-abdominal surgical intervention related to the CD 
diagnosis………………………………………………………………………………..183 
Figure 5.6 Time to first surgery following the diagnosis of CD stratified by MDR1 
3435C>T  and PXR -25385C>T………………………………………………………..184 
Figure 5.7 Time to first surgery following the diagnosis of CD stratified by MDR1 
3435C>T genotype……………………………………………………………………..185 
Figure 5.8 Time to first surgery following the diagnosis of CD stratified by PXR -
25385C>T genotype……………………………………………………………………186 
Figure 5.9 The mean FGF19 plasma concentrations stratified by FXR-1G>T genotype, 
GG or GT for the total population and for women……………………………………..189 
Figure 5.10 The mean total plasma bile acid concentrations, the ratio of primary to 
secondary mean bile acid concentrations and the ratio of mean unconjugated to 
conjugated bile acids stratified by FXR-1G>T genotype………………..……………..192 
Figure 5.11 The mean individual bile acid profiles expressed as mean concentrations in 
ng/ml and as a percentage of the total bile acid pool, stratified by FXR-1G>T genotype 
………………………………………………………………………………………….193 
Figure 6.1 The proposed effect of Crohn's disease on CYP3A4 drug metabolism…….204 
Figure 6.2 The proposed effect of genetic polymorphism FXR-1G>T on Crohn's disease 
………………………………………………………………………………………….205 
 
 
 
xix 
 
Appendices 
Appendix A: Ethics Approval…………………………………………………………222 
Appendix B: Copyright Approval……………………………………………………..228 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xx 
 
Abbreviations 
ABC  ATP-binding cassette protein 
ADR  Adverse drug reaction 
ANCA  antineutrophil cytoplasmic antibodies 
APC  antigen-presenting cell 
5-ASA  5-aminosalicylates 
ASCA  antibodies against Saccharomyces cerevisiae 
ATG16L1 Autophagy-related protein 16-1 
ASBT  apical sodium-bile acid transporter 
AUC  area under the concentration-time curve 
AZA  azathioprine 
BSEP  bile salt export pump 
CA  cholic acid 
CAR  constitutive androstane receptor 
CARD9 Caspase recruitment domain-containing protein 9 
CD  Crohn's disease 
CDAI  Crohn's disease Activity Index 
CDCA  chenodeoxycholic acid 
CI  confidence interval 
CKD  chronic kidney disease 
xxi 
 
CL/F  oral drug clearance 
CLs  systemic clearance 
Cmax   maximum plasma drug concentration  
CRP  c-reactive protein 
CYP  cytochrome P450 
CYP3A4 cytochrome P450 3A4 
DCA  deoxycholic acid 
DMSO  dimethyl sulfoxide 
DNA  deoxyribonucleic acid 
DSS  dextran sulfate sodium 
E2  estradiol 
E.coli  Escherichia coli 
Egi  gastrointestinal extraction ratio 
Eh   hepatic extraction ratio 
ELISA  enzyme-linked immunosorbent assay 
ER  estrogen receptor 
ESR  erythrocyte sedimentation rate 
F  oral bioavailability 
FCGR2A Fc Gamma Receptor 2A 
FGF  fibroblast growth factor 
xxii 
 
FMO  FAD-containing mono-oxygenase 
FXR  farnesoid X receptor 
GCA  glycocholic acid 
GCDCA glycochenodeoxycholic acid 
GDCA  glycodeoxycholic acid 
GI  gastrointestinal 
GST  glutathione-S-transferase 
HBI  Harvey-Bradshaw Index 
6βHC  6β-hydroxycortisol  
HepG2  hepatocarcinomaG2 
HLA  human leukocyte antigen 
HNF  hepatocyte nuclear receptor 
HR  hazard ratio 
IBD  inflammatory bowel disease 
IL  interleukin 
INF- γ  interferon- γ 
iNOS  inducible nitric oxide synthase  
IV  intravenous 
ke   terminal elimination rate constant  
LC-MS/MS liquid chromatography-tandem mass spectrometry 
xxiii 
 
LCA  lithocholic acid 
LHSC  London Health Sciences Centre 
Ln  natural log 
LXR  liver X receptor 
MAdCAM-1 mucosal addressin cell adhesion molecule-1 
MAO  monoamine oxidase 
Mcp  macrophage attractant protein 
MDR1  multi-drug resistance protein 1 
miRNA microRNA 
MRP  multidrug resistance protein 
mRNA  messenger ribonucleic acid 
NAFLD non-alcoholic fatty liver disease 
NFκB   nuclear factor κB 
NOD2  Nucleotide-binding oligomerization domain-containing protein 2 
NR  nuclear receptor 
ns  non-significant 
NTCP  sodium-taurocholate co-transporting polypeptide 
NUDT  Nudix hydroxylase 
OATP  organic anion transport polypeptide 
OCP  oral contraception 
xxiv 
 
4β-OHC  4β-hydroxycholesterol  
OR  odds ratio 
OST  organic solute trasporter 
PFIC  progressive familial intrahepatic cholestasis 
P-gp  P-glycoprotein 
Pk  pharmacokinetic 
PO  oral 
PPARα peroxisome proliferator-activated receptor 
PXR  pregnane X receptor 
Qh, blood  hepatic blood flow 
Qh, plasma  hepatic plasma flow 
R  Spearman correlation coefficient 
RXR  retinoid X receptor 
SHP  small heterodimer  
SNP  single nucleotide polymorphism 
std  standard deviation 
SULT  sulfotransferase 
TCA  taurocholic acid 
TCDCA taurochenodeoxycholic acid 
TDCA  taurocholic acid 
xxv 
 
TLCA  taurolithocholic acid 
TUDCA tauroursodeoxycholic acid 
tmax   time to the maximum plasma drug concentration  
TNBS  trinitrobenzenesulfonic acid 
TNF-α  tumor necrosis factor-α 
TPMT  thiopurine S-methyltransferase 
t1/2  half-life 
UC  ulcerative colitis 
UDCA  ursodeoxycholic acid 
UGT  UDP-glucuronosyltransferases 
UTR  untranslated region 
VDR  vitamin D receptor 
 
xxvi 
 
1 
 
 1 INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
Portions of this chapter have been published.  They are reprinted with permission from:  
1. Wilson A, McLean C, Kim RB. Trimethylamine-N-oxide: a link between the gut microbiome, bile 
acid metabolism, and atherosclerosis. Curr Opin Lipidol. 2016 Apr; 27(2):148-54 
2. Wilson A, Teft WA, Morse BL, Choi YH, Woolsey S, DeGorter MK, Hegele RA, Tirona 
RG, Kim RB. Trimethylamine-N-oxide: A Novel Biomarker for 
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1.1 Inflammatory bowel disease  
 Inflammatory bowel disease (IBD) is an illness of chronic intestinal inflammation 
that follows a remitting and relapsing course.  It is comprised of two distinct entities: 
Crohn's disease (CD) and ulcerative colitis (UC).  Classically, CD involves the full 
thickness of the bowel wall and follows a discontinuous path along the gut's full length 
from mouth to anus.  UC is characterized by continuous and superficial mucosal 
inflammation confined to the colon and rectum (Table 1.1).  The pathogenesis of IBD has 
not been fully elucidated.  The most widely held hypothesis suggests that there is an 
overly aggressive immune response to luminal microbial antigens and other adjuvants 
that occurs in genetically susceptible individuals facilitated by certain environmental 
factors 1. 
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Table 1.1: A comparison of Crohn's disease and  ulcerative colitis (adapted from 
Sleisenger & Fordtran's Gastrointestinal and Liver Disease 10th Edition)1 
Feature Crohn's Disease Ulcerative colitis 
Age of onset (years) 15-30 15-30 
Pattern of disease Small intestine, large 
intestine, rarely stomach 
Large intestine 
Inflammatory lesion Skip lesions/ulcers; 
cobble-stoning 
Continuous erythema 
and friability 
Depth of injury Transmural Mucosal 
Presence of diarrhea Common Common 
Presence of 
hematochezia 
Less frequent Frequent 
Presence of 
abdominal pain 
Mild to severe Mild to severe 
Complications Fistulae, abscesses, 
strictures 
Hemorrhage, toxic 
megacolon 
Extra-intestinal 
manifestations 
Anemia, ankylosing 
spondylitis, pyoderma 
gangrenosum, 
cholelithiasis, vitamin 
deficiency 
Anemia, ankylosing 
spondylitis, pyoderma 
gangrenosum , primary 
sclerosing cholangitis 
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1.1.1 Intestinal Immunity 
 The intestinal immune system is complex.  Firstly, it consists of the innate 
immune system that offers an initial rapid response to foreign antigen via immune cells 
bearing pattern-recognition receptors.  Secondly, there is the adaptive immune system 
that provides "immunologic memory" via antigen-specific recognition2.  The intestinal 
epithelium acts as another layer of defense.  It is a physical barrier between foreign and 
host microbiota and the lymphoid tissue of the gut and host circulation, preventing 
continuous stimulation of the mucosal immune system 3.  Under normal conditions, the 
lamina propria beneath the intestinal epithelium hosts a complex network of immune 
cells.  These cells preserve the balance between the need for immune tolerance of luminal 
microbiota with the need to defend against foreign pathogens and the disproportionate 
entry of microbiota1, 2.  In a healthy individual, tight junctions seal the spaces between 
adjacent epithelial cells, while interspersed goblet cells and paneth cells provide mucous 
and antimicrobial proteins, giving additional defense 4.  In IBD, disruption of the mucus 
layer, loss of epithelial tight junctions and increased intestinal permeability all serve to 
increase the intestinal immune system's exposure to bacteria allowing the dissemination 
of an immune response via its innate and adaptive arms 5-7.  There is also a shift in 
production from anti-inflammatory proteins to pro-inflammatory cytokines.  Activation 
of the nuclear transcription factor nuclear factor κB (NFκB) plays a role in this shift 8. 
 NFκB refers to a family of nuclear transcription factors consisting of p65, c-Rel, 
RelB, p50 and p52 that activate the transcription of target genes.  In the unstimulated cell, 
NFκB proteins remain within the cell's cytoplasm.  Activation of NFκB proteins leads to 
their release from bound inhibitors and translocation to the nucleus to exert a regulatory 
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effect.  Regulation of NFkB activity occurs via two pathways: one mediated by the 
inhibitor IκBα/β/ε, which aids in the retention of NFκB proteins within the cytoplasm, 
and the other mediated by the activating kinases IKKα/β, which when stimulated by 
specific cytokines led to the degradation of co-repressors and the activation of NFκB 
proteins 9.  Genes regulated by NFκB include: 1) inflammatory and immunoregulatory 
genes 2) cell cycle regulating genes 3) anti-apoptotic genes 4) negative regulators of 
NFκB.  Activation of NFκB can be mediated via bacterial wall products such as 
lipopolysaccharides as well as interleukin (IL)-1, tumor necrosis factor (TNF)-α and 
some viruses.  NFκB activity has been observed in the mononuclear cells (macrophages 
and lymphocytes) of the lamina propria as well as in the epithelial cells of the inflamed 
gut.  A key function of the NFκB pathway is the up-regulation of pro-inflammatory 
cytokines including, TNF-α, IL-1, IL-6, IL-12, IL-23, and inducible nitric oxide synthase 
(iNOS), all important in the dissemination of the immune response10.  Unchecked NFκB 
activity is a key component of the dysregulated inflammatory response seen in IBD11-14.  
IBD medications such as prednisone, methotrexate and anti-TNF-α exert their effects 
partly by targeting the NFκB pathway. 
 
1.1.2 Barrier Function 
 Defects in the epithelial barrier are well-documented in UC and CD 7, 15, 16. 
Intestinal permeability is regulated by changes in the cell cytoskeleton and tight 
junctions17.  A number of factors likely play a role in epithelial barrier dysfunction.  
Inflammatory cytokines such as TNFα, interferon (INF)-γ and IL-13 are involved in the 
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initiation and perpetuation of the dysregulated immune response in IBD 2.  These 
cytokines have also been implicated in the disruption of the epithelial barrier function 3.  
This provides a plausible reason as to why inflammatory cytokines have been the target 
of pharmacological therapy in IBD.   
 
1.1.3 The Intestinal Microbiome and Inflammatory Bowel Disease 
 In the healthy individual, the composition of the gastrointestinal (GI) microbiome 
is unique and consists of hundreds to thousands of species of bacteria, the majority of 
which can be categorized into four phyla: Firmicutes, Bacteroidetes, Proteobacteria, and 
Actinobacteria18-22.  Gut bacteria are closely intertwined with many human biological 
processes and modulate the processing of many nutrients and drugs, including lipids and 
amino acids23.  Factors such as age and diet are known to influence the composition of 
the gut microbiome24.  For example, a study by Wu et.al. (2011) showed that long-term 
diet was strongly associated with the composition of the gut microbiota, while 
Yatsunenko et.al. (2012) convincingly demonstrated a similar association with age25, 26. 
Disease state has also been linked to alterations in the bacterial composition of the gut.  
Multiple studies demonstrate that diversity in the intestinal microbiota is reduced in IBD 
compared to non-IBD controls27, 28.  There is loss of members of multiple genera 
including Bacteroides species, Clostridia species, Eubacterium species, and 
Lactobacillus species29, 30.  Moreover, microbiota varies with disease activity and 
distribution 31, 32.  Willing et.al. (2010)32 showed that the microbiota in inactive CD was 
different than that of non-IBD controls, while there was little difference between the 
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microbiota in inactive UC in comparison to non-IBD controls.  Whether this loss of 
diversity is a consequence or a precipitator of disease is unknown.  It is speculated by 
some that alterations in the gut microbial profile play a role in the pathogenesis and 
phenotype of IBD33.  This is supported by the increased detection of invasive Escherichia 
(E.) coli in inflamed ileal samples from patients with active CD34, 35.   Other pathogens 
have been associated with disease-onset; however, no causal link has been clearly 
identified33.  Additional evidence supporting the IBD-gut bacteria hypothesis is the 
modest benefit seen with the use of antibiotics, such as ciprofloxacin and metronidazole 
in CD colitis36.  Furthermore, many of the genetic defects associated with IBD are found 
in genes such as NOD2 and ATG16L1 which are important for innate immunity and the 
ability to sense and clear intracellular bacteria33.  Lastly, many strains of genetically-
susceptible mice predisposed to the development of a spontaneous immune-mediated 
colitis, such as the multi-drug resistance protein (MDR)-1 or IL-10 knock out murine 
models, fail to develop such colitis when maintained under germ-free conditions37, 38.   
 
1.1.4 Other Environmental Factors 
 In addition to the influence of the gut microbiome, other factors within the 
environment likely influence an individual's susceptibility to IBD.  Cigarette smoking is 
repeatedly shown to be protective against the development of UC, but conversely 
increases the risk of CD in Western populations39, 40.  In Western countries, childhood 
antibiotic exposure increases the risk of both UC and CD, while breastfeeding appears to 
be protective39.  In two large administrative database studies, oral contraceptives were 
8 
 
shown to increase the risk and severity of CD41, 42.  Similarly, low plasma concentrations 
of vitamin D increases CD risk, while appendectomy is protective against the 
development of UC43, 44.  The mechanisms by which these factors impact disease 
susceptibility are not well-defined. 
 Another important consideration is the influence of diet.  There is a rising 
incidence of CD and UC in nations not previously affected by IBD.  This may be 
attributable to improvements in health care technologies and accessibility; however, it has 
been hypothesized that the "westernization" of food products has contributed to this 
epidemiologic shift.  In a review by Kaplan and Ng (2017), it is discussed that "The 
increasing incidence of IBD in Europe and the United States since the 1950s, and in Asia 
in the early 1990s, coincided with the introduction and promotion of packaged food and 
fast food chains, as well as increased use of antibiotics in human beings and livestock."45  
In North America, there has been an expansion in the production of specialty starches and 
high fructose corn syrup.  This has necessitated the development of additives and novel 
methods for processing these products to ensure their shelf-life.  Interestingly, this has 
coincided with significant increases in CD and UC cases46.  In support of this, murine 
models have linked dietary additives such as sweeteners and emulsifiers to the 
development of intestinal inflammation47, 48. 
 
1.1.5 The Genetic Landscape of Inflammatory Bowel Disease 
 IBD is a polygenic disease: 241 risk loci within the human genome are associated 
with its onset49.  These associations tend to be weak, with odds ratios less than 2 and 
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explain only a small portion of an individual's risk for developing the disease50.  This is 
somewhat discordant with the high rates of heritability amongst individuals with affected 
family members as well as what has been reported in studies of monozygotic twins51.   
 Variation in the NOD2 gene was the first and most consistently replicated 
susceptibility locus in CD49, 52-54.  NOD2 codes for the nucleotide oligomerization domain 
2 (NOD2) protein, an intracellular protein found in epithelial cells, paneth cells, dendritic 
cells, and endothelial cells as well as macrophages55.  NOD2 contains a leucine-rich 
repeat region that acts as a receptor for bacterial muramyl dipeptide and allows the 
intracellular detection of bacteria by the innate immune system and the activation of the 
NFκB pathway56.  Three single nucleotide polymorphism (SNP)s within the leucine-rich 
receptor have been documented as conferring an increased risk of CD as high as two-fold 
in heterozygous carriers and twenty-fold in homozygous carriers49.  Interestingly, despite 
these findings, the role of NOD2 in IBD pathogenesis is unclear.  Thirty percent of 
individuals of Caucasian ancestry carry one of the risk SNPs and the majority do not 
develop CD.   Moreover, NOD2 deficient mice do not develop a spontaneous colitis, 
despite increased presence of intestinal bacteria57.  Taken together, it would appear that 
defects in NOD2 are insufficient to cause CD.   
 Other risk loci associated with the onset of IBD include genes implicated in innate 
immune pathways such as CARD9, FCGR2A, and ATG16L158.  Genetic variation in 
various aspects of the adaptive immune system including SNPs in IL10 (T-cell tolerance) 
and IL23R (T-cell differentiation) also contribute to the genetic landscape of IBD and 
confer an increased risk of disease susceptibility58.  
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 The predictive value of genetics in IBD has also become of interest as a tool for 
determining a patient's response to their IBD medications, for example, azathioprine 
(AZA).  Variation in the TPMT gene, a determinant of AZA metabolism and 
bioavailability is associated with an increased risk of AZA-induced myelotoxicity.  
Individuals homozygous for a reduced function variant have preferential formation of 6-
thioguanine which can result in life-threatening bone marrow suppression 59.   The utility 
of pre-emptive TPMT genotyping is widely accepted.  Canadian, American and British 
Gastroenterology Society guidelines, all advocate for pre-emptive TPMT genotyping 
prior to the introduction of thiopurine-based therapies in IBD 60-63.  Variation in other 
genes such as HLA-DQA1 and HLA-DRB1 as well as NUDT15 are associated with an 
increased risk of AZA-induced pancreatitis (homozygous variant carriers, odds ratio 
15.83) and myelotoxicity (homozygous variant carriers, odds ratio 16.2) respectively64-67.  
These data highlight the role of genetic variation in IBD pathogenesis as well as in drug 
response. 
 
1.1.6 Clinical Presentation, Diagnosis and Biomarkers 
 The clinical manifestations of CD and UC are largely determined by the intestinal 
distribution of the disease.  Early in the disease course, both conditions are remitting and 
relapsing, with periods of activity punctuated by debilitating symptoms of abdominal 
pain, diarrhea with or without hematochezia, and weight loss as well as biochemical and 
endoscopic findings of inflammation.  Patients may also develop extra-intestinal 
manifestations of IBD such as inflammatory arthropathy, dermatological or ocular 
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abnormalities or disorders of the hepatopancreatobiliary system.  This can affect 
approximately 25-40% of patients68-70.  As the disease progresses over time, permanent 
damage to the intestinal structure may result, leading to an irreversible impairment of 
intestinal function, significant morbidity and long-term disability.  Disease severity is 
marked by the need for and time to surgery, failure of multiple medical therapies, need 
for hospitalization and the presence of complications such as fistulae or strictures 71, 72.   
The need for surgical intervention is relatively common amongst individuals affected by 
CD.  A recent systematic review and meta-analysis highlighted that the risk of surgery 1, 
5, and 10 years after a diagnosis of CD is 16.3% (95% CI,11.4%–23.2%), 33.3% (95% 
CI, 26.3%–42.1%), and 46.6% (95% CI, 37.7%–57.7%), respectively73.  The risk of 
surgery 1, 5, and 10 years after a diagnosis of UC is 4.9% (95% CI, 3.8%–6.3%), 11.6% 
(95% CI, 9.3%–14.4%), and 15.6% (95% CI, 12.5%–19.6%), respectively73. 
 Endoscopic depiction of mucosal inflammation by ileocolonoscopy is the gold 
standard test for diagnosis of CD in combination with histological evidence of chronicity.  
Similarly, endoscopic re-evaluation of the colon including the terminal ileum is needed to 
assess drug response.  Clinical and endoscopic scoring systems such as the Harvey-
Bradshaw Index, the Crohn's Disease Activity Index, or the Simple Endoscopic Score for 
CD are used to evaluate CD activity to allow clinicians to appropriately titrate 
treatment74-76 (Table 1.2).   More recently, deep remission defined as histological 
mucosal healing, has become the coveted endpoint for clinical trials and real-world 
practice77, 78. 
 
12 
 
 
Table 1.2: Clinical indices for the evaluation of disease activity in Crohn's disease  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Crohn's 
disease 
 
 
The simple 
endoscopic score 
for Crohn's 
disease 
Size of ulcer 0-3 
Ulcerated surface 0-3 
Affected surface 0-3 
Presence of narrowings 0-3 
Daperno et.al. 
Gastrointestinal 
Endoscopy 2004 
 
 
 
 
 
 
Crohn's disease 
activity index* 
Number of liquid stools 
Abdominal pain 0-3 
General well-being 0-4 
Presence of complications 
Taking lomotil 
Presence of an abdominal mass 0-5 
Hematocrit <0.42 women; <0.47 
men 
% deviation from standard weight 
Best et.al. 
Gastroenterology 
1976 
 
 
 
 
Harvey-Bradshaw 
Index 
Number of liquid stools 
Abdominal pain 0-3 
General well-being 0-4 
Presence of complications 
Presence of an abdominal mass 0-5 
Bradshaw Lancet 
1980 
*An additional weighting factor is applied to each variable to determine the final score 
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Ileocolonoscopy is an invasive, and sometimes arduous test that may be associated with 
complications such as bleeding, perforation and rarely death79.   Given this, biomarkers of 
disease may also aid clinicians in the diagnosis and quantification of disease as well as in 
predicting the risk for complications.  Such biomarkers include, but are not limited, to C-
reactive protein (CRP), erythrocyte sedimentation rate (ESR), fecal leukocyte markers 
(fecal calprotectin) and antibodies against Saccharomyces cerevisiae (ASCA) and 
perinuclear antineutrophil cytoplasmic proteins (ANCA)80-83.  Unfortunately, these 
biomarkers are not without their own respective limitations: CRP and ESR often lack 
specificity for intestinal inflammation, while fecal calprotectin and serologic antibodies 
lack accessibility through non-tertiary and quaternary care centres and whose diagnostic 
accuracy may be confounded by other factors80, 81.   Therefore, the role of biomarkers in 
clinical practice has not been consistently defined. 
 
1.1.7 The Therapeutic Landscape 
 CD and UC are largely incurable.  Affected individuals are often committed to 
long-term drug therapy with immunosuppressive agents.   Current treatments include the 
monoclonal antibodies known as biologics.  These drugs target various proteins involved 
in the dissemination of the inflammatory response, such as TNF-α, a variety of 
interleukins (IL-12, IL-23) and gut integrin complexes.  Other treatments include 
immunosuppressants, such as methotrexate and AZA, and anti-inflammatories such as the 
5-aminosalicylate (5-ASA) compounds and glucocorticoids, (prednisone or budesonide) 
84, 85.  Despite their different immune targets, these therapies all focus on suppressing the 
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host intestinal immune response and serve to dampen the effect of inflammatory proteins 
(IL-6, IL-1, TNF-α, IFN-γ) released by effector cells (cytotoxic and helper T cells) on the 
intestinal mucosa. 
 The 5-ASA agents are largely ineffective in CD and are used predominantly for 
the management of UC.  A systematic review evaluating the efficacy of oral 5-ASA for 
the maintenance of remission in CD found no evidence that 5-ASA agents were superior 
to placebo86.  It is hypothesized that the effect of the 5-ASA agents is limited to the 
mucosal surface of the intestine and are unlikely to benefit a trans-mural disease such as 
CD.  5-ASA compounds are metabolized by the ubiquitously expressed-N-
acetyltransferase (NAT) 187, 88.  They are also metabolized by NAT2,  though its 
intestinal expression is far less than what is seen in the liver. 5-ASAs are poorly absorbed 
and are largely excreted in the stool.  Their mechanism of action is poorly described.   
 Glucocorticoid agents such as prednisone and budesonide are highly effective for 
the induction of remission in CD, though the original evidence for glucocorticoids in IBD 
was derived from a UC cohort89-91.  The utility of these drugs in CD are highlighted by 
their frequent and pervasive use: by their 10th anniversary of disease, more than two 
thirds of patients will have been exposed to a glucocorticoid, with more than 20% 
receiving greater than 3000mg within their first 5 years of diagnosis92.  Glucocorticoids 
diminish the inflammatory response via several pathways: they suppress the cytokine-
mediated activation of T-cells, and antigen-presenting cells (APCs) including 
macrophages; they stabilize the liposomal membrane of neutrophils and  prevent the 
release of catabolic enzymes; they inhibit phospholipase A2 and decrease the release of 
histamine, prostaglandins, leukotrienes and other pro-inflammatory chemicals; and they 
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promote vasoconstriction and reduce capillary permeability93.  Both budesonide and 
prednisone are rapidly metabolized by cytochrome P450 (CYP) 3A494-96.  CYP3A4 
converts prednisone to its active metabolite, prednisolone.  Prednisone has a significant 
systemic anti-inflammatory effect97.  Conversely, budesonide undergoes substantial first-
pass metabolism mediated by hepatic and intestinal CYP3A498.  Budesonide, thus, has a 
greater local anti-inflammatory effect at the intestinal level compared to its systemic 
effect.   
 In the event that patients require prolonged or recurrent glucocorticoid exposure, 
clinicians have the opportunity to transition patients to one of two immunomodulators, 
AZA or methotrexate.  AZA antagonizes purine metabolism and inhibits DNA synthesis.  
It has a limited benefit for the maintenance of remission in CD as well as a modest 
steroid-sparing effect99, 100.  Similarly, methotrexate, a competitive inhibitor of 
dihydrofolate reductase, is effective for the maintenance of remission in CD and is used 
as a means for withdrawing patients from glucocorticoids101,102.   
 Lastly, the monoclonal antibodies known as biologics have revolutionized the 
management of CD and UC.  Biologics impair the function of the target molecule by 
inducing apoptosis of the target-expressing cell or by modulating the signaling pathway.  
In Canada, there are currently four biologic agents approved for the management of CD: 
infliximab, adalimumab, vedolizumab and ustekinumab. 
 Infliximab, the first biologic to be approved for the management of CD in 
Canada, is a chimeric human-murine monoclonal antibody directed against the pro-
inflammatory cytokine, TNF-α.  The efficacy of infliximab in CD was demonstrated in 
two landmark trials known as ACCENT 1 and ACCENT 2103, 104.  Its sister drug, 
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adalimumab, is a humanized monoclonal directed against TNF-α that is delivered via 
subcutaneous route.  The CHARM trial highlighted the benefit of long-term treatment 
with adalimumab in CD patients who responded to loading doses105.  Newer agents 
vedolizumab and ustekinumab target alternate pathways in CD.  Vedolizumab binds to 
the α4β7 integrin expressed on T-lymphocytes and inhibits their interaction with the 
mucosal addressin cell adhesion molecule-1 (MAdCAM-1) on endothelial cells within 
the gut, ultimately, preventing the trafficking of lymphocytes to the intestinal tissues106.  
The GEMINI 2 randomized-controlled studies were the basis of approval for 
vedolizumab in CD107.  The Health Canada approval of ustekinumab for CD is based on 
three pivotal studies (UNITI-1, UNITI-2 and IM-UNITI)108, 109.  These studies included 
more than 1,300 CD patients who were either new to, experienced with, or failed biologic 
therapy. Ustekinumab targets and binds the shared p40 subunit of interleukin-12 and 
interleukin-23, two pro-inflammatory cytokines produced by APCs involved in 
perpetuating the inflammatory response and suppressing regulatory T-cells110. 
 Of note, the metabolism of the biologics is very different from the processes 
applied to small molecule drugs.  Small molecules such as the glucocorticoids or 
immunomodulators are typically eliminated by hepatic metabolism or renal or biliary 
excretion.  As monoclonal antibodies, the biologics are captured from the vascular space 
by endocytosis and subjected to proteolysis within the lysosome or salvaged by the 
neonatal Fc receptor (to which they owe their long half-life)111. 
 
1.1.8 Limitations of Treatment 
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 Overall, CD patients are exposed to a heavy burden of medications over the 
course of their disease.  Inter-individual responses to commonly used IBD medications 
vary significantly and rates of resistance, loss of response, and adverse drug reaction 
(ADR) remain high, despite a long history of use 101-103, 112, 113. 
 
1.1.8.1 Adverse Drug Risks 
 The glucocorticoids, immunomodulators and biologics are associated with a 
number of adverse drug risks that in some cases are distinct and in others, overlapping.  
The glucocorticoids are associated with defects in bone metabolism as well as can 
negatively affect the cardiovascular, endocrine, psychiatric and immunologic systems114.  
The immunomodulators like AZA are associated with hepato- and myelotoxicity, an 
increased risk of malignancy, infection and malaise61, 115.  The biologics may carry an 
increased risk of malignancy and infection as well as neurologic impairment and 
worsening of any underlying cardiovascular disease116, 117.   
 
1.1.8.2 Variability of Drug Response 
 Currently, there is a lack of predictably to drug response in CD.  As an example, 
the corticosteroids have been used in the management of CD and UC for more than 70 
years118.  Data derived from Olmstead County administrative databases revealed that 
within 30 days of treatment with a corticosteroid, 60% of CD patients will have a 
complete response to therapy, while 25% will have only a partial response and 15% will 
have no response118.  Similarly, in clinical trials, we see that rates of non-response are as 
high as 30% and 50% for budesonide and prednisone respectively91, 119.  Many groups 
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have attempted to uncover predictors of glucocorticoid response, but no predictor has 
made it to large-scale clinical practice120, 121.   
 Likewise, response rates to biologic agents vary significantly between patients.  
Ben-Horin et.al. (2014) summarized rates of biologic resistance seen in clinical trials as 
well as what was reported in select "real-world" case series.  The authors found that 
approximately 40% of clinical trial subjects and 20% of "real-world" patients were 
resistant to the effects of infliximab or adalimumab122.  In a recent editorial by Jean-
Francois Colombel, an international expert in IBD management, the author identified the 
crux of the IBD therapeutic paradigm: "One of the biggest challenges we are now facing 
[in the management of IBD] is the search for biomarkers predicting efficacy or failure of 
biologics and small molecule drugs in the hope of personalized therapy."  The lack of 
predictability in drug response suggests a fundamental gap in our knowledge on how IBD 
impacts drug metabolism and exposure to large and small molecule drugs.  Gaining new 
insight into CD-specific modifications of drug metabolism and response may allow for 
improved drug efficacy and reduced drug toxicity as well a better understanding of 
disease pathogenesis. 
 
1.1.8.3 The Effect of Inflammation on Drug Metabolism 
 The effect of inflammation on the CYP enzymes is well-established.  In vitro 
studies, in vivo murine models and pharmacokinetic analysis in human subjects in an 
acute inflammatory state demonstrate that the expression and activity of CYP enzymes 
are down-regulated123.  Mechanisms of down-regulation have been suggested including 
inflammation-induced oxidative stress, the effect of inflammatory cytokines (TNF-α, IL-
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1, IL-6) or changes in the activation of NRs such as PXR123.  This has not been studied in 
any significant way in the setting of IBD or specifically in CD.  One small study 
conducted by Sanaee et.al. (2011) evaluated the impact of CD on a patient's systemic 
exposure to the CYP3A4 substrate verapamil.  The authors reported higher verapamil 
plasma concentrations in the CD cohort versus healthy controls.  Plasma concentrations 
increased with increasing disease activity124.  This suggests a dampening effect of CD on 
CYP3A4 activity and emphasizes the paucity of available data pertaining to CD-related 
changes in drug metabolism.  
 
1.2 Cytochrome P450  
 Drug metabolism is often divided into three phases: phase 1 metabolism 
characterized by reactions such as oxidation, reduction or hydrolysis that increase the 
hydrophilicity of a compound; phase 2 metabolism characterized by conjugation 
reactions that prepare compounds for excretion; and phase 3, where the products of phase 
1 or 2 metabolism are recognized by membrane-bound transporters and are transported to 
the extracellular space125.  The reactions that make up phase 1 drug metabolism are 
catalyzed by a number of enzymes including, but not limited to, the following enzyme 
families: CYP, monoamine oxidase (MAO) and FAD-containing mono-oxygenase 
(FMO)125.   
 The CYP superfamily is one of the most relevant determinants of drug 
metabolism in humans and is responsible for the metabolism and activation of a vast 
number of xenobiotics, including many of the drugs used today126. CYP enzymes are 
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hemoproteins that are able to reversibly catalyze oxidation and reduction reactions using 
their heme group through the transfer of electrons127.   The CYP enzymes are sub-
classified into families (1, 2, 3 and 4), sub-families and isoforms on the basis of their 
shared amino acid structures.  In addition to variations in their amino acid sequences, 
CYP isoforms vary with respect to their catalytic activity and tissue localization126, 127.  
CYP isoforms found in the hepatic parynchema are likely the most important enzymes 
for determining the disposition of drugs used in clinical practice today126 (Figure 1.1a). 
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Figure 1.1a Relative hepatic abundance of the cytochrome P450 enzymes (adapted from Xie et.al. 2009 
Chapter 1, pg 4)125   
 
Figure 1.1b Relative intestinal abundance of the cytochrome P450 enzymes (adapted from Paine et.al. 
2006)128 
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1.2.1. Cytochrome P450 3A 
 The CYP3A subfamily is a key mediator of drug metabolism and disposition in 
humans129.  Overall, its isoforms are highly concentrated in organs essential to first-pass 
metabolism such as the liver and the intestinal tract and act as a barrier to the systemic 
exposure of its orally-ingested substrates130.  CYP3A accounts for 28% and 80% of the 
human hepatic and intestinal CYP content respectively (Figure 1.1a, 1.1b) 125, 128.  Three 
functional enzymes have been indentified: CYP3A4, CYP3A5 and CYP3A7.   CYP3A4 
is the most abundant and comprehensively investigated of the CYP3A isoforms 131.  It is 
responsible for the metabolism of more than 50% of the drugs that are used in clinical 
practice 132.  It is also important for the inactivation of pollutants and environmental 
chemicals known as xenobiotics as well as the metabolism of endogenous substances 
such as steroids, sterols, fatty acids and bile acids132.  CYP3A4 is localized to the liver, 
intestinal tract and kidneys, with the highest expression in the liver 131.  In the liver, 
CYP3A4 is localized to the hepatocyte and biliary epithelium, while in the intestinal 
tract, CYP3A4 is found at the villous tip of individual enterocytes with the highest 
expression in the jejunum and ileum131, 133-135.  CYP3A5 is similarly distributed, but to a 
lesser degree.  Many of the CYP3A4 substrates are shared substrates of CYP3A5 due to 
their similar amino acid sequences (>85% shared)136.  It is often impossible to distinguish 
between the contributions of either enzyme to a specific substrate's disposition.  CYP3A7 
is present only in the fetal liver and plays a minimal role in drug metabolism125. 
 The expression of CYP3A4 is highly variable.  It is inducible by a wide selection 
of compounds including drugs and endogenous substances; however, its inter-individual 
variability may also be independent of inducers.  Studies by Rogers et.al. (2003)137 and  
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Floyd et.al. (2003)138 have found up to a 10-fold variation in inter-individual clearance of 
CYP3A substrates in healthy subjects, while other groups cite variation as high as 20-
fold139.  Different factors influence CYP3A4 expression to a varying degree.  This 
includes inducers and inhibitors such as a wide selection of drugs and endogenous 
compounds.  Signaling pathways, in particular the nuclear receptor superfamily136, 140, 141 
as well as sex, age, disease states and the presence or absence of inflammation are also 
important for determining its activity142. 
 
1.2.2. Regulation of CYP3A4 
 Complex signaling pathways mediated by nuclear receptors (NR) and other 
transcription factors appear to play an important role in the regulation of CYP3A4.  
Constitutive transcriptional regulation is mediated through CCAAT-enhancer binding 
proteins-α and - β,  hepatocyte nuclear receptor (HNF)-1α, -3γ, and -4α143 while inducible 
transcriptional regulation is mediated through ligand-induced activation of the pregnane 
X receptor (PXR), the constitutive androstane receptor (CAR), the farnesoid X receptor 
(FXR)144, the liver X receptor (LXR), the vitamin D receptor (VDR) and the peroxisome 
proliferator-activated receptor, (PPARα)136.  Specifically, in the case of PXR and CAR, 
the ligand-activated nuclear receptors migrate to the nucleus, bind to response elements 
on CYP3A4 and increase mRNA transcription significantly145. 
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1.2.3 Role of Age, Sex and Genetics in CYP3A4 Variability 
 The role of age as a contributor to CYP3A4 variability is controversial.  Several 
animal studies have described an age-dependent effect on CYP expression146.  The 
evidence for a similar effect in humans is less clear and studies have been contradictory.  
One study by Sotaniemi et.al. (1996) showed that the metabolism of the CYP3A4-probe 
drug, lignocaine was significantly less in individuals older than 65 years of age compared 
to a healthy young cohort (ages less than 25 years)147; however, other groups have not 
been able to demonstrate a similar finding using other modalities for assessing CYP3A4 
activity such as the C14 erythromycin breath test148.  Furthermore, age-related declines in 
hepatic CYP3A4 content are not consistently shown149, 150. 
 Sex appears to be a determinant of CYP3A4 expression.  Wolbold et.al. (2003) 
published an analysis in 94 surgical liver samples, evaluating the CYP3A4 content as 
well as the expression of P-gp, PXR and CAR.  Higher CYP3A4 expression was seen in 
the women compared to the men, with a 50% increase in the CYP3A-mediated 
metabolism of verapamil151.  This has been supported by other human studies using 
endogenous probes of CYP3A4 activity as well as in studies evaluating the 
pharmacokinetics of CYP3A4 substrates 152, 153.  The reasons for sex-specific differences 
in CYP3A4 expression and/or activity are unclear.  The role of estrogen in the activation 
of CYP3A4 pathways has been evaluated in a limited fashion.  Estradiol (E2) may 
interact with regulators of CYP3A4 such as PXR or CAR154, 155.  However, with respect 
to PXR, E2 only occupies a small portion of the receptor, making binding weak and 
estradiol-induced PXR activation  negligible154.  Furthermore, the E2-mediated 
repression of another CYP3A4 activator, FXR has been observed in vitro, with 
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downstream consequences for FXR target genes (bile salt export pump, BSEP)156, 157.  
This has not been directly evaluated with respect to CYP3A4.  At present, the 
mechanisms for sex-specific differences in CYP3A4 activity and expression as well as 
the role and degree of impact of estrogen on CYP3A4 are not known.         
 Genetic variability is also essential to CYP3A4 expression and in turn activity.  
To investigate this, Ozdemir et.al. (2000) conducted a systematic review of 13 healthy-
volunteer  studies and 3 patient-volunteer studies158.  They assessed the inter- and intra-
individual differences in the disposition of different CYP3A4 substrates based on genetic 
variability.  They concluded that 90% of inter-individual variability in CYP3A4 activity 
is genetically determined in healthy individuals.  This was reported to be less of a factor 
in patient populations.  No allelic variants were identified in this study; however, it 
prompted further investigation into the contribution of genetic variation in CYP3A4 
activity.    
 A variant within CYP3A4 intron 6 (C>T, rs35599367), CYP3A4*22 has been 
associated with diminished CYP3A4 mRNA expression in cultured cells. It also 
accounted for a small fraction of the variability in mRNA expression in a cohort of 
healthy human livers159.  Otherwise, no common CYP3A4 genotypes have been identified 
that explain the variability in CYP3A4 expression160.  It has thus been hypothesized by 
Lamba et.al. (2010) that CYP3A4 expression may be related to genetic variation in the 
transcription factors regulating CYP3A4, because its activity and protein expression is 
highly correlated with its mRNA expression, as shown in previous studies161-164.  Lamba 
et.al. (2010) found that variation in CYP3A4 mRNA expression was related to genetic 
variation in the following nuclear transcription regulators: pregnane X receptor (PXR), 
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hepatic nuclear factor 3β (HNF3β, FOXA2), hepatic nuclear factor 4α (HNF4α), and 
hepatic nuclear factor 3𝛾 (HNF3γ, FOX A3) as well as to the MDR1 polymorphism 
3435C>T161.  They concluded that SNPs in these factors contributed to up to 24.3% of 
the variation seen in CYP3A4 expression.  Similarly, another group showed that SNPs in 
VDR, another transcriptional regulator of CYP3A4 influenced the activity of intestinal 
CYP3A4 161, 165.   
 
1.2.4. Epigenetic Modification of CYP3A4 Expression 
 "Epigenetics" refers to "the heritable changes in gene expression that are not 
coded in the DNA sequence itself."166  Epigenetic mechanisms such as histone 
modification by acetylation or methylation, DNA methylation and RNA-mediated gene 
silencing by non-coding RNAs, all play a significant part in, most-often, silencing DNA 
transcription.   
 DNA methylation is the system most-studied in the regulation of drug 
metabolizing genes.167  Peng et.al. reported that 90% of the "identified epigenetic 
regulation" in genes involved in drug metabolism pertains to DNA methylation168.  
However, in the case of CYP3A4, it is the post-transcriptional changes mediated through 
non-coding RNAs such as various microRNAs (miRNAs) that appear to be the most 
impactful on its expression.  As examples, the binding of miRNA-27b and -206 to the 3' 
untranslated region (UTR) of CYP3A4 results in a decrease in CYP3A4 mRNA levels169, 
170.  Epigenetic mechanisms mediated through alterations in the expression of NRs such 
as PXR and VDR also contribute to the variability in CYP3A4 expression169, 171. 
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1.2.5. The Impact of Disease on CYP3A4 
 Several non-hepatic diseases appear to affect hepatic CYP3A4 expression and 
activity.  Patients with chronic kidney disease (CKD) are exposed to a wide number of 
CYP3A-metabolized drugs.  Down-regulation of hepatic CYP3A has been documented in 
this patient population in human studies as well as in in vivo models172, 173.  Velenosi 
et.al. (2014) suggested that changes in CYP3A activity in CKD may be due to changes in 
"NR binding and histone acetylation"174.  Similarly, down-regulation of CYP3A has been 
documented in individuals with non-alcoholic fatty liver disease (NAFLD).  Woolsey 
et.al. (2015) demonstrated that individuals with biopsy-proven non-alcoholic 
steatohepatitis had a near 3-fold increase in midazolam (CYP3A4 probe drug) plasma 
concentrations versus healthy controls175.  This was validated by quantifying the plasma 
concentrations of the CYP3A-endogenous probe, 4β-hydroxycholesterol (4β-OHC).  The 
plasma concentration of 4β-OHC was significantly lower in the NAFLD population.  
Decreased CYP3A4 expression and activity were also demonstrated using in vivo murine 
and in vitro cell models by the same group175. 
 Other animal models of inflammation such as lipopolysaccharide-exposed mice 
demonstrate down-regulation of hepatic CYP3a11 mRNA (equivalent to human 
CYP3A4)176.  Similarly, the 3% dextran sulfate sodium (DSS) mouse model of colitis 
shows reduced CYP3a11 expression which is reversed with pre-treatment with 
metronidazole177.  In acute inflammation, such as with surgery or infection, CYP3A4 
activity is diminished 178, 179.  Several mechanisms by which inflammation alters 
CYP3A4 activity have been posited and are outlined by Aitken et.al (2006)123.  Increases 
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in oxidative stress and inflammatory cytokines as well as changes in NR signaling are 
highlighted as important. 
 The impact of IBD on CYP3A4 activity is less clear and has not been extensively 
studied.  A study in 21 subjects with CD, versus 10 with UC and 26 healthy volunteers 
found a significant reduction in the 4β-hydroxycholesterol plasma concentrations of the 
individuals with CD, suggesting a total body decrease in CYP3A4 activity in this 
cohort180.  Conversely, a case-control study in a small pediatric CD population evaluating 
CYP3A4 mRNA expression in non-inflamed duodenal pinch biopsies found an increase 
in CYP3A4 expression181.  Ultimately, further work is needed to clarify the impact of CD 
on CYP3A4-mediated metabolism as this may impact non-IBD drugs prescribed to CD 
patients as well as commonly used CYP3A4 substrates such as the glucocorticoids 
prednisone and budesonide.      
 
1.2.6. Important Drug-Drug and Food-Drug Interactions and CYP3A4  
 Interactions with other compounds, either prescribed drugs, food stuffs or herbal 
medicines taken at a patient's own discretion, influence CYP3A4 activity and likely 
account for a significant portion of the inter-individual variability seen within patient 
populations182.  A list of CYP3A4 substrates, inhibitors and inducers are included in 
Table 1.3.  Substances interact with CYP3A4 either to enhance or impair its catalytic 
activity or to serve as a substrate for CYP3A4-induced metabolism.  This is the basis for 
many drug-drug or food-drug interactions that may lead to varying degrees of patient 
toxicity or loss of drug efficacy.  For example, the co-administration of ketoconazole, a 
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potent inhibitor of CYP3A4, with terfenadine, a non-sedating anti-histamine approved for 
the treatment of allergic rhinitis, led to reports of a deadly drug-drug interaction mediated 
through changes in CYP3A4 metabolism183.    In addition to its effects as an anti-
histamine, terfenadine is also a cardiac potassium channel blocker with low systemic 
bioavailability due to extensive metabolism by CYP3A4.  Unfortunately, ketoconazole-
mediated inhibition of CYP3A4 activity led to increased plasma concentrations of 
terfenadine and, in past, has precipitated fatal ventricular arrhythmias184.  Similarly, the 
reduced systemic exposure and lack of efficacy of various CYP3A4 substrates such as 
benzodiazepines when co-administered with CYP3A4 inducers such as carbamazepine or 
of tacrolimus when co-administered with rifampin illustrates the importance of CYP3A4 
to clinically relevant drug-drug interactions185, 186.         
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Table 1.3: Selected CYP3A4 substrates, inducers and inhibitors (adapted from 
United States Food and Drug Administration – Drug development and drug 
interactions)  
Substrates Inducers Inhibitors 
Tyrosine kinase 
inhibitor:  
Imantinib 
Dasatinib 
 
Benzodiazepines: 
Midazolam 
Triazolam 
Alprazolam 
 
Glucocorticoids: 
Budesonide Prednisone 
 
Non-sedating 
antihistamines: 
Terfenadine 
Astemizole) 
 
Immunosuppressive 
agents: 
Tacrolimus 
Cyclosporine 
Sirolimus 
 
HIV protease 
inhibitors: 
Saquinavir 
Indinavir 
Nelfinavir 
Ritonavir 
 
HMG-COA reductase 
inhibitor:  
Simvastatin 
Atorvastatin 
Lovastatin 
 
Non-dihydropyridine 
calcium channel 
blockers:  
Verapamil 
Diltiazem 
 
 
Rifamycin antibiotics: 
Rifampin 
Rifabutin 
 
Anticonvulsants: 
Carbamazepine 
Phenytoin 
Primidone 
Phenobarbital 
 
Other: 
Hypericum perforatum 
(St.John’s wort)  
Tyrosine kinase inhibitor:  
Imantinib 
 
Azole antifungals: 
Ketoconazole  
Itraconazole 
Fluconazole 
 
Macrolide antibiotics: 
Erythromycin 
Troleandomycin 
Clarithromycin 
 
Non-dihydropyridine 
calcium channel blockers:  
Verapamil 
Diltiazem 
 
Proton pump inhibitor: 
Omeprazole 
 
Other: 
Grapefruit juice 
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 Other non-traditional medicines, such as Hypericum perforatum also known as St. 
John's wort, interact with CYP3A4 and have important consequences for other 
concomitantly administered CYP3A4 substrates.  St. John's wort, a commonly used 
herbal therapy for treatment of depression, is a potent inducer of CYP3A4 metabolism 
via PXR187.  A number of interactions with CYP3A4 substrates have been identified and 
reported125, 188. 
 Lastly, aspects of an individual's diet likely play an important role in inter-
individual CYP3A4 variability.  Bailey et.al. (1998) discovered that grapefruit juice is an 
inhibitor of CYP3A4 metabolism189.  This group and others have demonstrated 
significant increases in the bioavailability of orally administered drugs such as felodipine, 
cyclosporine and midazolam when administered concurrently with grapefruit juice190-192 .   
 
1.2.7. Quantifying CYP3A-Mediated Metabolism In Vivo 
 Given the breadth of CYP3A substrates and the potential for numerous drug 
interactions, several techniques are available for evaluating CYP3A activity in vivo using 
a variety of "probe" substances. A probe substance is defined as a compound whose 
pharmacokinetics are determined by a single elimination process and from which a 
enzyme's catalytic activity can be infered125.  Criteria for a valid probe are outlined in a 
review by P. Watkins in a 1994 review invited by Pharmacogenetics193.   In vivo 
measures of CYP3A4 catalytic activity include the assessment of midazolam or quinine 
pharmacokinetics, the C14-erythromycin breath test,  and the measurement of endogenous 
metabolites such as 4βOHC  in plasma or 6β-hydroxycortisol (6βHC) in urine131.   
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 Certain limitations exist for each of these modalities: conflicting reports regarding 
the accuracy of urinary 6βHC concentrations for estimating CYP3A activity exist; C14-
erythromycin breath testing is only useful for the estimation of hepatic (not intestinal) 
CYP3A activity and requires the administration of a radiolabeled carbon193. 
 Currently, the assessment of midazolam pharmacokinetics appears to satisfy all 
the tenants of a CYP3A probe drug outlined by Watkins193.  Midazolam is rapidly 
oxidized by CYP3A4 to its 1- and 4-hydroxymidazolam metabolites, detectable in blood 
by liquid chromatography-tandem mass spectrometry (LC-MS/MS)194, 195.  It can be 
administered intravenously and orally to capture the contribution of hepatic and intestinal 
CYP3A activity131.  Furthermore, studies have validated the substitution of midazolam 
microdosing (in comparison to standard dosing) for the evaluation of hepatic and 
intestinal CYP3A activity196, 197.  This eliminates concerns around a subject's exposure to 
the sedative and amnestic properties of midazolam. 
 The cholesterol metabolite, 4βOHC has also been proposed as a biomarker of 
CYP3A activity.  Cholesterol undergoes transformation to form oxysterols, of which 
4βOHC appears to be the product of CYP3A-mediated oxidation198.  Plasma 
concentrations of 4βOHC appear to correlate with CYP3A activity: patients exposed to 
increasingly potent CYP3A inducers had similarly matched increases in their 4βOHC 
plasma concentrations199.  Furthermore, in vitro data support a mechanistic role for 
CYP3A in the formation of 4βOHC versus other metabolites198. The utility of plasma 
concentrations of 4βOHC for evaluating CYP3A activity may be limited by its relatively 
slow rate of elimination and in conditions where cholesterol concentrations may be 
altered.      
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1.3 Nuclear Receptors 
 CYP3A4 expression and activity are regulated by the NRs, FXR and PXR.  Both 
of these NRs are implicated in CD and UC pathogenesis.  Disease-dependent changes in 
FXR and PXR activity may have important consequences for drug metabolism sequences 
in general and CYP3A4-mediated metabolism specifically.  This section will provide an 
overview of IBD-related changes in PXR and FXR activity as well as the link to IBD 
pathogenesis.    
 
1.3.1 Nuclear Receptors: a Brief Overview 
 NRs are a group of transcription factors that share a common structure: a ligand-
binding domain at the C-terminus and a DNA-binding domain at the N-terminus.  NRs 
regulate the transcription of genes that are important to the development of, metabolism 
and disease processes occurring within humans 200, 201.  They are activated by lipophilic 
substrates binding to a ligand-binding domain.  Substrates include endogenous hormones, 
vitamins A and D, and xenobiotics as well metabolic intermediates such as fatty acids, 
bile acids and sterols201. The binding of a ligand to the ligand-binding domain permits the 
dissociation of a bound co-repressor202 (Figure 1.2).  Subsequent recruitment of a co-
activator allows NRs to bind to specific DNA sequences in the regulatory domain of 
target genes and regulate their transcription.  
 To date, more than 48 members of the NR family have been identified 200.  This is 
including, but not limited to, FXR, PXR, LXR and the glucocorticoid receptor (GR).  
Many NRs have an identified ligand, while others are termed "orphan receptors" with no 
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recognized ligand.  PXR and FXR are important to drug metabolism and transport 
pathways and are increasingly recognized as being important to IBD pathogenesis.  
Herein, PXR and FXR will be discussed in greater detail.    
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Figure 1.2  Model of nuclear receptor molecular structure as well as signaling sequence.  
A represents the inactive cytoplasmic state bound to a corepressor.  B represents binding 
of the ligand, loss of the corepressor, and recruitment of a coactivator as well as the 
heterodimerization with another nuclear receptor.  There is translocation to the nucleus 
(C) and binding of the nuclear receptor complex DNA-binding domains to the target gene 
to induce transcription.  Activation domain, AD; hinge region, HR; ligand-binding 
domain, LBD; DNA-binding domain, DBD; corepressor, CoR; coactivator, CoA; nuclear 
receptor, NR. 
 
 
 
A B C 
36 
 
1.3.2 Pregnane X Receptor 
  PXR (gene NR1I2), also known as the steroid and xenobiotic-sensing NR  plays 
an important role in the "detoxification" of the human body203.  Similar to CYP3A4, it is 
abundantly expressed in the liver and intestine 204.  It is activated by a variety of 
endogenous and exogenous compounds and in turn heterodimerizes with the retinoid X 
receptor (RXR) to up-regulate the transcription of target genes that code for proteins 
necessary for the degradation and clearance of toxins from the body 203. 
 PXR is activated by a number of different ligands including, but not limited to 
rifaximin205, lithocholic (LCA) and deoxycholic acid (DCA) 206 in humans and 
pregnenolone 16-carbonitrile (PCN) 207 in rodents, from which its name is derived.  PXR 
regulates the expression of a variety of genes including, but not limited to the following: 
UDP-glucuronosyltransferases (UGT) 208, glutathione-S-transferases (GST) 209, 
sulfotransferases (SULT)210 as well as drug efflux transporters from the ATP-binding 
cassette (ABC) exporter families including P-gp (gene MDR1) and the multidrug 
resistance proteins 2 and 3 (MRP2, MRP3).  It also regulates members of the solute 
carrier organic anion transporter superfamily like organic anion transporter 
(OATP)1B1211 .  Most important to the discussion at hand, is the PXR-mediated 
regulation of CYP3A4 212.  This relationship has been confirmed using in vivo murine 
models, whereby disruption of the PXR gene impedes CYP3A4 activation via established 
PXR ligands206, 213.  In humans, CYP3A4 mRNA expression as well as the protein's 
activity are increased in response to known PXR activators; it is felt that most drugs that 
induce CYP3A4 are acting via PXR203.   
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1.3.3 Farnesoid X Receptor 
 FXR (gene symbol NR1H4) is a NR that acts as a sensor of intracellular bile acid 
concentrations within the liver and intestine and plays a key role in the regulation of the 
enterohepatic circulation 214, 215.  Activation of FXR by bile acids leads to significant 
changes in bile acid homeostasis as well as in the transcription of genes responsible for 
bile acid synthesis 214.  Similarly to PXR, FXR binds in tandem with RXRα to response 
elements within the promoter regions of target genes.  This leads to the up-regulation of 
bile acid export systems in the ileum (organic solute transporter, OST- α/β) and liver 
(BSEP) and down-regulates the expression of bile acid import systems (apical sodium-
bile acid transporter, ASBT, ileum; sodium-taurocholate co-transporting polypeptide, 
NTCP, liver) 216-220.  Bile acid-induced activation of FXR has also been found to reduce 
the transcription of genes encoding bile acid synthesis enzymes such as CYP7A1 (via the 
small heterodimer partner, an orphan nuclear receptor) thus reducing bile acid synthesis 
221.  Other target genes of FXR include CYP3A4 and PXR144, 222.   Gnerre et.al.(2004)144 
demonstrated an increase in CYP3A4 mRNA in HepG2 cells in response to the FXR-
specific agonist, GW4064.  A gel-mobility shift assay was used to highlight the capacity 
of FXR to bind to a 345-base pair sequence FXR-responsive unit within the CYP3A4 gene 
and confirmed the importance of this binding by introducing various mutations into 
different binding sites144.  They subsequently confirmed the PXR-independent nature of 
FXR-mediated CYP3A4 activation by showing that GW4064 administration in PXR null 
mice did induce the mRNA expression of murine Cyp3a11, while GW4064 did not 
increase Cyp3A11 mRNA expression in FXR null mice.  Similarly, Jung et.al. (2006) 
confirmed the FXR-mediated regulation of PXR222.  Wild type mice fed with GW4064 or 
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cholic acid (CA) had a robust induction of PXR detected by changes in PXR and SHP 
mRNA that was abolished when repeated in FXR null mice.  Furthermore, FXR binding 
sites were detected in the murine PXR gene. 
 In addition to using detectable changes in the mRNA expression of downstream 
gene targets, in vivo changes in FXR activity can be estimated by plasma concentrations 
of the ileal hormone, fibroblast growth factor (FGF) 19 in humans and its murine 
ortholog, FGF15223-225.  FXR is found in small and large bowel enterocytes.  It induces 
the expression of FGF19 which in turn represses the transcription of CYP7A1 and 
inhibits bile acid synthesis226.  Its plasma concentrations are affected by loss of viable 
ileal epithelium.  
 
1.3.4 A Role for Bile Acids in Differential Nuclear Receptor Signaling in 
IBD 
 PXR and FXR are activated by bile acids, though not all bile acids exert equal 
effects.  As previously stated, PXR is most robustly activated by free or conjugated LCA 
and DCA, while FXR is most robustly activated by free or conjugated CDCA and CA.  
There is limited data describing the pattern of bile acids in IBD; however, Duboc et.al. 
(2013) used LC-MS/MS technology to evaluate plasma and fecal bile acids in IBD 
subjects as well as healthy controls.  They detected fundamental differences in fecal bile 
acids and linked these apparent disease-dependent changes to alterations in the gut 
microbial profile227.  Similarly, Gnewuch et.al. (2009) described differences in the ratio 
of primary to secondary bile acids using LC-MS/MS in subjects with UC versus non-IBD 
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controls228.  Authors hypothesized that this finding was likely due to described IBD-
dependent differences in the gut microbial profile leading to differential de-hydroxylation 
of primary bile acids.  Differences in bile acid patterns may be an underappreciated 
determinant of NR signaling in CD; however, this has not been yet explored.    
 
1.3.5 Nuclear Receptors and a Role in IBD Pathogenesis 
 The role of NRs in CD and UC pathogenesis and, as a consequence, therapeutics 
has come under intense scrutiny within the last two decades.  This is unsurprising given 
their pervasive role as master regulators of a number of biological processes.  As 
discussed in earlier sections, NRs are important to drug metabolism sequences, 
specifically to the regulation of CYP3A4-mediated metabolism.  In the following section, 
the current evidence for NR involvement in IBD susceptibility will be presented.   
 
1.3.5.1 The Role of PXR in IBD: 
 PXR is down-regulated in the setting of CD and UC, independent of active 
inflammation210.  This finding was revealed in 2004, when Langmann et.al. demonstrated 
a concomitant reduction in the intestinal mRNA expression of PXR and its downstream 
targets such as UGT, GST, and MDR1, key genes involved in the detoxification and 
processing of xenobiotics in subjects with CD and UC.  Moreover, using three distinct 
intestinal model cell lines, they showed that TNF-α exposure blocked the PXR-mediated 
expression of CYP3A4 and MDR1 in LS174T cells.  A subsequent study by Shah et.al. 
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(2007) highlighted a protective role for PXR in the setting of an inflammatory insult.  
Ligand-induced activation of PXR in a DSS-mouse model of colitis showed symptomatic 
and histological improvement in the study animals211.  Though without established 
certainty, PXR-mediated amelioration of colitis has been hypothesized to occur through 
several different pathways including: the up-regulation of efflux transporter proteins such 
as P-gp or the suppression of the NFκB pathway. 
 As previously discussed, PXR is important to xenobiotic metabolism and up-
regulates the expression of several exporter proteins203, 210.  Intestinal efflux transporters 
such as P-gp contribute to the integrity of the epithelial barrier by increasing the export of 
toxic environmental substances and bacterial toxins from within the enterocyte 210.  This 
impedes the exposure of the host immune system to "foreign" antigen and reduces the 
risk of activating the host inflammatory cascade.  A correlation between intestinal 
inflammation and a reduction in P-gp expression has been shown in a cohort of 
individuals with inflammatory gastrointestinal diseases including IBD142.  
 Secondly, PXR-mediated suppression of NFkB proteins and in turn its target 
genes has been convincingly demonstrated in mouse models of colitis 211, 229.  Shah et.al. 
(2007) were able to show that the administration of the PXR ligand, (PCN) caused a 
significant reduction in the colonic mRNA expression of NFκB target genes, TNF-α, 
iNOS, IL-1β, IL-10.  This was confirmed in in vitro studies using HCT116 colon cancer 
cells.211  
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1.3.5.2 Genetic variation in PXR and its Influence on IBD 
 There is much interest in, not only the role of PXR in IBD pathogenesis, but in the 
link between IBD susceptibility and genetic variation in PXR (NR1I2).  To date, no 
consensus has been reached regarding variations in the PXR gene and their association 
with IBD susceptibility.  Of the existing studies, results remain conflicting.  In 2006, 
Dring et.al. reported that the SNPs, -23585 and -24381 in PXR were predictive of 
susceptibility to both UC, CD and IBD overall in an Irish cohort of 422 IBD patients and 
350 matched controls230.  They hypothesized that these SNPs, which have also been 
associated with a decrease in CYP3A4 activity, confirm a PXR-mediated contribution to 
the pathogenesis of IBD231.  
  However, in the same year,  Ho et.al. (2006) carried out a similar study in a 
Scottish cohort of 725 IBD patients and 328 controls and refuted the findings of the Irish 
study232.  They were unable to show an association between 5 different SNPs in PXR or 
in a variety of constructed haplotypes.  They concluded that the positive findings of the  
study by Dring et.al. (2006) were reflective of genetic heterozygosity amongst controls, 
unclear population stratification and type 1 error. 
 In 2007, Martinez et.al. were able to reproduce the data reported in the study by 
Dring et.al. (2006) to a limited extent in a Spanish cohort of 696 IBD patients and 550 
controls233.  They reported that the SNP, -23585, while not more common in IBD overall, 
was found more frequently in the subphenotype of UC-pancolitis.  Carriers of the T/T 
genotype also had a different distribution of P-gp compared to non-carriers. 
 Subsequently,  Glas et.al. (2011) carried out the largest genetic analysis in NR1/2 
in a cohort of over 2800 individuals, over 1300 of which had IBD234.  They analyzed 8 
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SNPs, including -23585 and 24381, as well as several haplotypes.  They found a weak 
association between the SNP 8055 and UC and more notably a haplotype consisting of 
multiple SNPs, including -23585 and -24381 that was associated with CD susceptibility 
in a sub-cohort of patients.  They concluded that further investigation is needed to clearly 
define the relationship between PXR variation and the functional role of PXR in IBD. 
 
1.3.5.3 PXR as a Target for IBD Therapy: Rifaximin Studies In Vivo 
 The activation of PXR activation by a variety of ligands has been shown to be an 
effective treatment of inflammation in mouse models of colitis 211, 229, 235.  These studies 
have also demonstrated that the beneficial effects are mediated through the down-
regulation of NFkB target genes.  Studies by Cheng et.al. (2010)235 and  Ma et.al. 
(2007)236 used PXR-humanized and PXR null mice to show the protective effect that 
PXR agonists, such as the rifamycins, have on inflammatory changes in the intestine 
induced in a DSS model of IBD.  The rifamycin antibiotics include rifaximin and 
rifampicin, with the former stimulating intestinal PXR target genes alone due to its poor 
absorbability and low systemic bioavailability and the latter stimulating both intestinal 
and hepatic PXR target genes 236.  Some success in CD and UC patients has been seen in 
short, open-label trials involving small cohorts of patients 2, 237-241 as well as in slightly 
larger blinded and randomized studies 242.  The largest study to date in CD (n=402) 
showed that at the end of a 12-week treatment period, 62% of CD patients who received 
an 800-mg dose of extended release rifaximin were in remission, compared with 43% of 
patients who received placebo, a result that reached statistical significance 243.  To date, 
this has not been applied to clinical practice. 
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1.3.5.4 The Role of FXR in IBD 
 It has been shown that bile acid-induced activation of FXR plays a role in 
regulating several genes that protect against intestinal inflammation, increased intestinal 
permeability and bacterial overgrowth 8, 244, 245.  Limited data suggest that FXR activity is 
repressed in CD180, 246, 247. While, FXR deficiency in mice and humans is not associated 
with the development of a spontaneous colitis, FXR deficiency appears to portend a more 
severe disease phenotype in the setting of a primary insult244, 248.  These concepts will be 
discussed herein.   
 Researchers have highlighted that FXR-regulated pathways are important to 
intestinal integrity.  Raimondi et.al. (2008) demonstrated that bile acids modulate 
intestinal paracellular permeability: CA, chenodeoxycholic acid (CDCA), DCA increased 
intestinal permeability, DCA- and CDCA- induced phosphorylation of the epidermal 
growth factor receptor, occludin dephosphorylation, and occludin redistribution, all key 
components of intestinal permeability249.  Stojancevic et.al. (2012) and Luettig et.al. 
(2015) showed FXR regulates other proteins, such as keratin-13 and claudin-1 and 
claudin-2 involved in maintenance of the intestinal barrier250, 251. 
 Vavassori et.al. (2009) investigated the role of FXR activation in the regulation of 
inflammatory responses in a murine model of colitis244.  At baseline, it was noted that 
increased cellular infiltrate and collagen deposition as well as increased expression of 
inflammatory genes (TNFα, IFNγ, IL-1β) were seen in FXR-null mice in comparison to 
wild type  mice.  Acute and chronic colitis were then induced in wild type and FXR-null 
mice using rectal administration of trinitrobenzenesulfonic acid (TNBS) in 40% ethanol.  
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Colitis was prevented in 60% of the wild type mice receiving synthetic chenodeoxycholic 
acid (INT-747) and a reduction in the transcription of pro-inflammatory genes was seen.  
No effect was seen in FXR-null mice, demonstrating the role of FXR in the intestinal 
immune response . 
 A complimentary study by Gadaleta et.al. (2011), linked FXR agonism to 
improvements in intestinal permeability in vivo and in vitro.  It was further demonstrated 
that FXR agonism counteracts proinflammatory cytokine expression and secretion by 
enterocytes8.  In wild type mice, INT747 treatment induced FXR target genes in both 
ileum (small heterodimer partner, SHP) and colon (Fgf15).  FXR null-mice expressed 
very low levels of SHP and Fgf15 at baseline and with INT747 administration.  In wild 
type mice treated with 2.5% DSS, INT747 reduced wt loss, improved rectal bleeding 
scores, and prevented colonic shortening.  At baseline, chemically-induced colitis was 
associated with complete disruption of the epithelial layer and acute inflammatory 
infiltrates in wild type and FXR-null mice.   INT747-treated wild type mice showed less 
intestinal morphological alteration and decreased inflammatory infiltrates and less goblet 
cell loss.  INT747 had no effect in FXR-null mice.  Measures of increased permeability 
were markedly elevated in wild type and FXR-null mice after induction of colitis, though 
this was abolished in INT747-treated wild type mice. Furthermore, in DSS-treated wild 
type mice, INT747 significantly decreased colonic mRNA expression of pro-
inflammatory genes IL-1β, IL-6 and macrophage attractant protein (Mcp)-1.  Also, 
antimicrobial proteins, iNOS and cathelicidin in the colon and angiogenin 1 (Ang1) in the 
ileum, were significantly induced by INT747 in wild type but not FXR-null mice.  It was 
concluded that FXR normalizes chemically-induced pro-inflammatory gene expression 
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and reduces inflammatory infiltrates in the intestine.  It also it induces the expression of 
several antibacterial defense genes. 
 Moreover, Nijmeijer et.al. (2011) evaluated the converse: is FXR activation 
repressed in the setting of chronic colitis246?  MRNA expression of FXR and its target 
gene, SHP were analyzed in ileal and colonic samples taken from IBD and healthy 
subjects.  FXR activation in the ileum was found to be reduced in subjects with CD 
colitis, while no difference was seen in subjects with UC versus healthy subjects.  
Subsequent studies by Lenicek et.al. (2011) and Iwamoto et.al. (2013) support the 
findings of Nijmeijer et.al. (2011) using the FXR activity surrogate marker, FGF19180, 247. 
 Ultimately, these studies highlight the potential importance of FXR to IBD 
pathogenesis. FXR activation contributes to the maintenance of intestinal epithelial 
integrity as well as down-regulates the expression of certain pro-inflammatory genes.  
This correlates with reduced intestinal inflammation in mouse models of colitis and 
human subjects with IBD.   
 
1.3.5.5 Genetic Variation in FXR and its Influence on IBD  
 Furthermore, it should be mentioned that genetic variation in FXR has been linked 
to IBD pathogenesis.  A study by Attinkara et.al. (2012) evaluated the association 
between IBD and 5 variants (2 common, 3 rare) of the FXR (NR1H4) gene214.  They 
found that one of the rare variants (rs3863377) was less common in the IBD population 
versus the healthy controls.  It was proposed that this variant confers a protective effect 
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against the disease.  The rare variant, FXR-1G>T (rs56163822) was more prevalent in the 
IBD group.  Our group demonstrated that this variant is associated with reduced 
activation of downstream FXR gene targets252.  Nijmeijer et.al. (2011) did not find any 
FXR polymorphisms associated with the CD or UC susceptibility246.  Genetic variation in 
FXR and the link to UC and CD remains poorly defined. 
 
1.3.5.6 FXR as a Target for IBD Therapy 
 Success has been seen with the use of obeticholic acid (INT-747), a semi-
synthetic and potent ligand of FXR in chronic liver diseases.  A recent randomized 
controlled study in the New England Journal of Medicine revealed the utility of 
obeticholic acid for patients with primary biliary cholangitis (PBC)253.  Phase 2 trials in 
diabetic subjects with NAFLD have shown promise with reduced liver inflammation and 
fibrosis seen over the short term254.    In vitro and in vivo models of FXR agonism 
demonstrated down-regulation of stellate cell activity with reduced collagen deposition 
and up-regulation of SHP 255, 256.  As stated above, INT-747 has also been used with 
success in animal and in vitro models of colitis 8, 244.  This has not been evaluated in 
human subjects with CD or UC. 
 
1.4 Summary 
 CD is an important disease due to its high prevalence, debilitating symptoms, 
associated complications and incurability. Patients are exposed to a high burden of 
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medications in addition to other treatments they may be receiving for co-morbid illnesses. 
CD pathogenesis is complex and multi-factorial with overlapping roles for the immune 
system, the human genome and the environment in the onset of disease.  Though 
substantial advances have been made in the last two decades regarding our understanding 
of its pathophysiology, we are still unable to prevent its onset, predict those at imminent 
risk or select the most efficacious treatment for affected individuals.  Disease severity 
based on patient demographic data or previous disease behavior often dictates the most 
appropriate therapy, but does not necessarily predict drug response. Small and large 
molecule drugs have found varying degrees of success in the management of CD; 
however, one of the unfortunate, overarching themes in CD therapeutics is a lack of inter-
individual predictability of drug exposure and drug response.  
 Significant overlap is seen in CD pathogenesis and drug metabolism pathways.  
CYP3A4-mediated metabolism is one of the most important systems for the processing of 
xenobiotics including human drugs.  Its activity is highly variable between individuals 
and, in the setting of other acute and chronic inflammatory illnesses, may be associated 
with additional variation in function.  Its intestinal location and PXR- and FXR-mediated 
regulation make its expression and activity plausible targets for CD-induced changes; 
however, CD-related alterations in drug metabolism, as a whole, are largely unexplored.  
Experts in the field recognize that our inability to predict drug response in both CD and 
UC and to personalize therapies for patients is a huge deficiency in a field dependent on 
long-term drug use.  Furthermore, CD-related changes in CYP3A4 activity may have 
important consequences for additional treatments patients receive for non-CD-related 
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diseases.  Ultimately, a better and more complete understanding of drug metabolism 
sequences in CD is needed. 
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 2 HYPOTHESES & AIMS 
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2.1 Hypothesis 
 The interplay between genes, nuclear receptors (NR), cellular transporters, 
metabolizing enzymes and the gut microbial profile affect drug metabolism pathways and 
ultimately drug disposition in humans.  The cytochrome P450 (CYP) family in general 
and CYP3A4 specifically play a principal role in an individual's systemic exposure to a 
drug.  CD is a primary intestinal illness where variation in the aforementioned factors 
forms the basis of a still-incompletely defined pathophysiology.   
 We believe the presence of CD will negatively affect CYP3A4 expression and 
activity in such patients and that genetic variation in key NRs, such as the farnesoid X 
receptor (FXR) regulating CYP3A4 may have important consequences for disease 
severity and are an indirect determinant of drug response. 
 
2.2 Aim 1: 
a) To assess the impact of CD on the activity of intestinal and hepatic CYP3A4 using 
exogenous and endogenous in vivo probes.  
b) To propose a molecular mechanism by which detectable changes in CD-specific 
CYP3A4 activity occur.   
 The activity of the enzyme, CYP3A4, is subject to significant inter-individual 
variation.  Diet, concomitant drug exposures, age, sex, genetic variation, and NR 
regulation are a short, but incomplete, list of factors that may alter its activity1-6.  Acute 
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and, to a certain extent, chronic inflammatory states appear to affect CYP3A4 activity7, 8.   
Any changes in the activity of CYP3A4, a key enzyme involved in phase 1 drug 
metabolism, are thought to have important consequences for the disposition of substrates 
in vivo.  Little is known regarding the in vivo influence of CD on this protein.  Given that 
the intestine, in addition to the liver, is the site of highest expression of CYP3A4, one 
could assume a primary, inflammatory intestinal illness may have a substantial impact on 
CYP3A4 activity.   
 We hypothesize that CD negatively impacts CYP3A4 activity in vivo, 
specifically in the intestinal compartment and such changes are due to a CD-specific 
effect on the activity of the NR, pregnane X receptor (PXR).   
 
2.3 Aim 2: 
To evaluate the impact of CD on the intestinal expression of CYP3A4 compared to a 
healthy population. 
 A hallmark of CD is disruption of the intestinal mucosal layer9, 10.  The intestinal 
mucosa consists of the following: the epithelium, made up of enterocytes as well as 
goblet, paneth and neuroendocrine cells; the lamina propria, home to a variety of immune 
cells; and the muscularis mucosae11, 12.  The onset of CD induces disruption of the 
epithelial cell tight junctions, epithelial cell apoptosis, expansion of the lamina propria 
with pro-inflammatory cells and recruitment of pro-fibrotic fibroblasts13-15.  As 
previously discussed, CYP3A4 is predominantly expressed in the liver and intestine, with 
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the highest expression of intestinal CYP3A4 on the enterocytes found at the villous tip of 
the small intestine16, a prime target of the inflammatory lesions of CD.  It likely acts in 
concert with the enterocyte-bound xenobiotic exporter P-glycoprotein (P-gp) to limit the 
oral bioavailability of several shared substrates17. 
 Thus, we hypothesize that individuals with CD have reduced intestinal 
expression of CYP3A4.   
 
2.4 AIM 3: 
To explore the role of genetic variation in FXR, a key regulator of CYP3A4 
metabolism, and its impact on CD severity, a surrogate marker of drug metabolism 
and response. 
 Genetic variation in key CYP3A4 transcriptional regulators, such as FXR and 
PXR may have important consequences for the function of the NR protein product and 
ultimately CYP3A4 expression and activity.  Defects in key functions carried out by FXR 
are closely linked to CD pathophysiology and genetic variation may further impair these 
pathways and portend a more severe CD phenotype18-20.    
 We hypothesize that the FXR -1G>T polymorphism confers a greater risk of 
severe CD phenotype and is associated with a reduction in the downstream FXR 
target, fibroblast growth factor (FGF) 19 and an expansion of the total bile acid 
pool.   
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3 EVALUATION OF CYP3A4 ACTIVITY IN 
CROHN'S DISEASE 
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3.1 Introduction 
 Inflammatory bowel disease (IBD) is a disease of chronic intestinal inflammation 
punctuated by episodes of active disease and quiescent remission.  IBD can be 
differentiated into ulcerative colitis (UC) and Crohn's disease (CD), which can follow 
markedly different clinical courses: UC affects the mucosal layer of the large intestine 
while CD causes transmural inflammatory lesions that may affect any part of the 
intestinal tract1.  The treatment of IBD focuses on effecting and maintaining remission at 
the level of the intestine as well as inducing symptomatic response.  CD therapeutic 
options have significantly improved over the past decade.  Immunosuppressants such as 
azathioprine, methotrexate and glucocorticoids as well as biologic treatments such as 
infliximab, adalimumab, vedolizumab and ustekinumab are important therapies for the 
optimal treatment of CD.  
 The Cytochrome P450 (CYP) 3A subfamily of CYP enzymes is a key mediator of 
drug metabolism and disposition in humans.  Three functional enzymes have been 
indentified: CYP3A4, CYP3A5 and CYP3A7.   CYP3A4 is thought to be involved in the 
disposition of approximately 40-50% of drugs in clinical use, including many used to 
treat CD or UC2, 3.  Specifically, CYP3A4 has been shown capable of metabolizing 
glucocorticoids used in CD, such as prednisone and budesonide3, 4.  Based on limited 
budesonide pharmacokinetic (Pk) data from patients with CD as well as Pk data from 
healthy populations demonstrates that budesonide exposure after oral administration is 
highly variable3, 5, 6.  This variability may be due to inter-individual differences in total 
CYP3A4 activity and may account for differences seen in clinical outcomes amongst CD 
patients treated with budesonide7, 8. 
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 CYP3A4 is the most thoroughly investigated of the CYP3A isoforms2.  CYP3A4 
is expressed predominantly in the liver and intestinal tract2.  In the intestinal tract, 
CYP3A4 is found at the villous tip of individual enterocytes and aids in the catabolism of 
specific drug substrates9.  The expression of CYP3A4 mRNA decreases longitudinally 
along the intestinal tract, from small intestine to colon, with the highest expression in the 
jejunum and ileum10, 11.  The interplay between intestinal CYP3A4 and intestinally-
expressed importers and exporters is considered to be of particular relevance to intestinal 
drug metabolism and transport and to significantly impact drug exposure and response.  
 Intestinal CYP3A4 may act in concert with other transporters, such as P-
glycoprotein (P-gp), and play a key role in first-pass metabolism in addition to the role 
played by hepatic CYP3A412.  P-gp bound to the cell membrane of enterocytes may 
regulate the exposure of specific drugs to metabolism by CYP3A4 via an active "counter 
transport" mechanism13, 14.  The influence of diseases such as infection and more chronic 
conditions such as cancer, organ transplantation and liver disease on in vivo CYP3A4 
activity have been well-documented in the literature15-20.  Interestingly, to our knowledge, 
in vivo human CYP3A4 activity has only been reported in one other study in the setting 
of IBD.  This study limited its evaluation of CYP3A4 activity to single-point 
determination of 4β-hydroxycholesterol (4βOHC) plasma concentrations21.   
 Moreover, the mechanisms by which disease-dependent changes in CYP3A4 
activity occur are not clearly defined.  One existing hypothesis is that circulating 
inflammatory cytokines such as interleukin (IL)-1, tumor necrosis factor (TNF)-α or 
interferon (IFN)-γ interfere with the transcription of CYP3A4 mRNA; however, data are 
limited to animal models and results have been conflicting20, 22.  Interestingly, key 
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regulators of CYP3A4 activity, the nuclear receptors (NR), farnesoid X receptor (FXR) 
and pregnane X receptor (PXR) are both down-regulated in IBD and are thought to 
contribute to the pathogenesis of the disease21, 23, 24.   Bile acids are important endogenous 
ligands of PXR and FXR, though not all bile acids are created equal25, 26.  Secondary bile 
acids, lithocholic acid (LCA) and deoxycholic acid (DCA) are potent activators of PXR 
and the primary bile acid, chenodeoxycholic acid (CDCA) is a potent activator of FXR.  
The composition of the bile acid pool is highly dependent on the gut microbial profile27, 
28.  Studies have demonstrated a loss of microbial diversity in the intestinal tract of those 
with IBD, particularly amongst the Firmicutes and Bacteroidetes phyla, key phyla 
involved in the processing of bile acids (deconjugation, dehydroxylation)27-29; thus, one 
could surmise that changes in NR activation due to changes in the bile acid pool may 
result in differential CYP3A4 activity. 
 Accordingly, we sought to assess the in vivo activity of CYP3A4 in CD using 
well-known in vivo probes midazolam30 and 4βOHC31 and to investigate the role of 
differential PXR activation on CYP3A4 activity in vitro. 
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3.2 Materials & Methods 
3.2.1 All Subjects 
 This study was conducted in two parts: in the first part, a detailed Pk analysis of 
oral and intravenous midazolam metabolism was carried out in 8 patients with CD to 
evaluate the in vivo activity of CYP3A4 in CD.  In the second part, a cross sectional 
study in an independent cohort of patients with CD (n=74) and non-CD controls (n=74) 
was carried out to evaluate the in vivo activity of CYP3A4 using the endogenous 
biomarker 4βOHC in plasma.  Written, informed consent was obtained from each patient.  
Both parts of the study received approval by the Western University Health Sciences 
Research Ethics Board (104914, 105930). 
 
3.2.1.1 Subjects Included in the Pharmacokinetic Study  
 Patient recruitment took place from March 2014 to September 2014.  Eligible 
subjects were 18 years of age or older with a history of CD who were starting on or 
currently taking the oral medication, budesonide.  Subjects receiving concurrent medical 
treatment for their CD (n= 8) were eligible for this study.  Subjects were excluded from 
the study for the following reasons: having a hypersensitivity to budesonide; having a 
hypersensitivity to midazolam; having a serum creatinine concentration greater than 1.7 
mg per deciliter; being pregnant or breastfeeding; having a pre-existing liver disease 
(examples include primary sclerosing cholangitis, autoimmune hepatitis, alcoholic liver 
disease, viral hepatitis, cirrhosis); taking other, concurrent benzodiazepines; being 
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unwilling to comply with the study protocol; having an estimated survival of less than 
one year; abusing or misusing alcohol; being an active smoker; receiving on-going 
therapy or treatment in the last 3 months with drugs known to be potent CYP3A 
inhibitors or inducers. These are as follows: macrolide antibiotics, ‘azole’ antifungals, 
nefazodone, verapamil, diltiazem, cyclosporine A, antiretrovirals, carbamazepine, 
phenytoin, lamotrigine, rifampin, rifabutin, dexamethasone, St. John’s Wort, bosentan.  
Subjects were screened for eligibility 4 weeks prior to enrollment.  Body weight and 
routine blood tests (blood count, biochemistries, liver enzymes and creatinine) were 
measured for each patient.  All female subjects were screened for pregnancy with a urine 
pregnancy test.  At baseline, demographic data, including age, sex, year of CD diagnosis, 
disease distribution, and current medications were collected from each patient.  Clinical 
parameters to assess for disease activity (Harvey-Bradshaw Index), and subjective 
response to budesonide, including efficacy and toxicity were noted.     
Subjects were instructed to avoid citrus fruit products for one week prior to their 
study day due to the inhibitory effect on CYP3A4 activity. They were also instructed to 
avoid alcohol or caffeine one day prior to their study day.  Subjects were instructed to 
take nothing by mouth the morning of their study day.  At the commencement of each 
study day (time 0), subjects were administered an oral dose of budesonide (3-9mg).  The 
dose of budesonide was chosen based on the standard practice of care carried out at 
London Health Sciences Centre (LHSC) for inducing remission in individuals with CD.  
Subjects were also given a prepared 100µg dose of oral midazolam.  At the 8-hour time 
interval, subjects were given a prepared 50µg dose of intravenous (IV) midazolam.  The 
dose of oral and IV midazolam were selected based on previous studies conducted to 
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assess the in vivo activity of CYP3A4 and P-gp.30, 32, 33 Blood samples were collected 
from each subject at 19 pre-specified time points measured in hours (0, 0.25, 0.5, 1, 2, 3, 
4, 5, 6, 7, 8, 8.08, 8.25, 8.5, 9, 9.5, 10, 11, 12).  Samples were spun down using a 
centrifuge and plasma was extracted and stored at -80◦C. 
 
3.2.1.2 Subjects Included in the Cross Sectional Study 
 A cross sectional cohort was derived from patients being seen as part of the 
Personalized Medicine Program at Western University, London, Canada as well as 
healthy individuals being seen for colorectal screening consultation between March 2013 
and March 2017.  Each subject provided two blood samples for analysis.  Subjects from 
the CD arm had a histopathological diagnosis.  CD subjects were excluded if there was 
missing information pertaining to their CD medical history.  Individuals were included in 
the control arm if there was no history of cardiovascular, neurological, pulmonary, renal, 
hepatic, malignant or auto-immune disease.  Controls were required to be never-smokers, 
to consume less than 5 alcoholic beverages weekly and to have had no prior history of 
surgical intervention pertaining to the cardiovascular, neurological, pulmonary, renal, 
hepatic, or intestinal systems.  All subjects were required to be 18 years of age or older 
and to not be taking a concomitant CYP3A4 agonist or antagonist (macrolide antibiotics, 
‘azole’ antifungals, nefazodone, verapamil, diltiazem, cyclosporine A, antiretrovirals, 
carbamazepine, phenytoin, lamotrigine, rifampin, rifabutin, dexamethasone, St. John’s 
Wort, bosentan).   
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 Data collected from the CD cohort included age, weight, sex, smoking history, 
CD phenotype, activity (assessed by the HBI34), disease duration, medication use and 
history of surgical resections or hospitalizations.   Data collected from the control cohort 
included age, weight, sex, smoking history and alcohol consumption, medical and/or 
surgical history and any prescription or non-prescription drug use. 
 
3.2.2 Clinical Study Objectives and Outcomes: 
 The objective of this study was to test the hypothesis that CYP3A4 activity is 
decreased in CD.  The primary endpoint was the midazolam AUC0-∞ in individuals with 
CD compared to reported healthy cohorts.   Secondary outcomes included the intestinal 
and hepatic extraction ratios for midazolam as well as other Pk parameters outlined in the 
following section.  Pk parameters were also assessed for budesonide and the contribution 
of CYP3A4 to inter-individual differences in budesonide AUC0-∞ was evaluated. Other 
endpoints included the 4βOHC plasma concentrations in an independent of cohort of CD 
patients compared to non-CD controls as a means of confirming or refuting the primary 
outcome.  Any detectable differences in the bile acid pools of the controls versus the CD 
population were also assessed.  
 
3.2.3 Pharmacokinetic Analysis 
Pk analysis was performed by the non-compartmental method.  Pk parameters 
were calculated based on its concentration-time curve.  Collected parameters included the 
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following: maximum plasma drug concentration (Cmax); time to the maximum plasma 
drug concentration (tmax); total drug exposure estimated by the area of under the plasma 
concentration-time curve (AUC0-∞); the drug half-life (t1/2); oral bioavailability (F); 
systemic (CLs) and oral drug clearance (CL/F).  Estimates of CYP3A4-mediated hepatic 
and intestinal extraction ratios were calculated.     
Cmax and tmax were obtained by visual inspection.  The AUC0-∞ for each patient 
was calculated using the trapezoidal rule (numerical integration) to the last measured time 
point and extrapolated to infinity using the terminal elimination rate constant (ke), 
estimated by log-linear regression of last 4-6 data points on the concentration-time curve.  
The t1/2 was obtained by dividing the constant 0.693 by ke. Oral clearance was calculated 
as the ratio of the oral dose divided by the oral AUC0-∞.  F was calculated by dividing the 
product of the oral AUC0-∞ and IV dose by the product of the IV AUC0-∞ and oral dose.  
CYP3A4-mediated extraction in the liver and intestine were estimated by the hepatic and 
gut extraction ratios (Eh and Egi), where Eh = CLs/Qh, plasma and Egi = 1-[F/(1-Eh)].  Qh, 
plasma represented the liver plasma flow and was equal to (1-hematocrit) x Qh, blood.  Qh, blood 
or liver blood flow was assumed to be 25.7ml/min per kg of body weight. 
 
3.2.4 Quantification of Midazolam Plasma Concentrations 
 Midazolam plasma concentrations were determined by LC-MS/MS using a 
previously described method by Gong et.al. (2012) Supplemental Data32.  The lowest 
limit of quantification was 0.025 ng/mL. 
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3.2.5 Quantification of Budesonide Plasma Concentrations 
 For measuring budesonide, a five hundred microlitre plasma sample was acidified 
using 50µl 4% formic acid (diluted in water) containing the internal standard, d6-
budesonide (10 µl, 500ng/ml in methanol; Toronto Research Chemicals, Toronto, ON).  
Standards made with drug free plasma were similarly spiked with budesonide internal 
standard as described above.  Protein was precipitated from samples and standards with 
the addition of 500 µl of 30% ethanol in water and incubation at 4◦C for 15 minutes.  
Precipitated proteins were pelleted by centrifugation at 14000g at 4◦C for 10 minutes.  
Supernatants were applied to OASIS HLB 96-well plates (5mg/well, 30 µm particle size, 
Waters, Milford, MA) pre-treated with 1ml of methanol and water each.  Wells were 
washed with 1ml of 20% methanol and eluted using 0.5ml of 100% methanol.  The eluate 
was dried with heat (70C) and reconstituted using the mobile phase (150µl of 
acetonitrile/5mM ammonium acetate in water [25%/75%]).  One hundred microlitres of 
sample was injected into the liquid chromatograph (Agilent 1200, San Jose, CA).   
 Analytes were separated using reverse phase chromatography on a Thermo 
Hypersil Gold C18 Column (50 x 5mm; 5µm) using gradient elution with Mobile Phase 
A (5mM ammonium acetate in water) and Mobile B phase (acetonitrile) over minutes: 1 
minute of 75:25 (A:B), from 75:25 to 20:80 (A:B) over 5 minutes, back to 25:75 (A:B) 
over 1 minute then held for 1 minute.  The retention time for budesonide and d6-
budesonide is 4.5 minutes.   
 Mass detection occurred on a Thermo TSQ Vantage triple quadrupole mass 
spectrometer, set in positive mode, with a quantitative and qualitative mass transition 
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measured for budesonide (431.2 →147.1 m/z).  The standard curve was linear over 0 to 
10ng/ml concentration range. 
 
3.2.6 Quantification of 4β-hydroxycholesterol Plasma Concentrations 
 Plasma concentrations of 4βOHC were determined by LC-MS/MS following 
sterol isolation by saponification and enhancement of the analyte product by picolinic 
acid derivatization as described by Honda et.al. (2009)35 and Woolsey et.al. (2016)36.  A 
4βOHC-standard curve from 0 to 200ng/ml was created in Krebs-Henseleit Bicarbonate 
buffer.  Fifty microlitres of subject plasma and 100µl of standard were spiked with 1µl of 
1mg/ml internal standard (d7-4βOHC) obtained from Avanti Polar Lipids (Alabaster, 
Alabama) .    Each aliquot was saponified in 500µl of 1M ethanolic potassium hydroxide 
at 37◦C for one hour followed by the addition of 150µl of water.  Sterols were twice 
extracted into hexane and further isolated by the evaporation of the hexane layers to 
dryness.  Following this, 250µl of a derivatization mixture (2-methyl-6-nitrobenzoic acid, 
4-dimethylaminopyridine, picolinic acid, pyridine, triethylamine) was added to each 
sterol extract and incubated at 80◦C for one hour. Hexane (1ml) was added to each aliquot 
and, following centrifugation at 14,000 rpm, the supernatant was collected and 
evaporated to dryness at 80◦C.  Following re-constitution in acetonitrile and sodium 
chloride, a 20µl-aliquot was injected into the LC-MS/MS system.  An Agilent C18 
Zorbax Eclipse Plus column (100 x 2.1mm, 1.8µm) was used with mobile phases of 0.1% 
formic acid in water and 50:50 acetonitrile in methanol with 0.1% formic acid.  The 
retention times for d7-4βOHC and 4βOHC were 8 minutes and 8.1 minutes respectively 
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with each analyte detected in positive mode ( mass transitions of 642.4>146.5m/z, d7-
4βOHC and 635.4> 146.5m/z, 4βOHC).  The lower limit of detection of plasma 4βOHC 
was 2.5ng/ml. 
 
3.2.7 Quantification of Bile Acid Plasma Concentrations 
 Plasma stored at -80◦C was used for quantification of 12 bile acids (cholic acid, 
CA; chenodeoxycholic acid, CDCA; deoxycholic acid, DCA; glycocholic acid, GCA; 
glycochenodeoxycholic acid, GCDCA; glycodeoxycholic acid, GDCA; lithocholic acid, 
LCA; taurocholic acid, TCA; taurodeoxycholic acid, TDCA; taurolithicholic acid, TLCA; 
tauroursodeoxycholic acid, TUDCA; and ursodeoxycholic acid, UDCA) using high 
performance liquid chromatography/mass spectrometry (LC-MS/MS).  Taurocholic acid-
d5 (TCA-D5) was used as an internal standard (I.S).   A standard curve of 1nM to 40µM 
was generated.   Patient samples were homogenized by vortexing for 15 minutes at 4 °C 
@1400 RPM and incubated at -20°C for 20 minutes. Samples were centrifuged at 
maximum speed at 4°C for 30 minutes. Finally, 100µL of supernatant was transferred to 
vials and 80µL was injected into the LC-MS/MS system. 
 A two-dimensional LC system was used (Agilent HILIC plus column (4.6*50) 
3.5µm followed by Phenomenex 00B-4462-Y0 Kinetex 2.6u C18 100A (3.0*50)). A 
gradient elution technique was employed using the Agilent 1290 system.  Mobile phase A 
consisted of 2mM ammonium acetate (pH 4.15) with 10% acetonitrile.  Mobile phase B 
consisted of acetonitrile: isopropyl-alcohol with water. The columns' temperatures were 
maintained at 60°C. Samples were eluted at a flow rate of 0.6ml/min to 1.4ml/min (0.1-
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12 minutes).  Before injection of the subsequent sample, columns were cleaned with 
100% mobile phase B for one minute and returned to a linear equilibrium for 7 minutes 
for a total run of 20 minutes for each sample. Mass detection occurred on a TSQ-
Quantum Ultra mass spectrometer equipped with HESI source and  operated in negative 
mode (4500 v spray voltage, 350°C vaporizing temperature, 45 sheath gas pressure, 15 
auxiliary gas pressure and 350 °C capillary temperature). 
 
3.2.8 In vitro CYP3A4 reporter activity 
 Human hepatocarcinoma (HepG2) cells, obtained from Cedarlane (Burlington, 
Ontario) were cultured in DMEM (VWR, Radnor, Pennsylvania) supplemented with 10% 
fetal bovine serum, penicillin and streptomycin.  Cell viability in the setting of bile acid 
exposure was assessed using the CellTiter-Glo Luminescent Cell Viability Assay 
purchased from Promega Corporation (Madison, Wisconsin) at serial concentrations and 
time points.  Cells were then cultured in 12-well plates to 80% confluency in 3 days.  
DNA was transiently transfected by lipofection method.  The ratio of plasmid used was 
0.5µg of CYP3A4-XREM-Luc, 0.5µg of hPXR-pEF.  Additionally, 0.5µg of renilla 
plasmid (pRL-CMV, Promega, Madison Wisconsin, USA) was co-transfected as an 
internal standard of transfection efficiency.  Plasmids, CYP3A4-XREM-Luc and hPXR-
pEF were previously prepared as described by Tirona et.al. (2003)37.  A corresponding 
"control" model was generated, with 0.5µg of pGL3 basic (Promega, Madison 
Wisconsin, USA) and pEF (Invitrogen, Carlsbad California, USA) control vectors and 
0.5 µg of pRL-CMV as a transfection a control.  Cells were treated with one of the 
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following: a pool of bile acids (25µM) representative of CD disease states (active CD, 
inactive CD) as well as that of a healthy individual; 0.1% DMSO in Optimem; or 10µl of 
one of GDCA, DCA or LCA.  Cohort-specific bile acid pools were derived from subject 
data presented in Table 3.7 and 3.8.  Cells were incubated for 24 hours, washed with 
phosphate buffered saline and lysed with passive lysis buffer.  Using the Promega 
Corporation Dual Luciferase Reporter Assay System (Madison, Wisconsin USA), 
luciferase activity was measured by Glomax 20/20 Luminometer (Promega, Madison 
Wisconsin, USA) and normalized by dividing the relative light units by the Renilla 
luciferase activity (firefly:renilla luciferase ratio, F/R ratio).  The fold-change in 
luciferase activity was then estimated by dividing the F/R ratio for each cell group by the 
control (pGL3 basic or pEF control vector).  Each experiment was performed in triplicate 
and repeated 2-3 times.   
 
3.2.9 Statistical Analyses 
 All statistical analyses were carried out in Graphpad Prism and SPSS.  For the 
midazolam Pk analysis, data are presented as the arithmetic mean with standard 
deviations.  Linear regression analysis was used to assess the possible relationship 
between the Pk values of budesonide and midazolam.   A one-way ANOVA with 
Student's t-test and Bonferroni post hoc test were used to compare 4βOHC plasma 
concentrations between CD (active, inactive disease, n=74) and control groups (n=74).  A 
p-value ≤0.05 was considered significant.  A multiple linear regression analysis was used 
to further evaluate the relationship between presence or absence of CD, other covariates 
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and the inter-individual variation in 4βOHC plasma concentrations (natural log-
transformed).  Other covariates assessed included the following: sex, age, weight, and 
disease activity.  Mean plasma concentrations for the 12 aforementioned bile acids were 
compared between the control group and the CD group (sub-divided by disease activity) 
using a Student's t-test.  A p-value ≤0.05 was considered significant.  Similarly, for the in 
vitro experiments, a one-way ANOVA with Student's t-test identified any significant 
differences between cell groups.  A p-value ≤0.05 was considered significant. 
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3.3 Results 
3.3.1 Subjects 
 Seven females and one male completed the midazolam Pk study protocol (n=8).  
The demographic data and clinical characteristics for each subject are presented in Table 
3.1.  There were no adverse events.  All subjects were on budesonide therapy for a 
minimum of 1 month prior to entry into the study.  All subjects had not received 
treatment with a CYP3A4-inhibiting or -inducing drug in at least 1 year (with the 
exception of budesonide).  Seventy-four subjects with CD and 71 controls were included 
in an independent cohort to evaluate in vivo CYP3A4 activity using the endogenous 
probe, 4βOHC.  Table 3.2 summarizes the demographic data as well as the clinical 
parameters for both populations   
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Table 3.1: Demographics (Pk Analysis) 
Patient Age 
(yrs) 
Sex Wt 
(kg) 
Ds 
Type 
Ds 
Location 
Surgery Additional 
Medications 
(oral) 
Bude 
dose, mg 
(Duration 
of tx, 
months) 
HBI 
pre-
Bude 
HBI 
on 
Bude 
1 61 F 78.3 CD ileal N Lansoprazole  9 (3) 9 1 
 
2 70 F 70.1 CD ileal N Rabeprazole, 
Paroxetine, 
Trazadone 
6 (3.5) 7 1 
 
 
 
3 28 F 75.0 CD ileal N Pantoprazole, 9 (4) 10 9 
 
4 62 F 57.4 CD ileocolonic N Salofalk  3 (2) 9 0 
 
5 25 F 70.0 CD ileal N Cipralex 9 (4) 12 8 
 
6 27 M 76.6 CD ileal N Nil 9 (3) 5 0 
 
7 41 F 69.0 CD Ileocolonic N Synthroid, 
methotrexate 
(SC) 
3 (6) 10 2 
 
 
 
8 45 F 104.0 CD Ileal N Metoprolol, 
cipralex, 
lansoprazole, 
methotrexate 
(SC) 
6 (1.5) 8 0 
Disease, Ds; years, yrs; Budesonide, Bude; Harvey Bradshaw Index of disease activity, HBI; Crohn's 
disease, CD; subcutaneous, SC; treatment, tx 
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Table 3.2: Demographics (Cross-sectional Study) 
Variables Crohn's disease 
(n = 74) 
Healthy 
Volunteer 
(n = 71) 
Age, years (mean, range) 38.46 (18-72) 45.3 (19-71) 
Female sex (%) 43 (58.1) 43 (60.6) 
Weight, kg (mean ± std) 79.25 ± 17.88 81.65 ± 19.33 
CD location   
Ileal (%) 32 (43.2) - 
Colonic (%) 6 (8.1) - 
Ileo-colonic (%) 36 (48.6) - 
Disease duration, years (mean ± 
std) 
6.79 ± 7.90 - 
Disease activity (%) 30 (40.5)  
Smoking history (%) 17 (23.0) 0 (0) 
Current medications  0 (0) 
5-ASA (%) 0 (0.0%) - 
Glucocorticoid (%) 25 (21.6%) - 
MTX (%) 10 (8.6%) - 
Thiopurine (%) 62 (53.4%) - 
Anti-TNF (%) 64 (55.2%) - 
Combination therapy 
(%) 
42 (36.2%) - 
Surgery (%) 0 (0) 0 (0) 
Hospitalizations (mean ± std) 0.41 ± 0.93 - 
Kilograms, kg; standard deviation, std; inflammatory bowel disease, IBD; Crohn's disease, CD; ulcerative 
colitis, UC; tumor necrosis factor, TNF; 5-aminosalicylate, 5-ASA;  methotrexate, MTX 
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3.3.2 Pharmacokinetic Assessment 
The Pk parameters for budesonide, IV and oral midazolam are presented in Table 
3.3.  Budesonide values are standardized to a 1mg-dose.  Mean plasma concentration-
time curves for budesonide, IV and oral midazolam are shown in Figure 3.1.  Budesonide 
plasma concentration-time curves for individual subjects are shown in Figure 3.2.  Panel 
A illustrates the budesonide plasma concentration-time curves standardized to a 1mg-
dose and panel B illustrates the budesonide plasma concentration-time curves colour-
coded by dose.  There was significant inter-patient variability in budesonide exposure 
(Figure 3.2) (coefficient of variation = 0.626; p<0.001). 
T
ab le 3.3: Pharm
acokinetic param
eters in a cohort of C
rohn's disease patients (n= 8) 
Param
eter 
Subject 
1 
Subject 
2 
Subject 
3 
Subject 
4 
Subject 
5 
Subject 
6 
Subject 
7 
Subject 
8 
M
ean ± s.d. 
M
idazolam
 
C
L
s  (m
l/m
in) 
69.0 
139.4 
245.0 
95.1 
46.5 
129.2 
180.7 
32.1 
117.1±71.8 
t1/2 (h) (po) 
3.7 
1.6 
1.5 
5.5 
3.0 
2.6 
1.9 
2.0 
2.7±1.3 
C
m
ax  
(ng/m
l)(iv) 
14.3 
3.6 
0.7 
8.6 
25.2 
5.3 
3.7 
42.9 
13.05±14.4 
C
m
ax  
(ng/m
l)(po) 
5.20 
5.05 
0.57 
1.29 
2.19 
2.37 
3.29 
1.90 
2.73±1.67 
C
L
s /F (m
l/m
in) 
268.9 
206.7 
899.3 
525.6 
480.0 
322.2 
317.2 
483.0 
437.9±218.6 
F 
0.26 
0.67 
0.27 
0.18 
0.10 
0.40 
0.57 
0.07 
0.31±0.22 
E
H  
0.06 
0.12 
0.21 
0.10 
0.04 
0.12 
0.16 
0.02 
0.11±0.06 
E
G
I  
0.73 
0.23 
0.66 
0.80 
0.90 
0.54 
0.32 
0.93 
0.64±0.25 
B
udesonide 
C
m
ax  (ng/m
l)* 
0.39 
0.41 
0.09 
0.51 
0.20 
0.05 
0.44 
0.26 
0.29±0.17 
C
L/F (m
l/m
in) 
6034.7 
6839.6 
39841.5 
4465.0 
10174.4 
178140.2 
5653.4 
7630.8 
32347.5±12617.6 
t1/2 (h) 
3.2 
3.8 
2.2 
1.9 
2.8 
3.6 
7.1 
3.5±1.7 
*norm
alized to a 1m
g-dose
Intravenous, iv; system
ic clearance, C
L
s ; half-life, t1/2 ; m
axim
um
 concentration, C
m
ax ; oral bioavailability, F; oral clearance, C
L/F; hepatic 
extraction ratio, E
H ; intestinal extraction ratio, E
G
I; standard deviation, s.d. 
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Figure 3.1 Mean intravenous midazolam (50µg-dose) (A), oral midazolam (100µg-dose) 
(A), and budesonide (standardized to a 1mg-dose) (B) plasma concentrations versus time 
(hours) for subjects with Crohn’s disease (N= 8); error bars represent the standard 
deviation upper limit.  Oral, PO; intravenous, IV; hour, hr. 
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Figure 3.2 Budesonide plasma concentrations (ng/ml) versus time (hours) for 8 subjects with 
Crohn’s disease.  Panel A shows values standardized to a 1-mg dose of budesonide received by 
each subject.  Panel B shows values separated by the dose of budesonide administered to each 
subject (light grey notched line = 3mg; solid black line = 6mg; dark grey dotted line = 9mg). 
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 An individual's exposure to a drug is represented by the area-under-concentration-
vs.-time curve extrapolated to infinity (AUC0-∞).  The mean oral AUC0-∞ of budesonide 
and midazolam were 2.02ng/ml*hr ± 1.25 and 4.57ng/ml*hr ± 2.08 respectively (Table 
3.4 & 3.5).  Mean oral clearance (CL/F) was 32,347.5ml/min ± 12,617.6 (budesonide), 
and 437.9ml/min ± 218.6 (midazolam).  The systemic clearance (Cls) of midazolam was 
117.1ml/min ± 71.8 (Table 3.3).   
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Table 3.4: Comparison of the pharmacokinetic parameters of oral budesonide in a cohort of 
subjects with Crohn's disease to healthy populations¥ 
Study Population N BUDE 
po 
dose 
(mg) 
Cmax 
(ng/ml) 
Tmax 
(hr) 
AUC po 
(ng/ml*hr)  
AUC po 
(ng/ml*hr) 
T1/2 
(hr)  
Current 
study 
CD 8 1 0.27 3.38 2.02 2.02 3.5 
Dilger et.al. 
2007 
Healthy 12 3 1.00 4.5 4.88 1.62* 2.6 
Ufer et.al. 
2008 
Healthy 18 9 2.03 5.47 11.82 1.31* 3.4 
Seidegard 
et.al. 2000 
Healthy 8 3 0.39^ 4.87 4.51^ 1.50^* 4.9 
¥ All date are presented as previously published, with the exception of values indicated by "*" 
* Data values are normalized to a 1mg oral dose of budesonide by dividing the AUC po value by the 
reported dose in mg. 
^ Data are converted from nmol to ng 
Crohn's disease, CD; N, number; budesonide, BUDE; oral, PO; maximum concentration, Cmax; time to 
maximum concentration, Tmax; area under the concentration time curve, AUC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T
able 3.5: C
om
parison of the pharm
acokinetic param
eters of oral and intravenous m
idazolam
 in a cohort of subjects w
ith 
C
rohn's disease to healthy populations ¥ 
Study 
C
ohort 
N
 
M
ID
 
po 
dose 
(µg) 
M
ID
 iv 
dose 
(µg) 
C
m
ax  
(ng/m
l) 
T
m
ax  
(hr) 
A
U
C
 po 
(ng/m
l*hr
) 
A
U
C
 po 
(ng/m
l*hr) 
C
L
s/F 
(m
l/ 
m
in) 
C
L
s 
m
l/ 
m
in) 
E
G
I  
E
H  
F 
C
urrent 
Study 
C
D
 
8 
100 
50 
2.73 
0.53 
4.57 
4.57 
437 
117 
0.64 
0.11 
0.31 
Eap et. 
al. 2004 
H
ealthy 
21 
75 
- 
0.31 
0.8 
0.68 
*0.91 
2133 
-
- 
- 
- 
Lappin 
et. al. 
2006 
H
ealthy 
30 
100 
100 
0.37 
0.56 
1.02 
1.02 
1491 
340 
- 
- 
0.22 
G
ong et. 
al. 2012 
H
ealthy 
23 
100 
- 
0.47 
0.57 
0.86 
0.86 
- 
- 
- 
- 
- 
H
ohm
an 
et. al. 
2015 
H
ealthy 
16 
3 
1 
0.011
9 
0.5 
0.026 
*0.87 
1880 
439 
0.53 
0.44 
0.23
H
ohm
an 
et. al. 
2015 
H
ealthy 
16 
3000 
1000 
9.99 
0.5 
8.13 
- 
2050 
428 
0.61 
0.43 
0.2 
D
resser 
et. 
al.2003 
H
ealthy 
21 
4000 
1000 
20.2 
- 
- 
- 
1182 
383 
0.47 
0.36 
0.33 
Thum
m
el 
et. 
al.1996 
H
ealthy 
20 
2000 
1000 
N
R
 
- 
- 
- 
1413 
370 
0.44 
0.43 
0.30 
X
ie et. al. 
2005 
H
ealthy 
30 
5000 
2000 
N
R
 
- 
- 
- 
2200 
385 
0.30 
0.62 
0.19 
¥ A
ll date are presented as previously published, w
ith the exception of values indicated by "*" 
* D
ata values are norm
alized to a 100-µg oral dose of m
idazolam
 by dividing the A
U
C
 po value by the reported dose in µg and m
ultiplying it by 100µg
C
rohn's disease, C
D
; N
, num
ber; m
idazolam
, M
ID
; oral, PO
; m
axim
um
 concentration, C
m
ax ; tim
e to m
axim
um
 concentration, T
m
ax ; area under the 
concentration tim
e curve, A
U
C
; not reported, "-"; intestinal extraction ratio, E
G
I ; hepatic extraction ratio, E
H
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3.3.3 Comparison between drugs 
 The mean hepatic and intestinal extraction ratios for midazolam representing the 
proportion of CYP3A4 activity occurring were 0.11 ± 0.06 and 0.64 ± 0.25 respectively 
(Figure 3.3a, b).  The mean oral bioavailability (F) of midazolam was 31% ± 22% (Figure 
3.3c).  There was no significant relationship between budesonide exposure (AUC0-∞) and 
the oral clearance or exposures of midazolam (Figure 3.4).   
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Figure 3.3. Hepatic (A), intestinal (B) extraction ratios and oral bioavailability (C) 
separated by subject.  The mean value is presented following the final individual subject 
value. 
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Figure 3.4 Correlation between budesonide exposure (AUC0-∞; normalized to a 1mg-
dose) and oral midazolam exposure (AUC0-∞, ng/ml*hr) (panel A), oral midazolam oral 
clearance (Cls/F, ml/min) (panel B) using the Spearman correlation coefficient (Rs).  
AUC, area under the curve. 
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3.3.4 4β-hydroxycholesterol Plasma Concentrations Are Decreased in 
Crohn's disease 
 A second cohort of subjects with CD (n=74) provided a blood sample for the 
quantification of 4βOHC in plasma as did a cohort of non-CD controls (n=71) to estimate 
CYP3A4 activity in vivo.  The 4βOHC plasma concentrations were significantly lower in 
the total CD population compared to the non-CD controls (CD= 18.68ng/ml±13.02ng/ml, 
non-CD= 58.14ng/ml±61.76ng/ml, p≤0.0001) (Figure 3.5) on bivariate analysis or when 
adjusting for the covariates, age, sex, and disease activity (Table 3.6).  The multiple 
linear regression analysis accounted for 33.6% of the inter-individual variation in 4βOHC 
plasma concentrations.  No significant difference was seen in 4βOHC plasma 
concentrations between CD subjects stratified by disease activity (inactive CD= 
19.75ng/ml±13.34ng/ml, active CD= 17.11ng/ml±12.60ng/ml, p=0.99) (Figure 3.5). 
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Table 3.6. Multiple linear regression model for the effect on Ln-transformed 
4βOHC plasma concentrations for the total population (n = 145) 
Variable β-coefficients Standard error P-value 
Intercept 2.721 0.447 ≤0.0001 
Sex 0.548 0.151 ≤0.0001 
Age 0.130 0.005 0.008 
Weight 0.000 0.004 0.92 
Crohn's disease   -0.832 0.162 ≤0.0001 
Disease activity -0.200 0.197 0.31 
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Figure 3.5  The mean 4βOHC plasma concentrations for subjects with active and inactive 
Crohn's disease (CD) as well as non-CD controls.  Median values (thick horizontal line), 
25th and 75th percentile values (box outline), minimum and maximum values (whiskers), 
and outlier values (circles).  4β-hydroxycholesterol, 4βOHC. 
 
108 
3.3.5 Plasma Bile Acid Profiles Differ Between Individuals with and 
without Crohn's Disease 
Plasma bile acid profiles consisting of 12 bile acids were determined for all 
subjects (n=145).  Tables 3.7 and 3.8 summarize the plasma bile acid profiles as whole 
concentrations and as a percentage of the total bile acid pool respectively.   
T
able 3.7: B
ile acid profiles presented as concentrations (ng/m
L
) 
B
ile acid (ng/m
L
) 
C
ontrol (n=71) 
Inactive C
D
 (n=44) 
A
ctive C
D
 (n=30) 
p-value* 
C
A
 
200.6 
176.6 
184.6 
ns 
TC
A
 
47.8 
43.9 
44.7 
<0.01 
G
C
A
 
71.5 
276.3 
256.5 
<0.001 
C
D
C
A
 
342.8 
519.3 
472.3 
ns 
G
C
D
C
A
 
1705.3 
1984 
2730 
<0.001 
D
C
A
 
202.2 
368.3 
274.9 
ns 
TD
C
A
 
106.8 
253.8 
176.8 
ns 
G
D
C
A
 
473.2 
2523 
3587 
<0.001 
LC
A
 
96.5 
114.6 
86.8 
<0.001 
TLC
A
 
11.1 
8.3 
17.5 
ns 
U
D
C
A
 
175.8 
331.4 
434.7 
ns 
TU
D
C
A
 
1.7 
0.7487 
0.8586 
ns 
*C
om
parison of control to active and inactive C
D
 
C
rohn's disease, C
D
; cholic acid, C
A
; chenodeoxycholic acid, C
D
C
A
; deoxycholic acid, D
C
A
; glycocholic acid, G
C
A
; glycochenodeoxycholic acid, G
C
D
C
A
; glycodeoxycholic acid, 
G
D
C
A
; lithocholic acid, LC
A
; taurocholic acid, TC
A
; taurodeoxycholic acid, TD
C
A
; taurolithicholic acid, TLC
A
; tauroursodeoxycholic acid, TU
D
C
A
; and ursodeoxycholic acid, U
D
C
A
; 
not significant, ns. 
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T
able 3.8: B
ile acid profiles presented as a percentage of the total bile acid pool by group 
Plasm
a B
ile acids 
C
ontrol 
(n=71) 
Inactive C
D
 
(n=44) 
A
ctive C
D
 
 (n=30) 
p-value* 
Prim
ary B
ile 
acids plus 
conjugates 
C
D
C
A
 
4.87%
 
6.75%
 
8.76%
 
ns 
G
-C
D
C
A
 
47.11%
 
33.11%
 
37.02%
 
<0.001 
T
otal 
51.98%
 
39.86%
 
45.78%
 
C
A
 
4.87%
 
2.61%
 
2.84%
 
ns 
G
-C
A
 
1.08%
 
4.79%
 
4.98%
 
<0.001 
T-C
A
 
3.01%
 
1.31%
 
0.90%
 
<0.01 
T
otal 
8.96%
 
8.71%
 
8.72%
 
Secondary bile 
acids plus 
conjugates 
D
C
A
 
5.44%
 
5.74%
 
3.19%
 
ns 
G
-D
C
A
 
14.46%
 
32.00%
 
31.32%
 
<0.001 
T-D
C
A
 
3.20%
 
3.97%
 
2.19%
 
ns 
T
otal 
23.10%
 
41.71%
 
36.70%
 
LC
A
 
6.49%
 
3.50%
 
1.46%
 
<0.001 
T-LC
A
 
1.33%
 
0.09%
 
0.38%
 
ns 
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Subjects with CD had a higher ratio of conjugated to unconjugated bile acids compared to 
controls (active CD= 5.9; inactive CD= 6.9; control= 3.0, Figure 3.6).  Significant 
differences in the composition of the bile acid pool were seen based on presence or 
absence of CD.  Differences in the percent composition of GCDCA, GCA, TCA, GDCA, 
LCA were most significant (Figure 3.7). CDCA and DCA were different between 
controls and CD subjects with active disease.  There was no difference in UDCA, TDCA, 
CA.   
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Figure 3.6 The ratio of the plasma concentration of conjugated to unconjugated bile 
acids stratified by cohort (control, active CD, inactive CD).  The 95%CI is represented by 
the vertical T-line.  *, p<0.05; **, p<0.01; ***, p<0.001.  Crohn's disease, CD. 
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Figure 3.7 Bile acid profiles.  The mean individual bile acid profiles expressed as mean 
concentrations in ng/ml  and as a percentage of the total bile acid pool, stratified by cohort 
(control, active CD, inactive CD).  The 95%CI is represented by the vertical T-line.  *, p<0.05; 
**, p<0.01; ***, p<0.001.  Crohn's disease, CD; cholic acid, CA; chenodeoxycholic acid, CDCA; 
deoxycholic acid, DCA; glycocholic acid, GCA; glycochenodeoxycholic acid, GCDCA; 
glycodeoxycholic acid, GDCA; lithocholic acid, LCA; taurocholic acid, TCA; taurodeoxycholic 
acid, TDCA; taurolithicholic acid, TLCA; tauroursodeoxycholic acid, TUDCA; and 
ursodeoxycholic acid, UDCA. 
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3.3.6 Activation of PXR by Individual Bile Acids and Cohort-Specific Bile 
Acid Profiles  
 To explore the impact of CD-dependent alterations in the plasma bile acid profile 
on PXR-mediated CYP3A4 activity,  a transient transfection and dual luciferase assay 
were used. We found that luciferase activity (a surrogate of CYP3A4 activity) was 
markedly elevated in cells exposed to known PXR activators, DCA (12-fold), GDCA 
(10-fold) or LCA (23-fold) (Figure 3.8).  These data are in agreement with other reports 
of bile acid-induced activation of PXR38, 39.  Conversely, no difference was seen in the 
luciferase activity amongst the transfected cells exposed to the cohort-specific bile acid 
pools (Figure 3.8).    
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Figure 3.8 Effect of known bile acid PXR agonists and patient-derived bile acid 
profiles on CYP3A4-pGL3 basic reporter activity in HepG2 cells co-transfected with 
hPXR.  One of DCA, LCA, GDCA (10µM)  a bile acid pool (25µM) representative of 
inactive or active CD or a healthy population were incubated with cells for 24 hours. All 
experiments were completed in triplicate and repeated 3 times.  Error bars indicate the 
95% confidence interval. 
Deoxycholic acid, DCA; lithocholic acid, LCA; glycol-deoxycholic acid, GDCA; Crohn's 
disease, CD; dimethyl sulfoxide, DMSO; pregnane X receptor, PXR; cytochrome p450, 
CYP; hepatocarcinoma, Hep;  
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3.4 Discussion 
 CYP3A4 is considered to be one of the most clinically-relevant determinants of 
drug metabolism and exposure today. Although there is a significant amount of data in 
terms of CYP3A4 activity in vivo in human subjects, nearly all such studies have been 
conducted in healthy volunteers.  In disease conditions, such as CD, remarkably little is 
known with regards to the extent of CYP3A4 activity. In this study, we evaluated 
subjects with active CD on stable doses of the glucocorticoid drug, budesonide, where 
pharmacokinetic analysis of an exogenous probe substrate of CYP3A4 was utilized to 
better delineate the difference in hepatic versus intestinal CYP3A4 activity.  We were 
also able to evaluate the impact of CYP3A4 activity on budesonide exposure, a known 
CYP3A4 substrate.  Furthermore, we were able to validate our findings of reduced 
CYP3A4 activity in CD in an independent cohort of CD patients as well as explore a 
possible mechanism for this difference.  To our knowledge, this is the first study to assess 
CYP3A4 activity in a CD population using both in vivo probes midazolam and 4βOHC. 
 Of high clinical relevance, is the near  5-fold higher AUC0-∞ for oral midazolam 
in our patient Pk population compared to what has been reported in healthy populations 
(Figure 3.9b, Table 3.5)30, 32, 40, 41.  This suggests that total CYP3A4 activity is profoundly 
reduced in CD compared to healthy individuals.  Interestingly, the decrease in CYP3A4 
activity cannot necessarily be attributed to a reduction in intestinal CYP3A4 activity as 
one might suspect in a primary intestinal illness.  A higher degree of midazolam 
extraction and subsequently CYP3A4 activity occurred in the gut (Egi= 0.64 ± 0.25) 
compared to the liver (Eh= 0.11 ± 0.06) (Figure 3.3a, b).  And while, to date, the degree 
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of extraction in the liver versus the intestine has been reported at varying levels, the 
degree of difference seen between the liver and gut extraction in our CD population has 
not been seen in healthy populations33, 41-43.   One potential limitation of our Pk study 
might be the absence of a control population. However, in comparison to a cohort of 
healthy volunteers who participated in a previous study conducted in our laboratory 32 
using the same midazolam microdose-based phenotyping approach for CYP3A4 and the 
same LC-MS/MS assay used in the current study, we observed a marked reduction in our 
CD subjects (Figure 3.9b, Table 3.5). 
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Figure 3.9 A comparison of oral budesonide (Panel A), and oral midazolam (Panel B) 
exposure (AUCpo0-∞, ng/ml*hr) between our Crohn's disease population and reported 
values for healthy populations standardized to the same drug dose.  AUC, area under the 
curve; po, oral 
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 In this study, we note that subjects with CD have a comparable exposure to 
budesonide, a known substrate of CYP3A4, to what has been reported in studies of 
healthy individuals when standardized to the same dose (Figure 3.9a, Table 3.4)3, 5, 44.  
We also see that budesonide exposure is highly variable in subjects with CD (Figure 3.2); 
consistent with what has been shown in healthy populations as well as in a single adult 
CD population 3, 6.  This may account for the some of the variability seen in response to 
budesonide treatment.  Based on our data, CYP3A4 activity accounts for only a small 
fraction of the variability in budesonide exposure.  This suggests that there are other 
factors determining budesonide exposure in CD and that CYP3A4 may not have a 
significant impact on its disposition in this population; however, our sample size may be 
too small to draw any firm conclusions.   
 Moreover, we independently confirm a reduction in CYP3A4 activity in CD using 
the CYP3A4-in vivo probe, 4βOHC.  The evaluation of hepatic CYP3A activity using 
this endogenous marker has been well-documented31.  CYP3A4 and 3A5 regulate the 
production of 4βOHC and it is useful for the evaluation of CYP3A induction by specific 
drugs.  The plasma concentration of 4βOHC is significantly lower in the CD population 
compared to a control population (Figure 3.5).  The effect of CD presence on CYP3A4 
activity remains even when age, sex, weight and disease activity (assessed by HBI) are 
taken into account (Table 3.6).   Of note, some groups endorse the use of the ratio of the 
plasma concentrations of 4βOHC to cholesterol31, 45, 46.  In some populations, plasma 
concentrations of cholesterol may differ based on treatment, which may impact the ability 
to form 4βOHC from its parent compound.  Though, plasma cholesterol was not 
measured in our population, no subjects included in our study were being treated for 
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dyslipidemia.  This may have minimized confounding in our population, though does not 
entirely eliminate it.  Furthermore, some groups suggest there is only a weak correlation 
between midazolam Pk parameters (total and liver CYP3A4 activity) and 4βOHC plasma 
concentrations.47  However, this may be partially explained by the fact that 4βOHC is a 
substrate of both CYP3A4 and 3A5, while midazolam is only a substrate of CYP3A431.  
Moreover, 4βOHC has a long half-life (1-3weeks) and therefore cannot be used to assess 
rapid fluctuations in CYP3A activity.31, 47  It has been concluded that 4βOHC may be 
most useful for assessing constitutive CYP3A4 activity.  Midazolam Pk parameters are 
considered the gold standard for assessing CYP3A4 activity in vivo31.  Despite, these 
possible limitations, we are able to show, using both modalities, that CYP3A4 activity is 
reduced in CD.   
 Reduced hepatic CYP3A4 activity in the setting of systemic or non-hepatic 
inflammation has been reported, although our study is the first to demonstrate such an 
effect in CD using multiple CYP3A4-phenotyping modalities.  In vitro and in vivo animal 
studies both conclusively show that in the setting of acute non-hepatic inflammation, 
hepatic CYP3A4 expression is down-regulated.22  Studies in humans show an increase in 
the plasma drug concentrations of CYP3A4 substrates in the setting of acute 
inflammation48.  The effect of chronic inflammation on CYP3A4 activity and expression 
in humans is not well defined and there is a paucity of literature on this subject.  One 
small study did assess CYP3A4 activity in IBD.  Iwamoto et.al. (2013) evaluated single-
point 4β-OHC plasma concentrations in subjects with IBD as well as healthy 
volunteers21.  They found a significant reduction in the 4β-OHC plasma concentrations of 
their CD cohort compared to a cohort of healthy controls; however, their sample size was 
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small (21 CD patients, 26 controls), limiting the generalizability of their findings.  They 
also did not account for CD disease activity in their analysis nor any other factors that 
may have confounded CYP3A4 activity.  It has been suggested that hepatic CYP3A4 is 
down-regulated due to the effects of IL-1𝛽, IL-6, TNF-α, and IFN-α and 𝛾20, 22; however, 
in our cross-sectional cohort, no difference is seen in the CYP3A4 activity of CD subjects 
with and without active disease, suggesting an alternate mechanism for this reduced 
activity. 
 We tested the hypothesis that changes in bile acid-mediated activation of PXR 
account for detectable differences in CYP3A4 activity in CD using a HepG2 cell model.  
We show that there are differences in the bile acid profiles of CD (active and inactive) 
and non-CD cohorts (Table 3.7, 3.8; Figure 3.7).  These data provide a more detailed 
analysis of bile acid pool composition in CD; however, they re-iterate principles already 
established in the literature49, 50.  Specifically, that individuals with IBD have a different 
pattern of bile acids compared to healthy controls, perhaps due to documented changes in 
the presence of bile acid-modifying gut bacteria29, 50.  We then applied these cohort-
specific bile acid pools to a HepG2 cell model and evaluated the effect of bile acid-
induced PXR on CYP3A4 activity.  Our findings confirm that glycine-conjugated and 
unconjugated DCA as well as LCA are potent PXR agonists.  Conversely, we did not find 
an appreciable difference in the activation of CYP3A4 based on exposure to our cohort-
specific bile acid pools (Figure 3.8).  The reasons for this may be multi-factorial: 1) 
plasma bile acid composition is a relatively dilute compared to what is seen in the liver 
and bile51; thus small differences in individual bile acid concentrations in plasma may 
under-represent the ultimate impact of these changes in the liver or bile on downstream 
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target pathways 2) other bile acid-activated NRs, such as FXR, with impact on CYP3A4 
activity, may need to be accounted for.  Ultimately, more studies are needed. 
 In summary, this is the first study in CD populations evaluating CYP3A4  activity 
using dual in vivo probes.  CYP3A4 activity is lower in the setting of CD based on 
midazolam Pk and single point-4βOHC plasma concentration measurements.  
Interestingly, this effect is mainly due to a reduction in hepatic CYP3A4 activity based 
on the midazolam data.  Our findings suggest that a disease-dependent reduction in 
CYP3A4 needs to be taken into consideration when prescribing substrate drugs such as 
certain HMG-CoA reductase inhibitors, benzodiapines or oral anticoagulants to a CD 
population.  The molecular mechanisms responsible for these findings remain to be 
explored.   
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4.1 Introduction 
 The intestinal mucosa plays a vital role in human health: it is the key interface for 
the absorption of nutrients including electrolytes and water as well as an effective barrier 
against host exposure to environmental pathogens and toxins.  It is composed of a 
monolayer of columnar epithelial cells known as enterocytes, as well as goblet cells, 
paneth cells and enteroendocrine cells.  Cells are arranged in villi, superimposed over the 
lamina propria and inferiorly bound by the muscularis mucosae1, 2.  The enterocytes, 
overlaying the lamina propria, are tightly joined by a series of junctional proteins (tight 
junctions, adherens junctions, desmosomes) and are arranged in a folded pattern, 
producing crypts and villi on a cytoskeleton framework3.  The lamina propria, the 
bedrock of the epithelium, houses a number of different cell types that carry out a host of 
important functions for maintaining the integrity of the mucosal layer and its 
immunological role in barrier function.  Fibroblasts, lymphocytes, plasma cells, 
granulocytes, macrophages and dendritic cells form part of the rich cellular fabric of the 
lamina propria amidst an extensive vascular network4.   
 An extension of the barrier function of the intestine is its contribution to first-pass 
metabolism.  It is well established that an individual's exposure to an orally-dosed 
medication may differ considerably from their exposure to its intravenously-dosed 
counterpart5.  The concept of first-pass metabolism refers to the extensive processing 
applied to orally-dosed drugs in the hepatic parenchyma and now, increasingly 
recognized, in the gut mucosa that limits the delivery of active drug to the systemic 
circulation6, 7.  The cytochrome P450 enzyme (CYP) 3A4 is an integral part of the "first-
pass" phenomenon in humans given its abundance in both liver and intestinal tissue.  It 
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accounts for up to 40% and 80% of their respective CYP burdens and is involved in the 
metabolism of up to 50% of drugs used in clinical practice8-10.  Within the intestine, 
CYP3A4 is localized to enterocytes found at the tips of villi and is expressed in highest 
concentrations within the jejunum and ileum7, 11.  Intestinal CYP3A4 may act in a 
coordinated manner with key xenobiotic exporters, such as P-glycoprotein (P-gp), a 
member of the ATP-binding cassette protein (ABC) superfamily12.  This idea is 
reinforced by the findings of multiple shared substrates and inhibitors as well as co-
localization within villous tip-enterocytes.  P-gp bound to the cell membrane of 
enterocytes may regulate the exposure of specific drugs to metabolism by CYP3A4.  It is 
thought that P-gp reduces the concentration of a drug within the enterocyte by actively 
moving the drug back into the intestinal lumen across the plasma membrane.  This limits 
the saturation of intestinal CYP3A4 and leads to more effective and complete metabolism 
of drugs13.      
 The impact of chronic liver and kidney disease on the expression of hepatic 
CYP3A4 has been evaluated and reductions in CYP3A4 expression are observed14-16.  
Similarly, research pertaining to P-gp reveals that there is over-expression of P-gp and 
the gene by which it is coded, MDR1, in a multitude of cancers17, 18.  The effect of a 
primary intestinal illness on the intestinal expression of CYP3A4 and P-gp has only been 
explored in a limited capacity 19-25. Crohn's disease (CD) is a primary, chronic illness of 
the intestinal tract that produces transmural, discontinuous inflammatory lesions along 
the gut's longitudinal access.  It is often confined to the small and large intestines, but can 
be found anywhere from the oral cavity to the most distal colon26.  Hallmarks of CD 
include disruption of the epithelial cell tight junctions, epithelial cell apoptosis, expansion 
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of the lamina propria with pro-inflammatory cells and the recruitment and activation of 
pro-fibrotic fibroblasts27-29.  Such changes in barrier function lead to the trademark 
clinical profile of CD including abdominal pain, profuse diarrhea, intestinal stricturing 
and fistulization.  Disruption of the intestinal mucosa may also have important 
implications for epithelial-based processes such as phase 1 and 2 drug metabolism and 
drug transport.  Specifically, the loss of mucosal surface area may result in the loss of 
intestinally-expressed CYP3A4 and P-gp protein.  The impact of CD on the protein 
expression of both CYP3A4 and P-gp has not been well-evaluated, particularly in an 
adult population. 
 The aim of this study was to evaluate the intestinal expression of CYP3A4 and P-
gp at two intestinal sites in adult patients with CD compared to non-CD controls. 
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4.2 Materials & Methods 
4.2.1 Subjects 
 The study protocol was approved by the University of Western Ontario Health 
Sciences Research Ethics Board (13067) and was carried out in accordance with the 
Declaration of Helsinki.  Written and informed consent was obtained from all 
participants. Twenty three subjects with CD and 37 non-CD controls were recruited from 
a single centre in London, Ontario between August 2009 and December 2014.  Eligible 
CD subjects were 18 years of age or older with a history of CD confirmed by previous 
histopathologic examination.  Eligible controls were 18 years of age or older with no 
clinical history of gastrointestinal pathology.  Subjects in either group taking CYP3A4 or 
P-gp agonists or antagonists (with the exception of budesonide) were excluded.  Clinical 
data pertaining to CD subject age, sex, weight, smoking history, medication history and 
drug response, diagnosis, disease location, disease activity were collected.  Demographic 
data were collected for each non-CD control.  All participant data is summarized in Table 
4.1.   
 
4.2.2 Study Objectives and Outcomes 
 The objective of this study was to test the hypothesis that individuals with CD 
have reduced expression of intestinal CYP3A4 and P-gp protein relative to a healthy 
population.  The primary endpoints were the density ratios of ileal CYP3A4 and P-gp 
protein to villin in subjects with CD compared to non-CD controls.  Secondary endpoints 
included the density ratios of colonic CYP3A4 and P-gp protein to villin in CD versus 
non-CD cohorts, as well as the relative densities of ileal and colonic CYP3A4 and P-g 
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protein stratified by one of age, sex, or CD activity (by Harvey Bradshaw Index, HBI) 
respectively for the CD cohort as well as by age and sex in the non-CD cohort.  
 
4.2.3 Tissue Collection 
 Tissues samples from the terminal ileum and ascending colon were obtained from 
all subjects at the time of colonoscopy.  Tissue sampling from the CD cohort was 
obtained exclusively from non-inflamed areas (based on endoscopic examination) in the 
presence or absence of active disease.  All tissue samples were immediately frozen on dry 
ice after excision and stored at -80ºC until further use. 
 
4.2.4 Protein Quantification: 
 Total protein was isolated from the ileal and colonic tissue samples and quantified 
using bovine serum albumin as an internal standard.  Twenty micrograms of isolated 
protein was separated on a 4-12% tris-acetate gel and transferred to a nitrocellulose 
membrane.  P-gp-expressing caco2 cells and human liver samples were used as controls 
for P-gp and CYP3A4 respectively.  Blots were blocked overnight at 4ºC in 10% non-fat 
dried milk in Tris buffer containing 1% Tween 20.  Blots were incubated with the 
primary antibody, 3H8 directed against CYP3A4 (Thermoscientific, Rockford IL, USA; 
dilution 1:500) and C219 directed against P-gp (Covance, Dedham MA, USA; dilution: 
1:500) respectively.  Villin (CWWB1) was used as the internal standard (Santa Cruz 
Biotechnology; dilution 1:500).  Horse radish peroxidase conjugate-labeled goat anti-
mouse IgG was used as a secondary antibody (dilution 1:10,000).  Detection was 
achieved by chemiluminescence with enhanced chemiluminescence western blot 
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detecting reagents (GE Healthcare, Chicago Illinois, USA).  Quantification by 
densiometry was performed using Image J software.  Relative CYP3A4 and P-gp protein 
expression were represented as the ratios of densities of the target protein to villin. 
 
4.2.5 Statistical Analysis: 
 All statistical analyses were carried out in Graphpad Prism and SPSS.  The 
distribution of the protein expression data was assessed using the D'Agostino & Pearson 
omnibus normality test.  The Mann-Whitney test was used to assess any statistically 
significant differences in protein expression between two groups, while the Kruskal-
Wallis test was used to assess any statistically significant differences in protein 
expression between three or more groups.  Dunn's multiple comparison test was used to 
conduct a post-hoc analysis of data evaluated by the Kruskal-Wallis test.  A linear 
regression analysis was used to assess the relationship between one of sex or age and the 
relative densities of ileal and colonic CYP3A4 and P-gp respectively in both CD and non-
CD cohorts.  A multiple linear regression model was to evaluate the effect of multiple 
covariates (age, sex, disease presence, disease activity) on inter-individual variation in 
ileal and colonic CYP3A4 and P-gp relative densities. 
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4.3 Results: 
 
4.3.1 The effect of disease presence and activity on intestinal CYP3A4 
protein expression 
 Demographic data are presented in Table 4.1.  The expression of intestinal 
CYP3A4 protein is presented as the density of CYP3A4 protein on Western Blot relative 
to the density of villin (Figure 4.1 and 4.2).  The protein expression patterns of CYP3A4 
relative to villin in ileum and ascending colon are presented for CD and non-CD 
populations in Figure 4.3.  CYP3A4 expression in both the CD cohort and the controls 
mirrored physiological patterns previously reported in healthy individuals: CYP3A4 
content was higher in the ileum than in the colon (CD, p<0.0001; control, p<0.0001).  
Ileal CYP3A4 expression was decreased in CD compared to controls (CD, 0.40±0.35; 
control, 0.72±0.33; p<0.01) (Figure 4.3).  Similarly, colonic CYP3A4 expression was 
decreased in CD compared to controls (CD, 0.08±0.08; controls, 0.37±0.34; p<0.0001) 
(Figure 4.1).   Significant inter-individual variation was observed in ileal (CD, 39-fold; 
control, 93-fold) and colonic (CD, 49-fold; control, 67-fold) CYP3A4 expression.   
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Table 4.1: Demographics 
Variables 
 
CD 
(n=23) 
Non-CD Controls 
 (n=37) 
Age, years (mean, range)  48.87 (22-80) 63.77 (27-85) 
Female sex (%) 16 (69.6) () 
Smoking history (%) 6 (26.1) 0 (0.0) 
Disease location   
Ileal disease (%)  11 (47.8) - 
Ileo-colonic disease (%)  9 (39.1) - 
Colonic disease (%) 3 (13.1) - 
Active disease (%)* 9(39.1) - 
Previous resection (%) 4 (17.4) - 
Duration of disease 10.71±8.54 - 
Medication use 38 (95.0) - 
Glucocorticoids 19 (82.6) - 
5-aminosalicylates 0 (0) - 
Azathioprine 11 (47.8) - 
Methotrexate 14 (60.9) - 
Biologics 11 (47.8) - 
Crohn's disease, CD 
*Disease activity is based on the Harvey-Bradshaw Index for individuals with CD; 
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Figure 4.1 Intestinal expression of CYP3A4 and P-gp by Western blot for 21 of 23 CD 
participants (ileal data for subject 6 is not included in this figure nor data for subjects 22 
and 23).  Cytochrome P450 3A4, CYP3A4; P-glycoprotein, P-gp; Crohn's disease, CD; +, 
positive control.  
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Figure 4.2 Intestinal expression of CYP3A4 and P-gp by Western blot for 37 non-CD 
controls (data for subjects 28 and 32 are not included in this figure).  Cytochrome P450 
3A4, CYP3A4; P-glycoprotein, P-gp; +, positive control. 
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Figure 4.3 The relative protein expression of CYP3A4 to villin in the ileum and 
ascending colon of individuals with (n=23) and without (n=37) CD.  Per the box plot, 
mean values (thick horizontal line), 25th and 75th percentile values (box outline), 
minimum and maximum values (whiskers), and outlier values (circles).  ***, p <0.0001, 
**, p<0.01.  Cytochrome, CYP; Crohn's disease, CD. 
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Neither, disease location nor disease activity, assessed by the Harvey-Bradshaw Index 
(HBI), accounted for any appreciable difference in ileal or colonic CYP3A4 expression in 
the CD cohort.   Multiple linear regression was performed on the relative densities of ileal 
and colonic CYP3A4, adjusting for age, sex, weight, disease presence, and disease 
activity (Table 4.2 and 4.3).  Disease presence had a persistently significant and negative 
impact on the relative expression of both ileal and colonic CYP3A4 protein. 
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Table 4.2: Multiple linear regression model for the effect on relative densities of ileal 
CYP3A4 for the total population (n = 60) 
Variable β-coefficients Standard error P-value 
Intercept 0.740 0.277 0.011 
Sex -0.034 0.110 0.762 
Age 0.000 0.004 0.991 
Crohn's disease   -0.279 0.131 0.048 
Disease activity -0.001 0.180 0.995 
 
   
Table 4.3: Multiple linear regression model for the effect on relative densities of 
colonic CYP3A4 for the total population (n = 60) 
Variable β-coefficients Standard error P-value 
Intercept 0.596 0.206 0.006 
Sex -0.091 0.008 0.309 
Age -0.002 0.003 0.392 
Crohn's disease   -0.279 0.106 0.012 
Disease activity -0.062 0.143 0.669 
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4.3.2 The Effect of Age and Sex on Intestinal CYP3A4 Expression 
 CYP3A4 expression varied significantly with age in both the CD and control 
cohorts (Figure 4.4).  Ileal CYP3A4 expression decreased with advancing age in the 
control cohort (Figure 4.4a); however, this was not observed in the corresponding colonic 
samples (Figure 4.4b).   Conversely in the CD cohort, ileal CYP3A4 expression increased 
with age (Figure 4.4c).  This was not seen in the CD ascending colon samples (Figure 
4.4d).  Sex did not have significant impact on CYP3A4 expression in either cohort at 
either intestinal location. 
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Figure 4.4 The influence of age on the relative densities of ileal and colonic CYP3A4 
protein in control (Panel A and B) and CD (Panel C and D) populations.  The solid line 
represents the linear regression.  Cytochrome P450, CYP; Spearman correlation, R; 
Crohn's disease, CD; non-significant, ns. 
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4.3.3 The Effect of Disease Presence and Activity on Intestinal P-Gp 
Protein Expression 
 The expression of intestinal P-gp protein is presented as the density of P-gp 
protein on Western Blot relative to the density of villin (Figure 4.1 and 4.2).  The protein 
expression patterns of P-gp relative to villin in ileum and ascending colon are presented 
for CD and non-CD populations in Figure 4.5.  No difference was seen in the relative 
ileal P-gp expression in CD compared to controls (CD, 0.095±0.10; control, 0.11±0.09; 
p=ns) (Figure 4.3).  Conversely, the relative colonic P-gp expression was decreased in 
CD compared to controls (CD, 0.026±0.029; controls, 0.17±0.21; p<0.01) (Figure 4.3).   
Significant inter-individual variation was observed in ileal (CD, 18-fold; control, 13-fold) 
and colonic (CD, 22-fold; control, 207-fold) P-gp expression. 
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Figure 4.5 The relative protein expression of P-gp to villin in the ileum and ascending 
colon of individuals with (n=23) and without (n=37) CD.  Per the box plot, mean values 
(thick horizontal line), 25th and 75th percentile values (box outline), minimum and 
maximum values (whiskers), and outlier values (circles). **, p<0.01.  P-glycoprotein, P-
gp; Crohn's disease, CD. 
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Similar to CYP3A4 expression, neither disease location nor disease activity, assessed by 
HBI, affected P-gp expression in the ileum or ascending colon of the CD cohort.   
Multiple linear regression was performed on the relative densities of ileal and colonic P-
gp, adjusting for age, sex, weight, disease presence, and disease activity (Table 4.4 and 
4.5).  Disease presence had a persistently significant and negative impact on the relative 
expression of colonic P-gp protein (Table 4.5), but not in the ileum (Table 4.4). 
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Table 4.4: Multiple linear regression model for the effect on relative densities of ileal 
P-gp for the total population (n = 60) 
Variable β-coefficients Standard error P-value 
Intercept 0.186 0.073 0.015 
Sex -0.052 0.031 0.099 
Age -0.001 0.001 0.479 
Crohn's disease   -0.002 0.036 0.947 
Disease activity -0.032 0.047 0.497 
 
 
Table 4.5: Multiple linear regression model for the effect on relative densities of 
colonic P-gp for the total population (n = 60) 
Variable β-coefficients Standard error P-value 
Intercept 0.360 0.113 0.003 
Sex 0.043 0.047 0.368 
Age -0.004 0.002 0.028 
Crohn's disease   -0.179 0.055 0.002 
Disease activity -0.037 0.071 0.602 
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4.3.4 The Effect of Age and Sex on Intestinal P-Gp Expression 
 Colonic P-gp expression varied significantly with age in both the CD and control 
cohorts (Figure 4.6).  Colonic P-gp expression decreased with advancing age in the CD 
and control cohorts (Figure 4.6b, d).  This remained significant based on the multiple 
linear regression analysis (Table 4.5).  Conversely, this was not observed in the 
corresponding ileal samples (Figure 4.6a, c).   Sex did not have significant impact on P-
gp expression in either cohort at either intestinal location. 
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 Figure 4.6 The influence of age on the relative densities of ileal and colonic P-gp protein 
in control (Panel A and B) and CD (Panel C and D) populations.  The solid line 
represents the linear regression.  P-glycoprotein, P-gp; Spearman correlation coefficient, 
R; Crohn's disease, CD; non-significant, ns. 
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4.4 Discussion: 
 The intestine is essential for nutrient absorption, host defense and plays a key role 
in drug metabolism in concert with the liver.   The interplay of numerous factors likely 
contributes to inter-individual variation in drug exposure and response.  Key phase 1 drug 
metabolism enzyme, CYP3A4 has been proposed to act in a synchronized manner with 
xenobiotic exporter, P-gp to significantly affect the oral bioavailability of numerous 
shared substrates.  This theory is further supported by their co-localization in enterocytes. 
 Disease-dependent decreases in hepatic CYP3A4 activity and expression are 
observed in a myriad of chronic hepatic and non-hepatic diseases14-16, 30.  Similarly, the 
endothelial expression of P-gp at the blood-brain barrier is noted to be decreased in 
Alzheimer's disease31, 32.  The impact of disease on the intestinal fractions of the highly 
abundant and relevant CYP3A4 and P-gp has only been evaluated in a limited capacity.  
Specifically, studies assessing the impact of a chronic, primary intestinal illness on 
intestinal CYP3A4 expression are few.  Data are mainly derived from pediatric 
populations and are contradictory. 
    Two small studies in pediatric patients with celiac disease and inflammatory 
bowel disease (IBD, either CD or ulcerative colitis, UC) showed a decrease and an 
increase in duodenal CYP3A4 mRNA expression respectively19, 20.  Similarly, a more 
recent study in a pediatric CD population showed a relative reduction in ileal CYP3A4 
mRNA compared with CYP3A4 mRNA taken from non-inflamed duodenal biopsies21.  In 
an adult population of individuals with UC, decreased CYP3A4 mRNA expression was 
seen in rectal samples taken from inflamed tissue22. 
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 The effect of an inflammatory bowel disease on P-gp expression has received 
more attention, with a large focus on ulcerative colitis (UC).  Of 4 studies identified to 
date evaluating the mRNA and/or protein expression of P-gp (gene MDR1), reductions in 
the colonic expression of P-gp protein or MDR1 mRNA are documented predominantly 
in UC patients with active disease23-25, 33.  
 Our study is the first to evaluate the concomitant protein expression of intestinal 
CYP3A4 and P-gp in a CD population.  We demonstrate a significant reduction in ileal 
and colonic CYP3A4 as well as colonic P-gp expression in subjects with CD compared to 
those without.  Based on our findings, one could hypothesize that alterations in the 
intestinal expression of important drug disposition regulators may account for a portion 
of the heterogeneity seen in CD-oral drug response. 
 A limitation of our study is the absence of further experimentation to confirm the 
mechanism by which CYP3A4 and P-gp protein are decreased in the setting of CD.  
Other studies have shown a decrease in mRNA, suggesting that the change is reflective of 
changes in gene expression19, 21; however, further study is needed to evaluate the 
contribution of other factors such as RNA polymerase recruitment, histone acetylation 
and methylation, the binding of transcription factors as well as a diverse range of possible 
epigenetic modifications. 
 Our data re-enforce the principal that age and disease appear to affect CYP3A4 
expression, but highlight the specific impact on intestinal CYP3A4 rather than on hepatic 
CYP3A4.  We show that CD independently and negatively affects CYP3A4 expression in 
the ileum and colon.  Moreover, we show that CYP3A4 varies with age.  Our data 
support an age-related decline in ileal CYP3A4 expression in our control cohort.  The 
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literature, though inconsistently, demonstrates a similar decrease in hepatic and total 
body CYP3A4 with age34-36.  Interestingly, we see an increase in ileal CYP3A4 
expression with age in our CD cohort.  The reasons for this remain unexplained.   
 Colonic P-gp expression declined with age in both the CD and non-CD cohorts.  
The effect of age on intestinal P-gp expression is not well-studied.  Decreases in the 
endothelial expression of P-gp at the blood-brain barrier are documented in Alzheimer's 
disease31, 32.  It is unclear if this is secondary to the aging process or related to 
pathophysiologic changes of the disease.     
 There are several hypotheses to explain the decrease in hepatic CYP3A4 activity 
and/or expression seen in disease states such as acute infection, cancer, liver and kidney 
disease.  It is has been proposed that during an acute inflammatory process, hepatic 
CYP3A4 is down-regulated due to the effects of IL-1𝛽, IL-6, TNF-α, and IFN-α and 𝛾37, 
38.  Intestinal CYP3A4 may likewise be down-regulated.  Other theories pertain to 
disease-dependent changes in the activation of nuclear receptor (NR) such as the 
farnesoid X receptor or the pregnane X receptor.  These transcription factors and master 
regulators of homeostasis control transcription of CYP3A4 and are increasingly shown to 
be relevant to and changed in those affected by IBD24, 39-42.  This may have important 
consequences for intestinal CYP3A4 expression.  Specific to intestinal CYP3A4, 
disruption of the intestinal mucosa by the discontinuous, transmural inflammatory 
changes of CD may also be a contributor to altered CYP3A4 expression; however, our 
data do not support differential CYP3A4 protein expression based on CD activity or 
location. 
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 Overall, reasons for the molecular changes in the intestinal epithelium of CD 
patients may extend beyond the presence or absence of active inflammation and may be 
due to the inherent changes in the host's physiology that predispose them to this 
condition.  Here, we see that CYP3A4 protein expression is appreciably different in the 
setting of endoscopically normal intestinal tissue irrespective of disease activity.  
Langmann et. al. (2004) showed that MDR1 mRNA coding for P-gp was reduced to the 
same degree in inflamed and non-inflamed UC colonic samples 24.  It was proposed that 
that loss of P-gp function may be an initiating factor pre-disposing to the development of 
chronic intestinal inflammation, rather than being a consequence of it.  P-gp is co-
localized in the enterocyte with CYP3A4; it is concentrated at the enterocyte brush 
border with CYP3A4 found below in the cytoplasmic endoplasmic reticulum.  CYP3A4 
and P-gp share many substrates, inducers and inhibitors7.  They are hypothesized to act in 
a coordinated manner in the determination of the disposition of their shared endogenous 
and exogenous substrates, playing a key role in detoxification and intestinal barrier 
function43, 44.  Therefore, one could surmise that changes in CYP3A4 expression (similar 
to P-gp) could predispose to CD rather than be a downstream effect of its presence.  
Further studies are needed to explore these theories. 
 In conclusion, these data emphasize the loss of expression of CYP3A4 and P-gp 
in the CD gastro-intestinal tract.  This appears to be independent of disease activity and 
location, highlighting a possible role for CYP3A4 and P-gp in CD pathogenesis and 
disease predisposition.  Replication of this study, as well as assessment of protein 
activity, in a larger patient population would be useful in further elucidating the impact of 
altered enzyme expression on drug response in CD as well as disease pathogenesis.   
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5  GENETIC VARIATION IN CYP3A4-REGULATOR 
FXR PREDICTS SEVERITY OUTCOMES IN CROHN'S 
DISEASE 
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5.1 Introduction 
 Crohn's disease (CD) is an autoimmune inflammatory bowel disease defined by 
remitting and relapsing episodes of intestinal inflammation1.  CD pathogenesis is 
complex.  Dysregulation of the host immune response in the setting of specific 
environmental and genetic factors are hypothesized to serve as disease precursors1-5.  A 
key component of this inappropriate immune response is the disruption of the mucus 
layer, loss of epithelial tight junctions and increased intestinal permeability and thereby 
an increase in the intestinal immune system's exposure to bacteria, resulting in an 
immune response via its innate and adaptive arms2-4.  Furthermore, there is a shift in 
production from anti-inflammatory proteins to pro-inflammatory cytokines through the 
activation of nuclear transcription factors such as nuclear factor κB (NFκB)6. Early in its 
course, CD is remitting and relapsing, with periods of activity punctuated by debilitating 
symptoms of abdominal pain, diarrhea, and weight loss as well as biochemical and 
endoscopic findings of inflammation.  As the disease progresses over time, permanent 
damage to the intestinal structure may result, leading to an irreversible impairment of 
intestinal function, significant morbidity and long-term disability.  Disease severity is 
marked by the need for and time to surgery, failure of multiple medical therapies, need 
for hospitalization and the presence of complications such as fistulas or strictures7.  
 Many studies have attempted to link genetic variation in key genes associated 
with inflammation, xenobiotic metabolism and transport as well as gene regulators of 
such pathways to CD susceptibility. Several single nucleotide polymorphisms (SNPs) in 
the multi-drug resistance-1 (MDR1) gene, the pregnane X receptor (PXR, NR1I2) gene 
and to a lesser extent the farnesoid x receptor (FXR, NR1H4) gene have been evaluated 
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and some linked to IBD susceptibility with varying degrees of success 8-14; however, none 
have emerged as a clinically translatable marker of IBD presence, drug response or 
disease severity.   
 There is now an increasing appreciation of the bile acid-sensing nuclear receptor, 
FXR, as the master regulator of bile acid homeostasis and transport pathways, intestinal 
inflammation, intestinal permeability and response to bacterial overgrowth 6, 15, 16.  FXR 
is also an important regulator of drug metabolism sequences, with the ability to activate 
key cytochrome P450 (CYP) family isoform 3A4 directly and indirectly via the pregnane 
X receptor17, 18.  Interestingly, the expression and activity of CYP3A4 is altered in CD, 
though this has not been conclusively linked to CD-related changes in FXR activity19, 20.  
In vivo models confirm that in the absence of FXR activation, there is an expansion of the 
bile acid pool and a more severe presentation of chemically-induced colitis, including 
increased intestinal cellular infiltrate, collagen deposition and expression of inflammatory 
genes.  FXR activation modulates fibroblast growth factor (FGF) 19 expression, and 
plasma FGF19 concentrations have been used as a surrogate marker of FXR activity 21, 22.  
Moreover, FXR agonism in these same models improves intestinal permeability and 
attenuates the production of pro-inflammatory cytokines such as IL-1β and TNFα via the 
nuclear factor κB (NFκB) pathway6, 15.  Defects in the epithelial barrier are well-
documented in CD and may contribute to disease onset and progression 4, 23, 24.  There is 
data to support a decrease in FXR activity and expression in CD14, 25, 26.   
Our group was the first to identify and demonstrate that a SNP adjacent to the 
ATG start codon, in a sequence known as the Kozak consensus motif, in FXR (NR1H4), -
1G>T, is linked to reduced transactivation of FXR gene targets27. Conservation of the 
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Kozak consensus motif is necessary to ensure ribosomal binding to mRNA transcripts 
and efficient protein translation28.  Genetic variation in the Kozak motif is associated with 
decreased protein translation28.   Van Mil et.al. (2007) demonstrated that the FXR1-1G>T 
SNP is associated with reduced FXR protein expression as well as decreased activation of 
its down-stream targets, citing translational inefficiency as the underlying cause29. Thus, 
despite being in a non-coding region of the FXR gene, the FXR-1G>T SNP may have 
important functional consequences.  Interestingly, SNPs in FXR tend to be rare, although 
they have been documented in FXR-deficiency, which presents as a more severe form of 
progressive familial intrahepatic cholestasis (PFIC), associated with coagualopathy, 
jaundice and a rapid progression to liver failure 30, 31. These data suggest major loss of 
function mutations in FXR as contributors to CD are unlikely; however, partial loss of 
function or expression of FXR due to changes in translational efficiency may contribute 
to CD progression or severity.  To date, the role of FXR-1G>T SNP has not been 
evaluated in a CD population.   
 Accordingly, we hypothesize that changes in the intestinal barrier regulated 
through reduced FXR expression among those who harbor the FXR-1G>T SNP are more 
likely to exhibit a severe CD phenotype including a more rapid progression to surgery.  
Alterations in FXR activity may in part be secondary to genetic variation in the FXR 
gene.  In this study, we demonstrate the impact of FXR-1G>T SNP on a CD population 
in comparison to genetic variation in PXR and MDR1. 
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5.2 Materials And Methods 
5.2.1 Subjects 
 This study was conducted in two parts: in the first phase, a retrospective, single 
centre, cohort study was carried out in 198 patients with CD, being seen as part of the 
Personalized Medicine Program at Western University, London Canada between March 
2013 and 2015.  The aim was to evaluate the utility of FXR-1G>T as a genomic 
biomarker of severity in CD.  In the second phase, a separate cohort of patients with CD 
(n=188) were retrospectively screened for the FXR-1G>T genotype between November 
2015 and June 2017 to validate the findings of the first phase.   The cohorts were then 
pooled for further analysis (n= 386).  In addition, all subjects were screened for MDR1 
3435C>T and PXR -25385C>T.  A subset of subjects underwent plasma FGF19 and 
plasma bile acid profile determination.  Subjects from each cohort provided written, 
informed consent.  Eligible subjects were more than 18 years of age.  All subjects had a 
histopathological diagnosis of CD.  Subjects were excluded if information pertaining to 
their medical history was unavailable or unknown or if they had a diagnosis of ulcerative 
colitis.  Each subject provided one blood sample.  The study protocol was approved by 
the Western University Health Sciences Research Ethics Board (15586). 
 
5.2.2 Demographic and Covariate Data Abstraction 
 Data collected on subjects from both cohorts included age, sex, weight, smoking 
history, medical history, duration of disease as well as CD medication exposures and 
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responses (adverse drug reactions (ADRs), induction of remission, resistance or loss of 
response).  Data relevant to their CD diagnosis was also collected including disease 
phenotype, disease activity (based on the clinical scoring index, Harvey-Bradshaw Index, 
HBI) at the time of blood collection, hospitalizations, and history of and time to surgical 
resection.  This information was collected from patient records between the date of 
diagnosis and the study end period (cohort 1, March 30, 2015 and cohort 2, June 1, 
2017). 
 
5.2.3 Genotypic Analysis 
 DNA was extracted from whole blood using a standard DNA extraction protocol 
(MagNA Pure Compact System, Pleasanton California, USA).  Allelic discrimination 
using TaqMan assays and a 7500 RT-PCR System (Applied Biosystems, Carlsbad 
California, USA) was used to determine the presence of the variant, FXR (NR1H4) -
1G>T (rs56163822) in CD subjects with available DNA (n=386) as well as the variants, 
MDR1 3435C>T (rs1045642) and PXR (NR1I2) -25385C>T (rs3814055). Genotyping 
experiments included three positive controls and one negative control.  Five percent of 
samples were genotyped in duplicate.  Congruency was seen amongst all duplicated 
genotypes. 
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5.2.4 Fibroblast Growth Factor 19 Quantification 
 Blood samples were drawn from study subjects and plasma was extracted by 
centrifugation.  A commercial enzyme-linked immunosorbent assay (ELISA) kit (FGF19 
Quantikine ELISA kit, category no. DF1900; R&D Systems, Minneapolis, MN, US) was 
used for the colorimetric detection and estimation of FGF19 plasma concentrations 
following the manufacturer's instructions for subjects with available plasma samples who 
underwent surgical intervention (n=137).  All plasma aliquots as well as the standard 
curve (0pg/ml-1000pg/ml) were assayed in duplicate. 
 
5.2.5 Bile Acid Profile Determination 
  Plasma stored at -80◦C was used for quantification of 12 bile acids (cholic 
acid, CA; chenodeoxycholic acid, CDCA; deoxycholic acid, DCA; glycocholic acid, 
GCA; glycochenodeoxycholic acid, GCDCA; glycodeoxycholic acid, GDCA; lithocholic 
acid, LCA; taurocholic acid, TCA; taurodeoxycholic acid, TDCA; taurolithicholic acid, 
TLCA; tauroursodeoxycholic acid, TUDCA; and ursodeoxycholic acid, UDCA) using 
high performance liquid chromatography/mass spectrometry (LC-MS/MS).  Taurocholic 
acid-d5 (TCA-D5) was used as an internal standard (I.S).   A standard curve of 1nM to 
40µM was generated.   Patient samples were homogenized by vortexing for 15 minutes at 
4 °C @1400 RPM and incubated at -20°C for 20 minutes. Samples were centrifuged at 
maximum speed at 4°C for 30 minutes. Finally, 100µL of supernatant was transferred to 
vials and 80µL was injected into the LC-MS/MS system. 
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 A two-dimensional LC system was used (Agilent HILIC plus column (4.6*50) 
3.5µm followed by Phenomenex 00B-4462-Y0 Kinetex 2.6u C18 100A (3.0*50)). A 
gradient elution technique was employed using the Agilent 1290 system.  Mobile phase A 
consisted of 2mM ammonium acetate (pH 4.15) with 10% acetonitrile.  Mobile phase B 
consisted of acetonitrile: isopropyl-alcohol with water. The columns' temperatures were 
maintained at 60°C. Samples were eluted at a flow rate of 0.6ml/min to 1.4ml/min (0.1-
12 minutes).  Before injection of the subsequent sample, columns were cleaned with 
100% mobile phase B for one minute and returned to a linear equilibrium for 7 minutes 
for a total run of 20 minutes for each sample. Mass detection occurred on a TSQ-
Quantum Ultra mass spectrometer equipped with HESI source and  operated in negative 
mode (4500 v spray voltage, 350°C vaporizing temperature, 45 sheath gas pressure, 15 
auxiliary gas pressure and 350 °C capillary temperature). 
 
5.2.6 Study Objectives and Outcomes 
 The objective of this study was to test the hypothesis that the FXR-1GT genotype 
is a predictor of disease severity in CD.  The primary endpoints were the rate of surgery 
and time to surgery in subjects with an FXR-1GG genotype versus subjects with a -1GT 
genotype.  Secondary outcomes included other indicators of severity such as number of 
flares, number of hospitalizations and number of failed medications all standardized to 
per-year of CD diagnosis.  Other endpoints included determination of the plasma 
concentration of FGF19 in these two genotypic populations suggesting a mechanism by 
which FXR-1G>T is influencing intestinal barrier integrity.  Moreover, we evaluated the 
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rate of surgery, time to surgery, flares, hospitalizations and number of failed medications 
amongst wild type and variant carriers of the MDR1 3435C>T (rs1045642) and PXR -
25385C>T  (rs3814055) as well as evaluated the plasma bile acid profile in subjects with 
a the heterozygous variant genotype (FXR-1GT) versus sex-, age- and weight-matched 
controls (FXR-1GG, wildtype).   
  
5.2.7 Statistical Analysis 
 Statistical analysis was performed using Graphpad Prism, R, and SPSS statistical 
software.  Allele frequency distribution for the FXR -1G>T, MDR1 3435C>T and PXR 
25385 genotypes were tested for Hardy-Weinberg equilibrium using a χ2 goodness-of-fit 
test.  A Cox proportional-hazards regression model with or without adjusting covariates 
was used to assess the influence of FXR-1T, MDR1 3435T and PXR -25385T variant 
carrier status on the time to first surgical resection for the total population, males and 
females and hazard ratios (HR) were expressed with 95% confidence intervals (CI).  Risk 
of surgery associated with FXR-1T, MDR1 3435T and PXR -25385T variant carrier status 
was evaluated using a logistic model with and without adjustment and are expressed as 
odds ratios (OR) with 95%CI.  Covariates that were considered included the following: 
PXR-25385C>T genotype, MDR13435C>T genotype, exposure to combined therapy 
with an immunosuppressant and biologic, any biologic, methotrexate, glucocorticoid or 
thiopurine exposure, biologic failure32 (defined as development of an ADR requiring 
cessation of the biologic; primary non-response: a lack of improvement in clinical 
symptoms with induction therapy as defined by their treating physician; or loss of 
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response: a recurrence in disease activity during maintenance therapy despite an adequate 
response to induction dosing as defined by the treating physician), any drug failure, 
hospitalizations, smoking history, duration of disease, pre-operative biologic exposure, 
and time to biologic exposure.  A final model was constructed for the total population as 
well as stratified by sex, adjusting for FXR-1G>T genotype, age, weight and other, 
aforementioned covariates. 
 To test the hypothesis of an association between the FXR -1G>T SNP and a 
decrease in downstream products of the FXR gene, a Welch's t-test was used to compare 
FGF-19 plasma concentrations between genotype groups (FXR -1G>T variant carriers 
versus wild-type) within the surgical cohort (n=137).  A p-value ≤0.05 was considered 
significant.  A multiple linear regression analysis was used to further evaluate the 
relationship between FXR-1T carrier status, other covariates and the inter-individual 
variation in FGF-19 plasma concentrations (natural log-transformed) in participants who 
underwent a surgical intervention.  The analysis was performed for the total population as 
well as stratified by sex.   Other covariates assessed included the following: age, weight, 
disease activity, and disease location.  Lastly, mean plasma concentrations for the 12 
previously referenced bile acids were compared between FXR-1G>T variant carriers 
(FXR-1GT, n= 22) and age- and sex-matched wild type individuals (FXR-1GG) in a 2:1 
ratio using a Student's t-test.   A p-value ≤0.05 was considered significant. 
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5.3 Results 
5.3.1 Study Population 
 Baseline characteristics for all participants are presented in Table 5.1.  Five 
hundred and eighty-seven individuals with a diagnosis of inflammatory bowel disease 
(IBD) were screened at the time of visit to the Personalized Medicine Clinic.  Individuals 
with a diagnosis of UC were excluded (n=201).  Three hundred and eighty-six 
participants with CD were included in the final analyses (cohort 1, n= 198; cohort 2, n= 
188) of which 137 participants had undergone an intra-abdominal surgical intervention 
for their CD.  The rate of surgery increased with duration of diagnosis (1-year, 11.14%; 
5-year, 23.32%; and 10 years after diagnosis, 29.53%).  The most common indication for 
surgery was stricturing disease (GG, n = 61; GT, n = 8) followed by fistulizing disease 
(GG, n = 34; GT, n = 4).  Surgical interventions included small bowel or ileocolic 
resections with primary anastomosis and total colectomies with formation of an 
ileostomy.  Table 5.2 summarizes the demographic data for subjects undergoing a 
surgical intervention.  Table 5.3 summarizes the demographic data for subjects not 
undergoing a surgical intervention. 
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Table 5.1: Demographic Characteristics of Patients in Cohort 1 and Cohort 2 
Variables Cohort 1 
(n =198) 
Cohort 2 
(n = 188) 
Total population 
(n= 386) 
Age, years (mean, range) 43.04 (18-85) 41.55 (18-80) 42.31 (18-85) 
Female sex (%) 119 (60.1) 115 (61.2) 234 (60.6) 
Weight, kg (mean ± std) 77.06 ± 18.43 76.64 ± 20.38 76.81 ±19.42 
Disease location    
Ileal 75 (37.9) 60 (31.9) 135 (35.0) 
Colonic 36 (18.2) 39 (20.7) 75 (19.4) 
Ileo-colonic 87 (43.9) 89 (47.3) 176 (45.6) 
Disease duration, years 
(mean ± std) 
9.63 ± 10.36 9.11 ± 10.01 9.37 ± 10.18 
Smoking history (%) 63 (31.8) 36 (19.1) 99 (25.6) 
Biologic exposure (%) 81(40.1) 102 (54.3) 183 (47.4) 
Anti-TNF (%) 81 (40.1) 93 (49.5) 136 (35.2) 
Anti-integrin (%) 0 (0) 13 (6.9) 13 (3.4) 
Anti-IL12/23 (%) 0 (0) 10 (5.3) 10 (2.6) 
Combination therapy (%) 68 (34.2) 83 (44.1) 151 (39.1) 
Glucocorticoid exposure (%) 157 (79.2) 105 (55.8) 262 (67.9) 
Immunomodulator 
exposure 
   
MTX (%) 50 (25.2) 39 (20.7) 89 (23.1) 
Thiopurine (%) 131(66.1) 122 (65.0) 253 (65.5) 
Surgery (%) 62 (31.3) 75 (40.0)  137 (35.5) 
Mean number of surgeries 
(mean ± std) 
0.51 ± 0.99 0.67 ± 1.22 0.59 ± 1.11 
Hospitalizations (mean ± 
std) 
0.92 ± 1.67 1.42 ± 2.64 1.17  ± 2.22 
FXR -1GT carrier status 
(%) 
7 (3.5) 15 (8.0) 22 (5.7) 
FXR -1GG carrier status 
(%) 
191 (96.4) 173 (92.0) 364 (94.3) 
Kilograms, kg; standard deviation, std; Crohn's disease, CD; tumor necrosis factor, TNF; interleukin, IL; methotrexate, 
MTX; farnesoid X receptor, FXR 
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Table 5.2: Demographic Characteristics of CD Patients Undergoing Surgical 
Intervention by FXR -1G>T Genotype 
Variables FXR -1GG 
n = 124 
FXR-1GT 
n = 13 
Age, years (mean, range) 44.84 (19-85) 40.15(20-70) 
Female sex (%) 59 (47.6) 12 (92.3) 
Weight, kg (mean ± std) 76.23 ± 17.46 71.09 ± 20.53 
Disease location   
Ileal 38 (30.6) 1 (7.7) 
Colonic 22 (17.7) 1 (7.7) 
Ileo-colonic 64 (51.6) 11 (84.6) 
Duration of disease, years 
(mean  ± std) 
16.29 ± 12.10 14.67 ± 12.50 
Smoking history (%) 39 (31.4) 0 (0) 
Biologic exposure (%) 62 (50.0) 8 (61.54) 
Anti-TNF (%) 51 (41.1) 5 (38.46) 
Anti-integrin (%) 6 (4.8) 1 (7.69) 
Anti-IL12/23 (%) 5 (4.0) 3 (23.08) 
Pre-operative biologic 
exposure (%) 
27 (21.8) 4(30.77) 
Combination therapy (%) 43 (34.7) 3 (23.08) 
Glucocorticoid exposure (%) 104 (83.8) 13 (100) 
Immunomodulator exposure   
MTX (%) 32 (25.8) 5 (38.46) 
Thiopurine (%) 79 (63.7) 7 (53.85) 
Number of surgeries (mean ± 
std) 
1.60 ± 1.31 1.85 ± 1.07 
Time to first surgical 
intervention, years (mean ± 
std) 
5.99 ± 6.94 1.56 ± 2.08 
Hospitalizations (mean ± std) 2.31 ± 2.81  2.62 ± 1.85 
Farnesoid X receptor, FXR; kilograms, kg; standard deviation, std; Crohn's disease, CD; tumor necrosis factor, TNF; 
interleukin, IL; methotrexate, MTX 
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Table 5.3: Demographic Characteristics of CD Patients Who Did Not Undergo 
Surgical Intervention by FXR -1G>T Genotype 
Variables FXR -1GG 
n =240  
FXR-1GT 
n = 9 
Age, years (mean, range) 41.04 (18-80) 36.44(18-60) 
Female sex (%) 153 (63.8) 1 (11.1) 
Weight, kg (mean ± std) 77.28 ± 20.31 88.41 ± 16.54 
Disease location   
Ileal 90 (37.5) 2 (22.2) 
Colonic 56 (23.3) 2 (22.2) 
Ileo-colonic 94 (39.2) 5 (55.6) 
Duration of disease, years 
(mean  ± std) 
5.63 ± 6.66 5.92 ± 6.92 
Smoking history (%) 37 (15.4) 3 (33.3) 
Biologic exposure (%) 103 (42.9) 6 (66.7) 
Anti-TNF (%) 94 (39.2) 6 (66.7) 
Anti-integrin (%) 7 (2.9) 0 (0) 
Anti-IL12/23 (%) 2 (0.8) 0 (0) 
Combination therapy (%) 30 (12.5) 2 (22.2) 
Glucorticoid exposure (%) 187 (77.9) 6 (66.7) 
Immunomodulator exposure   
MTX (%) 44 (18.3) 3 (33.3) 
Thiopurine (%) 159 (66.3) 5 (55.6) 
Hospitalizations (mean ± std) 0.57 ± 1.64  0 ± 0 
Farnesoid X receptor, FXR; kilograms, kg; standard deviation, std; Crohn's disease, CD; tumor necrosis factor, TNF; 
interleukin, IL; methotrexate, MTX 
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5.3.2 FXR-1G>T Predicts Surgery Risk and Early Progression to Surgery 
Most Significantly in Women 
 All subjects underwent genotyping for the SNP FXR (NR1H4) -1G>T.  The minor 
allele (-1T) frequency was 2.8% in the total cohort.  FXR-1G>T was in Hardy-Weinberg 
equilibrium. Genotype frequencies classified by the presence or absence of surgery are 
displayed in Figure 5.1.  There was a strong association between carriers of the variant T 
allele and surgical intervention (odds ratio, OR=2.78, 95%CI=1.16-6.69, p=0.02) (Figure 
5.1a). However, this association did not remain (OR=2.21, 95%CI=0.65-7.50, p=0.20) 
with adjustment for covariates such as age, sex, weight, smoking history, drug exposures, 
hospitalizations, use of combination therapy or drug failures.   
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Figure 5.1 Genotype frequency separated by the presence or absence of an intra-abdominal 
surgical intervention related to the CD diagnosis for all subjects (A), female subjects (B), and 
male subjects (C).  Genotypes are expressed as a percentage of the total population of study 
subjects undergoing surgery (n=137) or not undergoing surgery (n=249).  *, p <0.05, **, p <0.01, 
***, p <0.001.  Crohn's disease, CD; farnesoid X receptor, FXR; number, n. 
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 FXR-1T variant carriers were more likely to go on to an early surgical 
intervention compared to wild type individuals (combined cohorts, 5.99 years ± 6.94 
versus 1.56 years ± 2.08; hazard ratio, HR=2.75, 95%CI=1.55-4.90, p < 0.001) (Figure 
5.2).   
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Figure 5.2 Time to first surgery following the diagnosis of CD stratified by FXR-1G>T 
genotype expressed as wild type (GG) or variant (GT) for individuals in cohort 1 (A), 
cohort 2 (B), and the combined cohorts (C).  *, p <0.05, **, p <0.01, ***, p <0.001.  
Crohn's disease, CD; farnesoid X receptor, FXR. 
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FXR -1T remained significant (p=0.002) as an independent predictor of early progression 
to surgical intervention in CD in a Cox proportional-hazards regression model with 
adjusting covariates.  Covariates included in the model were: age, sex, weight, smoking 
history, number of drugs or biologics failed, hospitalizations, glucocorticoid, thiopurine 
and methotrexate exposure, combination therapy (biologic with an immunomodulator) 
and pre-operative biologic exposure. (Table 5.4, Figure 5.3).   
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Table 5.4: Cox regression for the effects of covariates on time to surgical 
intervention in a CD cohort (n = 386) 
Covariate Hazard Ratio 95% Confidence 
interval 
P-value 
FXR-1T carrier status 2.70 1.45 – 5.02 0.002 
Age (years) 1.00 0.99 – 1.01 0.80 
Sex 0.87 0.60 – 1.26 0.47 
Weight (kg) 1.00 0.99 – 1.01 0.48 
Smoking history 0.77 0.51 – 1.17 0.22 
Hospitalizations 1.12 1.07 – 1.11 <0.001 
Exposure to 
glucocorticoids 
2.68 1.49 – 4.83 <0.001 
Exposure to 
methotrexate 
0.79 0.49 – 1.25 0.31 
Exposure to 
thiopurines 
0.87 0.58 – 1.31 0.51 
Exposure to 
combination therapy 
1.12 0.68 – 1.83 0.67 
Number of drugs 
failed 
0.69 0.53 – 0.89 0.004 
 Number of biologics 
failed 
1.76 1.22 – 2.53 0.003 
Exposure to biologics 
pre-operatively 
2.10 1.33 – 3.30 0.001 
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Figure 5.3 HR estimates with the corresponding 95%CI for the evaluation of 
demographic, medication exposures/responses and FXR-1G>T genotype and the impact 
on time to first surgery.  The HR estimate of each variable is marked with solid black 
square.  The 95%CI is represented by the horizontal T-line through the square.  The 
horizontal axis is plotted on a log scale.  Hazard ratio, HR; confidence interval, CI; 
farnesoid X receptor, FXR; number, No.; methotrexate, MTX. 
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 Most significantly, when data were stratified based on sex, the association 
between carriers of the variant T allele and risk of surgical intervention and early 
progression to surgical intervention was strongest and most striking in women on simple 
linear regression analysis (risk of surgery, OR=27.46 95%CI=2.28-330.50, p=0.01; 
progression to surgery, HR=9.08, 95%CI=4.72-17.48, p < 0.0001) (Figure 5.1b, Figure 
5.4) and with adjustment for covariates (risk of surgery, OR= 23.65, 95%CI=1.83-304.74 
p≤0.05; progression to surgery, HR=6.15, 95%CI=2.82-13.42, p < 0.0001) (Table 5.5).  
Of the FXR-1GT carriers going on to surgery, 92.1% were women compared to the FXR-
1GG carriers (47.6%) (Table 5.2).  Conversely in men, FXR genotype was not 
significantly associated with risk or time to surgery on simple linear regression analysis 
(risk of surgery, OR=0.18, 95%CI=0.02-1.5, p=0.11; progression to surgery, HR=0.27, 
95%CI= 0.04-1.94, p=0.19) or multiple linear regression analysis (risk of surgery, 
OR=0.27, 95%CI=0.03-2.85, p=0.28; progression to surgery, HR=0.41, 95%CI=0.05-
3.21, p=0.40). 
 Other indicators of severity evaluated included: number of drugs failed, number 
of surgeries, hospitalizations, number of flares.  There was no difference between FXR-
1G>T genotypes in any of these parameters of severity, even when adjusting for weight, 
age, sex and disease duration. 
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Figure 5.4 Time to first surgery following the diagnosis of CD stratified by FXR-1G>T 
genotype expressed as wild type (GG) or variant (GT) and female sex in cohort 1 (A), 
cohort 2 (B), and the combined cohorts (C).  *, p <0.05, **, p <0.01, ***, p <0.001.  
Crohn's disease, CD; farnesoid X receptor, FXR 
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Table 5.5: Cox regression for the effects of covariates on time to surgical 
intervention in a female CD cohort (n =234) 
Covariate Hazard Ratio 95% Confidence 
interval 
P-value 
FXR-1T carrier status 6.15 2.82 – 13.42 <0.001 
Age (years) 1.00 0.98 – 1.02 0.85 
Weight (kg) 1.00 0.98 – 1.01 0.79 
Smoking history 1.01 0.58 – 1.76 0.98 
Hospitalizations 1.15 1.06 – 1.25 <0.001 
Exposure to 
glucocorticoids 
2.90 1.22 – 6.89 0.016 
Exposure to 
methotrexate 
0.95 0.52 – 1.73 0.86 
Exposure to 
thiopurines 
1.05 0.61 – 1.82 0.86 
Exposure to 
combination therapy 
1.41 0.70 – 2.83 0.34 
Number of drugs 
failed 
0.61 0.43 – 0.88 0.008 
 Number of biologics 
failed 
1.87 1.15 – 3.02 0.011 
Exposure to biologics 
pre-operatively 
1.24 0.68 – 2.26 0.47 
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5.3.3 Genetic Variation in PXR and MDR1 is not Associated with a Severe 
CD phenotype 
 Additionally, all subjects were screened for the SNPs, MDR1 3435C>T and PXR 
-25385C>T.  Minor allele frequencies were 53.7% and 40.2% respectively.  Overall, 
there was no significant association between either SNP and risk of (Figure 5.5) or time 
to surgical intervention (Figure 5.6-5.8).  In cohort 1, male carriers of PXR -25385T 
progressed to surgery more quickly than wild type men (HR=3.95, 95%CI=1.54-10.15); 
however, this was not confirmed in cohort 2 nor in analysis of the combined cohort.  
Furthermore, there was no significant association between either SNP and other 
indicators of CD severity (number of drugs failed, number of surgeries, hospitalizations) 
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Figure 5.5 Genotype frequency for MDR1 3435C>T (panel 1) and PXR -25385C>T 
(panel 2) separated by the presence or absence of an intra-abdominal surgical intervention 
related to the CD diagnosis for all subjects (A), female subjects (B), and male subjects 
(C).  Genotypes are expressed as a percentage of the total population of study subjects 
undergoing surgery (n=137) or not undergoing surgery (n=249). Multi-drug resistance 
protein 1, MDR1; pregnane X receptor, PXR. 
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Figure 5.6 Time to first surgery following the diagnosis of CD stratified by MDR1 
3435C>T (panel 1) and PXR -25385C>T (panel 2) genotype expressed as wild type (CC) 
or variant (CT or TT) for individuals in cohort 1 (A), cohort 2 (B), and the combined 
cohorts (C). Multi-drug resistance protein 1, MDR1; pregnane X receptor, PXR; wild 
type (WT).  
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Figure 5.7 Time to first surgery following the diagnosis of CD stratified by MDR1 
3435C>T genotype expressed as wild type (CC) or variant (CT or TT) for women in 
cohort 1 (A), cohort 2 (B), and the combined cohorts (C) and for men in cohort 1 (D), 
cohort 2(E) and the combined cohorts (F). Multi-drug resistance protein 1, MDR1; wild 
type (WT).  
 
186 
 
 
Figure 5.8 Time to first surgery following the diagnosis of CD stratified by PXR -
25385C>T genotype expressed as wild type (CC) or variant (CT or TT) for women in 
cohort 1 (A), cohort 2 (B), and the combined cohorts (C) and for men in cohort 1 (D), 
cohort 2(E) and the combined cohorts (F). Pregnane X receptor, PXR; wild type (WT).  
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5.3.4 FXR-1G>T is a Determinant of FGF19 Plasma Concentrations in 
Women 
 Another objective of this study was to evaluate FGF19 plasma concentrations in 
FXR-1G>T wild type and variant allele carriers.  FGF19 plasma concentrations were 
lower in FXR -1GT variant carriers, though this did not achieve statistical significance on 
bivariate analysis (GG = 0.35pg/L±0.04pg/L; GT = 0.23pg/L ±0.05pg/L , p=0.215) 
(Figure 5.9a) or multiple linear regression analysis (natural log transformed FGF19 
plasma concentrations, Table 5.6).  Furthermore, the multiple linear regression analysis 
only accounted for 6.5% of the inter-individual variation in FGF19 plasma 
concentrations.  
 Interestingly, when stratified by sex, women with an FXR-1GT genotype had a 
two-fold lower FGF-19 plasma concentration (p≤0.05) compared to women with a wild 
type genotype on univariate and multivariate analyses (Figure 5.9, Table 5.7).  This was 
not seen in the male population. 
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Table 5.6 Multiple linear regression model for the effect on Ln-transformed FGF-19 
plasma concentration for all subjects (n = 137, adjusted R2=0.065) 
Variable β-coefficients Standard error P-value 
Intercept -1.748 0.635 0.007 
FXR -1T carrier 
status 
-0.476 0.345 0.170 
Age -0.002 0.007 0.787 
Female Sex 0.317 0.208 0.130 
Weight 0.006 0.006 0.236 
Small bowel 
resection or disease 
-0.516 0.274 0.062 
 
Table 5.7 Multiple linear regression model for the effect on Ln-transformed FGF-19 
plasma concentration for females (n = 74) 
Variable β-coefficients Standard error P-value 
Intercept -1.287 0.738 0.086 
FXR -1T carrier 
status 
-0.714 0.367 0.050 
Age -0.003 0.009 0.693 
Weight 0.001 0.007 0.897 
Small bowel 
resection or disease 
0.054 0.274 0.062 
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Figure 5.9 The mean FGF-19 plasma concentrations stratified by FXR-1G>T genotype, 
GG or GT for the total population (A) and for women (B).  Median values (thick 
horizontal line), 25th and 75th percentile values (box outline), minimum and maximum 
values (whiskers), and outlier values (circles).  Fibroblast growth factor 19, FGF-19; 
farnesoid X receptor, FXR. 
 
190 
 
5.3.5 The Bile Acid Profile is not Significantly Altered in FXR-1GT 
Carriers 
 Plasma bile acid profiles were constructed for all subjects who carried the variant 
FXR-1T allele (n=22).  Similarly, a plasma bile acid profile was generated for age-, sex- 
and weight-matched wild type (FXR-1GG) subjects (n=40) (Table 5.8).  There was no 
significant difference in the total plasma bile acid pool, the ratio of primary to secondary 
bile acids or the ratio of unconjugated to conjugated bile acids (Figure 5.10) based on 
FXR-1G>T genotype.  Furthermore, there was no significant difference in any of the 
individual bile acids between FXR-1G>T genotypes, with the exception of GDCA 
(Figure 5.11).  FXR-1T carriers had an increased concentration of GDCA compared to 
wild-type subjects (p= 0.003).  No difference was seen in bile acid profiles when 
stratified by sex.  
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Table 5.8: Bile acid profiles 
Plasma Bile acids FXR-1GG (n=40) FXR-1GT (n=22) 
 ng/ml % ng/ml % 
Primary 
Bile acids 
plus 
conjugates 
CDCA 436.3 
 
8.5 421.6 8.6 
G-CDCA 2075.7 37.6 2665.3 48.8 
Total  2522.0 56.1 3086.9 57.4 
CA 103.6 2.2 195.4 3.3 
G-CA 277.1 5.0 371.2 6.6 
T-CA 39.2 1.3 43.6 1.0 
Total  419.9 8.5 610.2 10.9 
Secondary 
bile acids 
plus 
conjugates 
DCA 168.2 4.1 118.4 1.8 
G-DCA 1961.4 27.7 1335.9 15.0 
T-DCA 141.6 3.4 131.2 2.5 
Total  2271.2 35.2 1585.5 19.3 
LCA 108.6 3.2 57.1 1.3 
T-LCA 12.8 0.2 31.1 0.6 
Total  121.4 3.4 88.2 1.9 
Tertiary 
bile acids 
plus 
conjugates 
UDCA 354.5 6.7 492.7 10.5 
T-UDCA 1.9 0.1 3.1 0.0 
Total  356.4 6.8 495.8 10.5 
Total bile acids 5681.1  5866.4  
*Plasma bile acid are represented as a percentage of the total bile acid pool 
Cholic acid, CA; chenodeoxycholic acid, CDCA; deoxycholic acid, DCA; glycocholic acid, GCA; 
glycochenodeoxycholic acid, GCDCA; glycodeoxycholic acid, GDCA; lithocholic acid, LCA; taurocholic acid, TCA; 
taurodeoxycholic acid, TDCA; taurolithicholic acid, TLCA; tauroursodeoxycholic acid, TUDCA; and ursodeoxycholic 
acid, UDCA. 
 
 
 
 
 
 
 
192 
 
 
GG GT
0
5000
10000
15000
FXR-1 genotype
To
ta
l  
Pl
as
m
a 
Bi
le
 A
ci
d
C
on
ce
nt
ra
tio
n 
(n
g/
m
l)
GG GT
0
2
4
6
8
10
FXR-1 genotype
Pr
im
ar
y 
BA
:S
ec
on
da
ry
 B
A 
Ra
tio
GG GT
0
1
2
3
FXR-1 genotype
Un
co
nj
ug
at
ed
:C
on
ju
ga
te
d 
BA
  R
at
io
A B C
 
Figure 5.10 The mean total plasma bile acid concentrations (ng/ml) (A), the ratio of 
primary to secondary mean bile acid concentrations (B) and the ratio of mean 
unconjugated to conjugated bile acids (C) stratified by FXR-1G>T genotype expressed as 
wild type (GG) or variant (GT) for the total population of subjects with CD.  The 95%CI 
is represented by the vertical T-line.  Crohn’s disease, CD; farnesoid X receptor, FXR; 
bile acid, BA.  
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Figure 5.11 The mean individual bile acid profiles expressed as mean concentrations in ng/ml 
(A) and as a percentage of the total bile acid pool, stratified by FXR-1G>T genotype expressed as 
wild type (GG) or variant (GT).  The 95%CI is represented by the vertical T-line.  Cholic acid, 
CA; chenodeoxycholic acid, CDCA; deoxycholic acid, DCA; glycocholic acid, GCA; 
glycochenodeoxycholic acid, GCDCA; glycodeoxycholic acid, GDCA; lithocholic acid, LCA; 
taurocholic acid, TCA; taurodeoxycholic acid, TDCA; taurolithicholic acid, TLCA; 
tauroursodeoxycholic acid, TUDCA; and ursodeoxycholic acid, UDCA. 
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5.4 Discussion 
 FXR is an important determinant of intestinal barrier function, inflammatory 
response and drug metabolism.  In this study, we are able to demonstrate an important 
role for a genetic variation adjacent to the ATG start codon of the bile acid sensing 
nuclear receptor, FXR, as a predictor of CD progression to surgical intervention (Figure 
5.2).  Remarkably, FXR-1T variant carrier status remains an independent predictor of 
time to first surgery even when other important factors are taken into account (Figure 5.3, 
Table 5.4).   
 Most striking, is the discovery that women with a CD diagnosis carrying the FXR-
1GT genotype are most at-risk for progressing on to surgery (OR=27.46 95%CI=2.28-
330.50, p=0.01) and progressing on to surgery earlier in their disease course (HR=9.08, 
95%CI=4.72-17.48, p < 0.0001) compared to men or women with the FXR-1GG 
genotype.  Sex-specific differences in CD are largely unexplored; there is a paucity of 
data on how sex differences impact CD diagnosis and disease management.  
Interestingly, many important sex-related differences have been identified in other, 
common, chronic diseases such as coronary artery disease, rheumatologic autoimmune 
diseases, and renal disease33.  Despite these findings, disparity is seen in the management 
of men and women who suffer these conditions.  For example, despite better outcomes in 
females, women with congestive heart failure receive fewer guideline-based treatments 
and transplantations compared to men34.  Similarly, despite a greater risk of stroke, 
women are less likely to be anti-coagulated in the setting of atrial fibrillation compared to 
men35.  Such differences and potential disparities have not yet been addressed adequately 
in CD.  There are data to support a slightly higher incidence of CD in women across 
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several populations.36-38  Oral contraception (OCP) use has been linked to the onset of 
CD  in a large prospective cohort study of American women as well as to the risk of CD-
related surgery in a Swedish registry.39, 40  These findings allude to the importance of a 
female-specific factor to the susceptibility and severity of CD.  Our work further 
highlights the need to consider sex-related differences in CD management. 
  Interestingly, estradiol (E2), a major female sex hormone and the dominant form 
of estrogen present during a woman's reproductive years and the main form of estrogen 
used in OCP, has been shown to inhibit FXR activity via the estrogen receptor (ER) α in 
vivo and in vitro41, 42.  Authors examining the relationship of OCP use to CD 
susceptibility and severity were unable to explain the biological mechanisms for their 
data39, 40.  Our work suggests a plausible molecular mechanism for their findings.  More 
recent work by Goodman et.al. (2017), using a murine model of colitis, showed that ERα 
loss-of-function resulted in protection from chemically-induced colitis in female mice, 
directly linking E2-signaling to pathways of IBD. 43    
 Conversely, we found that the IBD-linked SNPs, MDR1 3435C>T and PXR -
25385 are not predictive of CD severity.  To date, there has been a lack of consensus 
regarding the relationship between CD susceptibility and genetic variation in MDR1 and 
PXR.  Brinar et.al. (2013) and Juyal et.al. (2009) both indicated a link between MDR1 
genetic variation and IBD, while a larger meta-analysis of existing studies refuted the 
finding8, 44, 45.  Similarly, Dring et.al. (2006) concluded that PXR -25385C>T was a 
significant predictor of IBD susceptibility9; however, more recent and larger genomic 
association studies have failed to confirm these original findings10, 12.  Our study confirms 
a lack of association between polymorphisms in either of these genes and CD severity, 
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while emphasizing the association and possible mechanism of the FXR gene.  A strength 
of our study is the replication of the primary objective (association of FXR-1GT genotype 
with time to and risk of surgery) in a second cohort of patients recruited at a separate time 
interval.  During the second time period, IBD therapies had expanded to include a wider 
range of biologic treatments, yet the association between FXR-1GT carrier status and risk 
and time to surgery persisted. 
 Additionally, a statistically significant difference in the FXR downstream product, 
FGF19 was seen between individuals with a variant versus wild type FXR-1G>T 
genotype when assessed in female CD patients (Figure 5.9b, Table 5.7).   An almost two-
fold increase is seen in the FGF19 plasma concentrations of women with a wild type 
FXR-1G>T genotype compared to carriers of the variant allele.  Our group has previously 
shown in vitro and in vivo that the FXR -1G>T SNP is associated with reduced activation 
of downstream products 27.  Data by Van Mil et.al. (2007) demonstrated a concomitant 
decrease in FXR protein and several of its down-stream gene targets29.  They concluded 
that variation in the Kozak consensus motif of the FXR gene is associated with inefficient 
protein translation, providing a plausible functional mechanism.  Interestingly, our 
finding regarding the downstream FXR target, FGF19, does not extrapolate to the total 
population, but is of particular relevance to women, highlighting the idea that a female-
specific factor(s), in addition to genetic variation in FXR, is influencing the function of 
the FXR protein.  A limitation of this data may be that FGF19 quantification was carried 
out in individuals with small bowel disease who underwent a small bowel resection of 
varying, non-quantifiable lengths.  This may have impacted FGF19 plasma 
concentrations and may have confounded our findings. 
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 Conversely, we found that plasma bile acid concentrations, another downstream 
product of FXR activity, are not increased in individuals with a FXR-1GT genotype.  This 
remained unchanged even with the stratification of bile acid profiles by FXR-1G>T 
genotype and sex.  This is in discordance with murine models of FXR deficiency where 
FXR null mice had an increase in the total bile acid pool15.  Due to the low FXR-1T allele 
frequency, only a small subset of study subjects (FXR-1GT, n= 22; FXR1GG, n= 40) 
underwent plasma bile acid quantification.  This may have impacted our ability to 
demonstrate a significant difference between FXR-1G>T genotypes. 
We note that two previous studies have evaluated polymorphisms in FXR and the 
link to IBD13, 14.  Nijmeijer et.al. (2011) did not find an association between FXR-1T 
variant carrier status and IBD disease presence, location or disease type among 2355 IBD 
patients.  Similarly, Attinkara et.al. (2012) failed to show an association between FXR-1T 
variant carrier status and IBD susceptibility in a cohort of 1138 individuals, half of whom 
had an IBD diagnosis.  However, no assessment was performed to evaluate the link 
between FXR-1G>T and parameters of disease severity. 
 In conclusion, we outline important new data in a largely neglected area of CD 
management: genetic variation in FXR has important clinical consequences, particularly 
for women with CD.  Screening female CD patients for FXR-1T variant carrier status 
may be useful for identifying female patients at risk for early, poor outcomes.  Female 
carriers of the variant allele may benefit from earlier, more aggressive medical 
management.  Further evaluation of sex-specific differences in CD management is 
needed to better personalize therapy and avoid the perpetuation of any unidentified 
disparities. 
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6 DISCUSSION AND CONCLUSIONS 
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6.1 Summary and Discussion 
The overall findings discussed in this work are summarized in Figures 6.1 and 6.2. 
Figure 6.1 The proposed effect of Crohn's disease on CYP3A4 drug metabolism.  Total CYP3A4 activity is 
decreased in CD.  In health, secondary bile acids such as LCA are potent activators of PXR, a known 
regulator of CYP3A4 activity.  Bile acid-induced activation of PXR leads to the translocation of PXR to the 
nucleus and binding of PXR to its response element contained within the CYP3A4 gene.  This results in 
downstream CYP3A4 expression and activity.  Bile acid patterns are altered in CD.  There is a greater 
proportion of unconjugated bile acids as well as primary bile acids compared to individuals without CD 
(Panel A).  This may lead to reduced bile acid-induced activation of PXR, with a resultant decreased in 
hepatic CYP3A4 activation.  There is decreased expression of CYP3A4 protein in the intestine in CD 
(Panel B).  Crohn's disease, CD; cytochrome P450 3A4, CYP3A4; lithocholic acid, LCA; pregnane X 
receptor, PXR. 
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Figure 6.2 The proposed effect of genetic polymorphism FXR-1G>T on Crohn's disease.  In health, FXR 
expression regulates bile acid homeostasis by  repressing bile acid synthesis.  Production of the ileal 
hormome, FGF-19 is a direct result of FXR activation and inhibits CYP7A1.  FXR activation is also 
important for attenuating the NFκB pathway and the downstream production of pro-inflammatory 
cytokines as well as enhancing the integrity of the intestinal epithelial barrier (Panel A).  In CD, FXR 
activity is attenuated with documented reductions in FGF19 production, an expansion of the bile acid pool, 
increased NFκB activity and disruption of the intestinal epithelial barrier (Panel B).   
A B 
C D 
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Figure 6.2 (continued) The presence of the genetic polymorphism, FXR-1G>T is associated with 
translational inefficiency of the FXR protein.  We have documented that female carriers of the FXR-1GT 
genotype with CD have a more severe CD phenotype.  This suggests that genetic variation in FXR and 
possibly the presence of estrogen further impair FXR activity in addition to changes already documented in 
CD (panel C and D).  Farnesoid X receptor, FXR; Crohn's disease, CD; fibroblast growth factor 19, 
FGF19; cytochrome P450 7A1, CYP7A1; nuclear factor κB, NFκB;  
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6.1.1 Chapter 3 
The cytochrome p450 (CYP) 3A family is the cornerstone of drug metabolism 
and drug disposition in humans1, 2.  Of the 3A family, the 3A4 isoform is the most well-
studied and makes up the highest CYP content in the liver and intestine, key organs of 
drug metabolism.  CYP3A4 activity is highly variable between individuals due to a 
myriad of patient-intrinsic (sex, age, genetics) and extrinsic (diet, medications) factors3-10. 
The impact of disease on CYP3A4 activity is still incompletely defined.  Given the 
importance of CYP3A4 to the disposition of a wide range of clinically-important 
substrates and its high concentration in the intestine, understanding the effect of Crohn's 
disease (CD), an exceedingly prevalent, chronic, primary intestinal illness, on CYP3A4 
activity is highly relevant.  In Chapter 3, we aimed to assess the impact of CD on 
CYP3A4 activity using two in vivo modalities in real-time (exogenous probe, midazolam 
and endogenous probe 4β-hydroxycholesterol, 4βOHC) as well as to propose a molecular 
mechanism for any detectable differences from non-CD controls.  Due to the previously 
documented effect of acute and non-CD chronic inflammatory states on CYP-mediated 
metabolism, we hypothesized that CD would negatively impact CYP3A4 activity in vivo, 
particularly intestinal CYP3A4.  We posited that a decline in CYP3A4 activity would be 
related to CD-specific changes in pregnane X receptor (PXR) signaling.  In fact, we 
observed that exposure to CYP3A4 substrate, midazolam, as represented by the oral area 
under the concentration-time curve (AUCpo), was significantly increased in our CD 
cohort compared to reports in healthy controls11-14; thus, we inferred there was a 
reduction in CYP3A4 activity in CD.  Moreover, the greatest reduction in midazolam 
extraction by CYP3A4 appeared to be at the liver rather than the intestine.  Similarly, we 
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were able to confirm a reduction in CYP3A4 activity in an independent CD cohort 
compared to non-CD controls using the endogenous biomarker, plasma 4βOHC.  
However, we were unable to provide a plausible mechanism for differential CYP3A4 
activity in CD.  Despite detectable differences in plasma bile acids, known PXR-
CYP3A4 pathway inducers,  in  individuals with CD versus non-CD controls, we were 
unable to show an appreciable impact on PXR-signaling and downstream activation of 
CYP3A4 in vitro.   
Ultimately, we were able to identify CD-specific changes to CYP3A4 activity in 
vivo.  Despite being a primary intestinal illness, there appeared to be more of an impact 
on hepatic CYP3A4 activity based on oral and systemic midazolam pharmacokinetics.  In 
other conditions, inflammatory cytokines are posited to decrease CYP3A4 activity8, 15; 
however, we did not see an appreciable difference between subjects with active and 
inactive CD.  This suggests changes in CYP3A4 activity in CD may be a precursor to 
disease rather than a consequence of inflammation.  Despite this observation, we were 
unable to provide a sound mechanism to explain CD-specific changes in CYP3A4 
activity.  PXR is an important regulator of CYP3A4 activity that is also known to be 
altered in CD16-18.  It is activated by bile acids, such as lithocholic acid (LCA) and 
deoxycholic acid (DCA)19, 20.  We observed differences in the plasma bile acid profiles in 
our CD cohort, perhaps due to alterations in the gut microbiome21.  However, these 
differences did not translate to differential PXR signaling or downstream CYP3A4 
activity in an in vitro hepatocarcinoma (Hep) G2 model.  Higher concentrations of bile 
acids reflective of hepatic concentrations (rather than blood) may be needed to further 
assess the impact of PXR on CYP3A4 activity in CD.  All in all, our data demonstrate a 
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CD-specific decrease in CYP3A4 activity across two separate CD cohorts.  This may 
have important implications for the disposition of CD-related and non-CD-related 
CYP3A4 drug substrates used in this patient population.  Though differences in PXR 
signaling, due to changes in the plasma bile acid profile, did not account for differences 
in CYP3A4 activity, bile acid concentrations reflective of hepatic concentrations as well 
as the effect of other nuclear receptors, such as the farnesoid X receptor (FXR), may need 
to be considered. 
6.1.2 Chapter 4 
The concept of first-pass metabolism is well-established.  A selection of orally-
ingested substrates are subject to extensive processing within the intestinal tract as well 
as in the liver.  CYP3A4 and P-glycoprotein (P-gp) play an important in this process.  It 
is a long-held notion that CYP3A4 and P-gp, both concentrated within enterocytes at the 
intestinal villous tip, act in a coordinated manner to limit drug and xenobiotic oral 
bioavailability.  According to Zhang and Benet (2001), this theory is built upon the 
findings of a common intestinal location, shared substrates and the poor oral 
bioavailability of such substrates1.  Given that the inflammatory bowel disease (IBD), CD 
introduces a transmural intestinal insult that disrupts the intestinal barrier function, one 
could assume that this has important consequences for intestinally-expressed proteins 
such as CYP3A4 and P-gp.  Thus, in Chapter 4, we aimed to evaluate the intestinal 
expression of CYP3A4 and P-gp protein in a cohort of individuals with and without CD.  
We hypothesized that individuals with CD have reduced intestinal expression of 
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CYP3A4 and P-gp.  We observed a significant reduction in ileal and colonic CYP3A4 
protein expression in subjects with CD compared to those without.  Similarly, a reduction 
in colonic P-gp protein expression was seen in the CD cohort.  Age appeared to play a 
role in CYP3A4 expression in both CD and non-CD cohorts, though with opposing 
effects.  Our data highlight important and novel findings pertaining to CD-dependent 
changes in the intestinal barrier function, first-pass metabolism with consequences for 
drug and xenobiotic exposure.  Further studies are needed to explore the mechanisms of 
these findings. 
6.1.3 Chapter 5 
Nuclear receptors (NR) are key regulators of development, metabolism and 
disease in humans22, 23.  Several NRs, such as PXR and FXR, play a detoxification role by 
regulating the expression and activity of CYP3A4 and P-gp24.  In vivo and in vitro models 
have demonstrated a decrease in PXR and FXR signaling in IBD, with a concomitant 
improvement in intestinal inflammatory lesions with PXR and FXR up-regulation18, 25-27.  
Interestingly, knocking out PXR and FXR in murine models does not induce a 
spontaneous colitis as is seen in the MDR1a -/- (codes for P-gp) murine model. Rather, it 
facilitates the onset and increases the severity of an inflammatory condition, suggesting 
that these NRs may contribute to, but are not wholly responsible for, IBD pathogenesis25.  
Genetic variation in FXR has been linked to deficits in FXR expression as well as a 
decrease in the activation of downstream targets28.  In Chapter 5, we aimed to explore the 
role of genetic variation in FXR, a key regulator of CYP3A4 metabolism, and its impact 
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on CD severity.  We hypothesized that the novel FXR -1G>T polymorphism confers a 
greater risk of a severe CD phenotype and is associated with a reduction in the 
downstream FXR target, fibroblast growth factor (FGF) 19 and an expansion of the total 
bile acid pool.  Indeed, we confirmed that the FXR-1GT genotype predicts surgery risk 
and early progression to surgery most significantly in women.  We also observed a 
significant reduction in FGF19 plasma concentrations in female carriers of the FXR-1T 
allele; however, no appreciable differences were seen in the plasma bile acid pool of the 
FXR-1GT carriers.  Our data highlight the importance of drug metabolism sequences to 
IBD pathogenesis.  Specifically, genetic variation in FXR, a key regulator of CYP3A4, 
appears to have important consequences for outcomes of disease severity in CD, 
indicating a role for more aggressive medical management in these individuals.  Most 
interestingly, our data point to a sex-specific difference in CD, whereby women with CD 
are most adversely affected by genetic variation in FXR as it pertains to CD outcomes.  
This has gone largely unexplored.  Our data offer a basis for exploring sex-specific 
differences in CD as they pertain to disease pathogenesis, outcomes and management.  
Ultimately, NRs such as FXR may be a key overlapping factor that links drug 
metabolism sequences and CD pathogenesis.   
 
6.2 Implications 
 To date, there is limited data evaluating the effect of CD on major drug 
metabolism pathways.  Ours is the first data set to confirm a decrease in CYP3A4 activity 
in CD using multiple modalities and to suggest that said decline may be driven by 
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decreases in hepatic CYP3A4 activity, beyond the impact of CD on the intestinal 
expression of CYP3A4.  Neither across in vivo biomarkers of activity, nor in gene 
expression, did we find that CD activity (defined by the Harvey-Bradshaw clinical index) 
impacted on CYP3A4.  This suggests that factors beyond inflammatory cytokines are 
contributing to CD-specific changes in CYP3A4.  One could even construe that changes 
in CYP3A4 expression and/or activity may be an antecedent event in CD onset rather 
than a byproduct of disease progression. 
These findings also have important implications for CYP3A4 substrates used in 
patients with CD.  The glucocorticoids, prednisone and budesonide, are substrates of 
CYP3A4 and are widely used for inducing disease remission in CD29-32.  There is 
significant inter-individual variation in CD patient response to prednisone and 
budesonide33.  Our data show that budesonide exposure is highly variable amongst 
individuals with CD and mirror the variability seen in healthy volunteer populations34, 35.  
Conversely, we did not observe a correlation between CYP3A4 activity and budesonide 
oral bioavailability, suggesting that CYP3A4 activity did not contribute significantly to 
budesonide variability in our population; however, our sample size may have been too 
small to draw definitive conclusions.  Additionally, there is little, if any, data evaluating 
the impact of CD on an individual's exposure to non-CD-related CYP3A4 drug substrates 
taken concomitantly for co-morbid illnesses.  In a single study by Sanaee et.al. (2011), 
the authors observed a marked increase in the plasma concentrations of CYP3A4-
substrate, verapamil compared to healthy volunteers36.  Further study is needed to assess 
the clinical impact of CD-related decreases in CYP3A4 activity. 
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Moreover, we draw attention to the overlap between drug metabolism sequences 
and CD pathogenesis.  Nuclear receptors, such as PXR and FXR are important regulators 
of drug metabolism.  They influence human exposure to xenobiotics including clinically-
used drugs by regulating the activity and expression of proteins involved in the different 
phases of drug metabolism; however, they are also increasingly recognized for their 
importance in the mechanisms of CD pathophysiology18, 25, 26.  In addition to contributing 
to barrier function and limiting drug absorption through the regulation of CYP3A4, FXR 
is important to the integrity of the intestinal epithelium37, 38.  Our data demonstrate a 
novel and important implication for genetic variation in FXR as it pertains to CD 
outcomes.  Specifically, novel polymorphism FXR-1G>T confers a greater risk of severe 
CD phenotype (as represented by risk and time to CD-related surgery) in women with CD 
and is associated with reduced expression of downstream FXR targets.  These findings 
are important to drug disposition and exposure in CD for two reasons: 1) they link drug 
metabolism pathways to CD pathogenesis and suggest that derailments in the expression 
of key enzymes and transporters may be a co-incident or antecedent event in IBD 
pathogenesis rather than a consequence of disease presence 2) they identify an at-risk 
group within the larger CD community who may benefit from more aggressive "top-
down" CD medical management39.  The latter reinforces concepts championed by experts 
in the field of CD therapeutics: that our approach to CD management needs to be tailored 
to the individual and that there needs to be a re-structuring of our current provincial 
approach to CD drug access.   
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6.3 Future Directions 
The clinical relevance of CD-specific changes in CYP3A4 activity remains to be 
determined.  Given the prevalence of CD worldwide, the clinical consequences of its 
impact on a major drug metabolism pathway is highly relevant to drug development and 
patient safety.  Observational studies and pharmacokinetic analyses are needed in CD 
populations to evaluate the impact of derangements in CYP3A4 activity and expression 
on drug exposure and drug response.  
In addition, our data evaluated changes in the hepatic and intestinal activity of 
CYP3A4 in CD as well as changes in the intestinal protein expression.  Interestingly, in 
the midazolam pharmacokinetic analysis, it was observed that the decline in CYP3A4 
activity was primarily related to hepatic CYP3A4.  There are no studies evaluating the 
impact of CD on the hepatic expression of CYP3A4.  Logistically, this may be a difficult 
feat to accomplish in human studies, as the gold standard-liver biopsy would likely be 
difficult to carry out in the setting of a non-hepatic disease.  In its place, the use of 
intravenous, exogenous, systemic probes in larger CD cohorts to assess CYP3A4 activity 
may provide an adequate alternative to further explore this finding. 
We also examined the role of bile-acid induced PXR signaling on CYP3A4 
activity in vitro as a means for better understanding differential CYP3A4 activity in CD.  
We observed CD-specific differences in the bile acid profiles of CD and non-CD 
populations.  Specifically, differences in the percent composition of potent PXR ligand, 
LCA were noted between groups.  However, despite this, no difference was observed in 
CYP3A4 activity in an in vitro cell model with exposure to a disease-specific bile acid 
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pool.  Of note, other CD-specific differences observed in the bile acid pools included an 
increase in glycine-conjugated deoxycholic acid (GDCA) and cholic acid (GCA) amongst 
the CD population as well as a relative decline in taurine-conjugated cholic acid (TCA) 
and glycine-conjugated chenodeoxycholic acid (GCDCA).  Activation of PXR by GDCA 
was noted and may have compensated for any declines in CYP3A4 activity due to 
differences in LCA.  In future, evaluating the effect of the CD-specific bile acid pool on 
FXR activation may also shed light on disparate CYP3A4 activation in CD.      
One of the most interesting findings to emerge from this work is that of a link 
between drug metabolism pathways and FXR to disease severity in women with CD.  We 
have identified a novel genomic biomarker of disease severity in women with CD with 
evidence of an impact on its downstream targets.  Beyond the predictive value of FXR-
1G>T in women with CD for poor outcomes, we have identified an area in need of 
further investigation pertaining to CD pathophysiology.  Validation of our retrospective 
study in an independent and external CD population would reinforce its utility as well as 
the application of this genomic test to a prospective cohort of woman to further 
characterize its impact on clinical outcomes.  Furthermore, using molecular technologies 
to better understand the relationship between FXR, estrogen and CD, concepts not 
currently well-explored in CD, may offer additional insights into a complex disease. 
6.4 Conclusions 
The effect of CD on drug metabolism pathways has only been considered to a 
limited extent, despite a significant overlap between metabolism sequences, CD  
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mechanisms and disease location.  The aim of this work was to systematically consider 
the impact of CD on key phase 1 enzyme CYP3A4, including its activity, expression and 
regulation.  We were able to show that CYP3A4 activity and protein expression are 
down-regulated in CD.  We observed a significant reduction in hepatic CYP3A4 activity 
in vivo, despite our initial hypotheses of CD having the greatest influence on intestinal 
CYP3A4.  We also identified a significant relationship between CYP3A4 regulator, FXR 
and outcomes of disease severity in women with CD.  We observed a reduction in 
downstream targets of FXR in female carriers of the FXR-1T allele, highlighting an area 
of future research in CD pathogenesis as it may pertain to women.   As a whole, these 
studies highlight the effect of CD on an important drug metabolism pathway and offer 
new insights into the overlap between CD pathogenesis and drug metabolism sequences.  
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